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 SUMMERY 
The intestinal epithelium has an enormously large surface, which is constantly 
exposed to high amounts of pathogens and commensal bacteria. In order to prevent 
pathogens or other microorganisms from overcoming this barrier, good protection is 
needed. In the small intestine, human α-defensin 5 (HD-5) and 6 (HD-6) are 
important components of this barrier. Paneth cells, which are secretory epithelial 
cells, produce these antimicrobial peptides. The cells are located at the base of the 
crypt in the small intestine, where they play a central role in the microbial defense 
and regulating the composition of the intestinal microbiota. In ileal Crohn's disease, 
which belongs to the inflammatory bowel diseases, HD-5 and HD-6 levels are 
reduced, which leads to a changed composition of the intestinal flora and a poorer 
barrier function of the intestinal mucosa. Underlying mechanisms are genetically but 
also non-genetically influencing the Paneth cell function on different levels. The Wnt 
signaling pathway plays a key role in maintaining intestinal homeostasis. On the one 
hand it keeps the intestinal epithelial cells in a proliferating state, on the other hand it 
regulates the differentiation and maturation of Paneth cells. It is also instrumental in 
the regulation of HD-5 and -6. Former results from our group revealed a link between 
the decreased expression of HD-5 and -6 and the Wnt transcription factor TCF-4. 
Independent of inflammation, patients with ileal Crohn's disease show decreased 
TCF-4 expression levels. But not only TCF-4 is affected, our group could also show 
that the receptor LRP6, which is essential for the stabilization of β-catenin in the 
cytoplasm is affected. Studies showed a decreased expression in ileal Crohn's disease. 
The results of genetic investigations are also exciting; In the LRP6 gene, a 
polymorphism was identified that occurs significantly more frequently in a subgroup 
(patients> 18) than in healthy subjects.  
In the present work the consequences of a disturbed Paneth cell function, but 
also potential causes were further investigated. Emphasis was placed on the patient 
side, but the microbial side of the balance was also examined using animal models. It 
could be shown that LRP6 directly regulates the expression of HD-5 and -6 whereas 
the expression of LRP5, as a co-expressed receptor of LRP6, is barely altered in 
patients and also in vitro there is no evidence for a direct regulation of HD-5 and -6.  
It was possible to show the high heterogeneity of LRP5 in several populations 
studied and no genetic association in all subgroups of Crohn's disease was found. 
Studying TCF-1 expression revealed decreased levels in patients with ileal Crohn's 
 disease. Further results from a knockout mouse model showed that a TCF-1 knockout 
leads to a lower expression of cryptdines (mouse α-defensins). Furthermore, the role 
of antimicrobial peptides in the intestine could be further clarified in a rat liver 
cirrhosis model, since the transfer of commensal bacteria occurring here through the 
intestinal epithelium could be explained by a reduced expression of some 
antimicrobial peptides. Although many factors which play a role in the development 
of ileal Crohn's disease are still unknown, the present work has provided new insights 
into the mechanisms that lead to a well-balanced homeostasis at the epithelial site in 
the small intestine. Furthermore, the important role of the Wnt signaling pathway for 
the development of ileal Crohn's disease was underlined. Hopefully, these additional 
insights into the complex pathogenesis of the disease will one day provide new 
approaches to therapy. 
 
ZUSAMMENFASSUNG 
Das Epithel des Darmes besitzt eine enorm große Oberfläche, welche ständig 
erheblichen Mengen von Pathogenen und kommensalen Bakterien ausgesetzt ist. Um 
zu verhindern, dass Pathogene oder auch andere Mikroorganismen diese Barriere 
überwinden, ist ein guter Schutz nötig. Im Dünndarm sind die humanen α- Defensine 
5 (HD-5) und 6 (HD-6) wichtige Komponenten dieser Barriere. Diese 
antimikrobiellen Peptide werden von Panethzellen produziert. Panethzellen sind 
sekretorischen Epithelzellen und befinden sich an der Basis der Krypte im 
Dünndarm. Dort spielen sie eine zentrale Rolle bei der mikrobiellen Abwehr und der 
Regulation der bakteriellen Zusammensetzung der Darmflora. Bei Morbus Crohn des 
Dünndarms, diese Erkrankung zählt zu den chronisch entzündlichen 
Darmerkrankungen, kommt es zu einer verminderten Expression von HD-5 und HD-
6 und dadurch zu einer veränderten Zusammensetzung der Darmflora und zu einer 
schlechteren Barrierefunktion der Darmmukosa. Grundlage hierfür sind 
verschiedene genetische aber auch nicht- genetische Defekte, welche die 
Panethzellfunktion auf verschiedenen Ebenen beeinflussen.  
Der Wnt Signalweg spielt eine zentrale Rolle, wenn es darum geht die Homöostase im 
Darm aufrecht zu erhalten. Er hält die intestinalen Epithelzellen einerseits in einem 
proliferierenden Zustand, andererseits reguliert er die Differenzierung und das 
Ausreifen der Panethzellen. Ebenso ist er an der Regulation von HD-5 und -6 
maßgeblich beteiligt. Unsere Arbeitsgruppe konnte bereits zeigen, dass es eine 
 Verbindung zwischen der verminderten Expression von HD-5 und -6 und dem Wnt 
Transkriptionsfaktor TCF-4 gibt. Entzündungsunabhängig zeigen Patienten mit 
Morbus Crohn des Dünndarms eine verminderte TCF-4 Expression. Aber nicht nur 
TCF-4 ist betroffen, es konnte auch gezeigt werden, dass der Rezeptor LRP6 betroffen 
ist, welcher für die Stabilisierung von ß- Catenin im Cytoplasma essentiell ist. 
Untersuchungen zeigten eine verminderte Expression bei Morbus Crohn Patienten. 
Spannend sind auch die Ergebnisse genetischer Untersuchungen; im LRP6 Gen 
wurde ein Polymorphismus identifiziert, der in einer Untergruppe (Patienten >18) 
deutlich häufiger auftritt als in Gesunden. 
In der hier vorgestellten Arbeit wurde an diese Ergebnisse angeknüpft und die 
Folgen einer gestörten Panethzellfunktion, aber auch die Faktoren die potentiell dazu 
führen, weiter untersucht. Hierbei wurde ein Schwerpunkt auf die Patientenseite 
gelegt, aber auch die mikrobielle Seite wurde mithilfe von Modellen untersucht. Es 
konnte gezeigt werden, dass LRP6 die Expression von HD-5 und -6 direkt reguliert 
während die Expression von LRP5, als ein Co-Rezeptor von LRP6, in Patienten kaum 
verändert ist und sich auch in vitro keine Hinweise auf eine direkte Regulation von 
HD-5 und -6 finden lassen. Ebenso zeigte sich, dass LRP5 sehr heterogen in 
mehreren untersuchten Populationen vorliegt und keine genetische Assoziation in 
allen untersuchten Subgruppen von Morbus Crohn vorliegt. Die Untersuchungen von 
TCF-1 zeigten eine erniedrigte Expression in Patienten mit Morbus Crohn des 
Dünndarms. Ergebnisse aus einem Knockout Mausmodell zeigten, dass ein TCF-1 
Knockout zu einer niedrigeren Expression von Cryptdinen führt. Weiter konnte in 
einem Leberzirrhose- Tiermodel die Rolle antimikrobieller Substanzen weiter geklärt 
werden, da der hier auftretende Übertritt von kommensalen Bakterien durch das 
Darmepithel mit einer verminderten Expression einiger antimikrobieller Peptide 
erklärt werden konnte. 
Obwohl immer noch viele Faktoren, die in der Entstehung von Morbus Crohn 
des Dünndarms eine Rolle spielen unbekannt sind, konnte die hier vorliegende Arbeit 
neue Einblicke in die Mechanismen liefern, die das Aufrechterhalten der Balance 
zwischen Bakterien und Mensch im Dünndarm ermöglichen. Weiter wurde die 
wichtige Rolle des Wnt Signalwegs für die Entstehung von Morbus Crohn des 
Dünndarms unterstrichen. Hoffentlich ermöglichen diese weiteren Einblicke in die 
komplexe Pathogenese der Erkrankung eines Tages neue Ansätze für eine Therapie
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1. INTRODUCTION   
1.1 The human gastrointestinal tract  
The gastrointestinal tract (GIT) consists of different compartments (figure 1). 
The first part is the oral cavity followed by the pharynx, the oesophagus and the 
stomach, which can be subdivided into four sections. The last of these sections and 
the pylorus enables the emptying into the small intestine (Tortora and Derrickson 
2008). These upper parts of the GIT mediate the ingestion and the digestion of food. 
The lower part is responsible for the absorption of nutrients and water. It consists of 
the small intestine (duodenum, jejunum and ileum) with an approximate length of 5  
meters. 
 
Figure	1:	The	gastrointestinal	tract	(adapted	from	William	Crochet	(science-et-vie.net)) 
 
Its surface is covered by finger-like structures, called villi, which increase the surface 
to ensure optimal nutrition uptake. Most of the digestion takes place in the small 
intestine, catalysed by enzymes produced in the pancreas and released into the small 
bowel (Clark 2005). The small intestine is followed by the large intestine; whereas the 
colon mediates absorption of water and electrolytes and then, finally, unneeded 
material is released through the rectum and the anus as stool (Tortora and 
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Derrickson 2008). The microscopically composition of the gut wall resembles each 
other in all sections of the gut. The outer layer, which is named serosa, consists of 
thin connective tissue. The subjacent layer is the submucosa followed by the mucosa, 
which is subdivided into three layers: The lamina muscularis mucosae, consisting of 
thin muscle tissue, which enables the gut to contract crosswise as well as lengthwise 
to convey the food bolus. A layer of connecting tissue, called the lamina propria, 
harbouring blood vessels and lymphatic nodules supplying the epithelium. The 
intestinal epithelium forms the innermost layer. It is responsible for most of the 
absorptive, digestive and secretory processes, but also has a critical role in 
maintaining an effective barrier against invading pathogens and in controlling the 
normal gut microbiota (Dorland n.d.; Tortora and Derrickson 2008, Lüllmann-Rauch 
2009). This aspect will be discussed in the following section.   
1.2 Immunity  
1.2.1 Innate immunity and the microbiology of the human GIT  
In humans, like in all mammals, the immune system is divided into a fast 
responding, simpler structured part, called the innate immune system and a more 
complex part with a slower but very specific response to pathogens, called the 
adaptive immune system. Whereas the adaptive immunity reacts to specific antigens, 
facilitates vaccinations and even recognises non-infectious structures, the innate 
immunity aims on a faster but more generic first line of defence (Janeway 2001). The 
intestinal epithelium is a constantly renewing self-regenerating tissue, with a renewal 
rate which exceeds all other tissues in the human body (Gregorieff and Clevers 2005). 
The enormous surface of the small intestinal epithelium with its crypts and villis is 
constantly challenged with high numbers of microorganisms comprising the healthy 
gut microbiota but also pathogens. The microbiota makes up to 1-2 kg, and consists of 
1013 to 1014 microorganisms and outnumbers the amount of cells in the human body 
by far (Martín et al. 2014, Lee and Mazmanian 2010). The numbers of bacteria are 
rising with increasing distance from the stomach and therefore increasing pH. 
Because of the high amounts of bactericidal properties, gastric and bile acids, the 
stomach, and also the proximal small intestine are relatively depleted from bacteria 
in comparison to the ileum. The ileum is colonized by large amounts of anaerobic and 
aerobic bacteria. The colon however represents the most densely populated part of 
the GI-tract, harbouring 1012 bacteria/g of intestinal content (Sekirov et al. 2010). 
Due to this enormous bacterial load it is elementary to have a well-balanced 
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homeostasis at the epithelial site. The epithelium, which is the first line of defence 
against invading pathogens, confers an efficient mechanical barrier and restricts 
bacteria, fungi, yeasts and even viruses from invading the mucosa and preserves the 
homeostasis towards symbiotic microorganisms. Besides generating mechanical 
borders, epithelial cells maintain a chemical barrier system; including the low pH of 
the stomach acid, produced by parietal cells and the mucus which is secreted by 
goblet cells. Moreover there is a complex array of antimicrobial peptides and 
polypeptides as well as proteins with bactericidal properties produced by different 
cell types, mainly the Paneth cells in the small intestine but also all epithelial cells 
(Tollin et al. 2003; Howell et al. 2003). Germ-line encoded pattern recognition 
receptors (PRRs), including Toll-like receptors (TLRs) located in the outer 
membrane, or intracellular NOD-like receptors (NLR), recognize specific highly 
conserved patterns, the so called “microbe associated molecular patterns” (MAMPs) 
on the microbial surface of the resident gut microbiota but also on pathogens 
(Litman, Cannon, and Dishaw 2005). As a consequence of PRR stimulation by their 
corresponding ligands, a pro-inflammatory response takes place which often occurs 
via activation of MyD88 and NF-κB or MAP-kinases (Takeda and Akira 2004). The 
rapid and generic first line of defence additionally leads to PRR signaling in immune 
cells in the lamina propria. This also enables an adequate inflammatory reaction in 
response to invading pathogens (Fukata and Arditi 2013; Tosi 2005). Low expression 
of the TLRs and their location at the basolateral side enables very low inflammation 
rates in the healthy gut despite the high bacterial load (Abreu 2010; Cario 2010).  
But not only the number of bacteria is controlled, also their composition. The 
commensal microbiota consists of Firmicutes, Bacteroidetes, Proteobacteria and 
Actinobacteria (Nuding et al. 2009). In the ileum the bacterial composition mostly 
consists of aerobic and anaerobic bacteria like Enterobacter and Lactobacilli whereas 
predominately anaerobic phyla like Bacteroides, Bifidobacteria, Fusobacteria, 
Clostridium and Peptostreptococci provide most of the microbiota in the colon 
(Peterson et al. 2008). Antimicrobial peptides (AMPs) produced constitutively or 
inducible are abundant in a broad range. They are provided by almost all epithelial 
cells but, as mentioned, also by specialised cells. AMPs are not only produced by 
humans, but also found in every organism. In invertebrates they often are the major 
defence mechanism (Tincu and Taylor 2004). The human antimicrobial defence 
system has co-evolved with the microbes that have been challenging it. In our gut, 
this close exposure has led to a commensalism or in the ideal case to a mutualistic co-
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existence (Neish 2009). To maintain a healthy balance between these 
microorganisms, the human immune system, on the one hand, has to tolerate the 
healthy gut microbiota within certain parameters because it is essential for the 
absorption of nutrients, improvement of digestion, vitamin synthesis (Jones and 
Bevins 1992; Lehrer and Lu 2012) and also the inhibition of pathogen growth 
(Sekirov et al. 2010). On the other hand it has to tightly control the commensals and 
must protect the mucosa from invading pathogens (Eberl 2010).  
The crypts of Lieberkühn (figure 2), named after its discoverer Nathanael Lieberkühn 
(1711–1756), are home to enterocytes characterized by a luminal brush border 
absorbing electrolytes and water, mucus-secreting goblet cells, enteroendocrine cells, 
which secrete different hormones and tuft cells which sense substances of the lumen 
and Paneth cells. Paneth cells (PCs) are specific to the small intestine, where they are 
located at the bottom of the crypt in close contact to stem cells from which the 
develop (Clevers 2013). Their main role is to produce antimicrobial peptides (Jones 
and Bevins 1992; Lehrer and Lu 2012). This makes them important players of the 
innate immune defence in the small intestine. Their endogenously synthesized 
antibiotics can kill bacteria, viruses 
and fungi (Zasloff 2002). In many 
stages of the epithelial development, 
Wnt signaling plays an essential role, 
for example cell movement and 
polarity as well as tissue and cell type 
generation rely on this pathway (Verzi 
and Shivdasani 2008). 
	
	
	
	
Figure	 2:	 The	 Crypt:	 Paneth	 cells	 at	 the	
button	of	the	crypt	secrete	defensins	(green),	
mostly	the	α-defensins	human	defensin	5	and	
6,	 to	protect	 the	host	against	pathogens	and	
shape	 the	 microbiota	 (pink)	 in	 the	 small	
intestine	(Teltschik	et	al,	unpublished).	
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1.2.2 Interplay with gut microbiota 
After a very variable time in early colonization in first months of life of the host, 
most individuals share a core composition of bacterial genera (Palmer et al. 2007). In 
later life, shaping the gut microbiota depends on many factors. There are three main 
parts: nutrition, immune development and innate host defence (O’Hara and 
Shanahan 2006). Therefore host health is highly dependent on a working interaction 
between gut bacteria, dietary nutrients and surface tissues in the gut. As an important 
environmental aspect, the human diet has influences on shaping the microbiota in 
the gut, which is known from different studies (Walter and Ley 2011; David et al. 
2014). Diarrhoea and inflammations are common problems in people with 
malnutrition as well as bacterial translocation, which could also be linked to 
decreased levels of antimicrobial peptides (Hashimoto et al. 2012. 2; Hodin et al. 
2011; Teltschik et al. 2012). In this context it is interesting to know that, under a lack 
but also abundance of nutrition, Paneth cells show decreased expression of 
antimicrobial peptides and aberrations in their granula (Hodin et al. 2011; Yilmaz et 
al. 2012). In turn, host metabolism relates to a certain part on the metabolism of gut 
microbes, enabling the host to use bacterial pathways for the absorption of dietary 
components (Nicholson, Holmes, and Wilson 2005). The microbiota takes the task of 
synthesizing vitamins and ferments non-digestible parts of the nutrition. K and B 
vitamins as well as essential amino acids and short-fatty acids must be supplemented 
to the feed of germ- free mice (Wostmann 1981; Gustafsson 1982; Hooper and 
Gordon 2001). The co-evolution of bacteria and men made it possible to use other 
sources to cover nutrient requirements, which were not available before. However, 
the bacterial site is also profiting from this relationship; it gained a niche full of 
nutrients, which facilitates bacterial growth as well as stable temperature and redox 
potential conditions. This in turn enables the beneficial microbiota to defend their 
habitat against invading pathogens (Hooper, Midtvedt, and Gordon 2002; Salyers 
and Pajeau 1989; Hultgren et al. 1993). The commensal microbiota is also involved in 
the regulation and development of the mucosal immune system (Cerf-Bensussan and 
Gaboriau-Routhiau 2010). During postnatal colonization all microbes have to 
compete for nutrients and have to resist the host’s antimicrobial defenses. For 
establishing a stable microbial composition, it is essential to form cross- feeding 
networks, where metabolites from one bacterial group act as substrates for other 
groups (Duncan et al. 2004). There is more and more evidence that disturbances in 
this stable microbial composition can promote the development of diseases (Neish 
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2009). Disturbed microbial colonization, called dysbiosis, has been linked to different 
diseases like inflammatory bowel diseases, obesity and even colon cancer (Bäckhed et 
al. 2007, 2004; Azcárate-Peril, Sikes, and Bruno-Bárcena 2011). This shows the 
importance of a better understanding of the molecular mechanisms behind these 
interactions.  
1.2.3 Antimicrobial peptides 
Antimicrobial peptides (AMPs) are found in different protein families and the 
most prominent ones are the defensins and cathelicidin (LL-37), c-type lectins (e.g. 
the Reg family), ribonucleases and S100 proteins (e.g. calprotectin) in the intestinal 
tract (Harder, Gläser, and Schröder 2007; C L Bevins 2003). Reduced antimicrobial 
defence in the gut can promote chronic inflammation (Wehkamp et al. 2008). These 
effects can be seen in inflammatory bowel diseases (IBD) and especially in Crohn´s 
disease (Koslowski et al. 2010). This demonstrates that AMPs are crucial to maintain 
a health promoting balance and a beneficial homeostasis between the microbial gut 
community and the host. AMPs are produced and secreted on-going or also on 
demand (Salzman et al. 2010). Transgenic human defensin 5 (HD-5) mice, which 
exhibit an altered antimicrobial activity, are protected against Salmonella infections 
(Salzman et al. 2003) and a significantly changed expression of α-defensins, either 
diminished or increased, lead to significant changes in the composition of the 
intestinal microbiota. This data demonstrates their in vivo homeostatic role towards 
the symbionts (Salzman et al. 2010). 
1.2.3.1 Defensins 
The predominant antimicrobial peptides in the gut are the defensins. Their 
outstanding role for an effective defence against bacteria, fungi, and some enveloped 
viruses in the intestine makes them essential to maintain a proper composition of the 
microbiota and restricting contact between resident microbes and mucosal surfaces 
(Wehkamp, Schauber, and Stange 2007). They are the most extensively studied 
intestinal antimicrobial peptide group and therefore will be explained in detail in this 
chapter. Their mechanism of action, functions and expression will be elucidated.  
Data from mouse models illustrated their importance in controlling the 
intestinal mucosal barrier and protecting the organism from pathogens. For example 
does an extensive release of Paneth cell antimicrobials, called degranulation, induced 
via TLR9 stimulation, protect mice against an infection with the bacteria Salmonella 
typhimurium (Rumio et al. 2004) as their transcriptional induction and secretion is 
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at least in part dependent of innate immune PRRs. In contrast, a lack of the 
metalloproteinase matrilysin, an enzyme which activates cryptdins (mouse Paneth 
cell α-defensins), leads to a high susceptibility to orally administered pathogens 
(Wilson et al. 1999).  
Paneth cells, which are specialised cells, located at the bottom of the crypts of 
Lieberkühn in the small intestine (figure 2) mostly secrete α-defensins. With their 
broad antimicrobial spectrum they are one of the major producers of AMPs in the 
small intestine (Wehkamp et al. 2006), actively contributing to the mucosal 
immunity by secreting  e.g. lysozyme, phospholipase A2 group IIA or REGIII, but 
their main products are human α-defensin 5 (HD-5) and 6 (HD-6) (Clevers and 
Bevins 2013a). HD-5 and HD-6 not only have antimicrobial but also antiviral activity 
(Doss et al. 2009; Klotman and Chang 2006) and even anti-parasitic properties have 
been described for HD-5 (Ericksen et al. 2005). However, it is also described that 
they increase infectivity of some viruses (Klotman et al. 2008). The expression of 
these two antimicrobials is controlled by different signaling pathways, amongst 
others signaling induced by the stimulation of the intracellular receptor NOD2 
(CARD15) or the β–catenin dependent Wnt signaling pathway (Koslowski et al. 2010) 
- but mainly assumed to be consistent. Although they have analogous 5’ region and 
are therefore similarly regulated (Mallow et al. 1996), the mode of action of HD-5 and 
HD-6 differs from each other. HD-5 has direct microbial and antiviral effects and 
diminishes the survival of microbes by killing them even in low concentrations 
(Ericksen et al. 2005; Porter et al. 1997; Zins et al. 2014). It´s mode of action and the 
exact details are not completely understood, but it is believed to disrupt the bacterial 
cell wall due to its amphipathic properties (Wei et al. 2009). HD-6 entraps bacteria in 
nanonets and thereby disables them and keeps them from entering the gut wall (Chu 
et al. 2012). It could however also been shown that HD-6 can additionally elicit direct 
antimicrobial effects when reducing conditions are present (B. O. Schroeder et al. 
2014). Deficiencies in antimicrobial peptide expression are associated with chronic 
inflammatory disorders like IBD, which is triggered by intestinal gut microbes 
(Wehkamp et al. 2004; Wehkamp et al. 2005). 
In contrast to α-defensins, the β-defensins are more ubiquitously expressed 
and can be found in various epithelia within the whole body. Like the α-defensins, 
they are small and have a cationic character and they also hold an important role in 
combating pathogens, particularly in the colon (Peyrin-Biroulet et al. 2010). Colonic 
Crohn’s disease (CD) is associated with decreased on demand inducibility and 
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secretion levels of human β-defensin 2 (hBD-2) (Wehkamp et al. 2003). Different 
from inducible β-defensins, hBD-1 seems to be stable in disease and inflammation 
but also shows low mRNA copies in colonic CD (Peyrin-Biroulet et al. 2010). HBD-1 
is one of the most prominent β-defensins but shows low bactericidal activity under 
aerobic conditions. B. Schröder from our group could show that this defensin, under 
reducing conditions, develops strong antimicrobial activity against the anaerobic, 
Gram-positive commensals species Bifidobacterium and Lactobacillus and even the 
fungus Candida albicans (Schroeder et al. 2011).  
1.3 Paneth cells  
Discovered already in 1872 by G. Schwalbe, these cells were named after J. 
Paneth, who has performed their detailed morphological analysis in 1888. Their 
function was discovered almost 100 years later. Today investigations focus on their 
role in innate immune defence and their function in regulation of intestinal stem 
cells. The pyramidal-shaped Paneth cells (PC) have a basally situated nuclei and a 
granula-rich cytoplasma where they produce and store their antimicrobial peptides 
(Bevins 2004; Wehkamp et al. 2006). Like all epithelial cell they originate from stem 
cells, which are located near the crypt bottom (Cheng and Leblond 1974). Different to 
the other epithelial cells, which are produced in the lower part of the crypt and 
migrate towards the villus tip, PC reside at the bottom of the crypt (Heath 1996; 
Marshman, Booth, and Potten 2002) (figure 2). Where they stay in close contact with 
intestinal stem cells. The intestinal epithelium has a rapid and continuous renewal 
rate, in comparison to that, the lifetime of PCs is long: their life span is around 60 
days, which is the only exception to the high renewal rate (Barker 2014; Ireland et al. 
2005). PCs can be identified by histochemical and immunochemical methods. They 
are stainable with eosin and phloxine-tartrazine. This staining shows the cationic 
charge of the granula content, which is typical for antimicrobial peptides, especially 
defensins (Jones and Bevins 1992). Because staining depends on different factors like 
tissue fixation, disease state and species its not easy to prove presence of PC relying 
only on histological methods (Porter et al. 2002). The produced antimicrobials are 
released from PCs granula after the stimulation of pattern recognition receptor (PRR) 
such as TLRs or NOD receptors by bacterial components like muramyldipeptide 
(MDP), which is the peptidoglycan motif common in all bacteria (Ayabe et al. 2000; 
Girardin et al. 2003). In chronic inflammation but also in other diseases, metaplastic 
PCs appear in other locations than the small intestine, for example the colon or the 
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oesophagus. Their specific role is not clear but it is possible, if you consider the 
relevant role of PC, that they could be meant to improve the antimicrobial defence in 
these diseased parts of the body (Bevins and Salzman 2011). Beyond that metaplastic 
PCs are also often associated with colorectal cancer (Polakis 2000; Roth et al. 2012). 
Causative could be the often over-active Wnt signaling pathway, which is essential for 
proliferation (and thereby a prevalent theme in the emergence of cancer) but also for 
the maturation of PCs (van Es et al. 2005). 
But PCs are not only essential for maintaining intestinal homeostastis; they also 
secrete factors, which are important for shaping the stem cell microenvironment, the 
so-called “niche”. These mediators are epidermal growth factor (EGF), the Notch 
ligand Delta like ligand (Dll) 4 and also Wnt signals (Sato et al. 2011). These factors 
are essential for cultivating intestinal stem cells in vitro. That PCs are supporting the 
maintenance of the stem cell niche was also shown by results revealing that stem cells 
improve growth in cell culture when co-cultured with PCs. Due to the important 
function in regulating proliferation the number of PCs in one niche is strictly 
controlled and does not exceed 10 PCs/niche. The regulation of PC number is due to 
Wnt antagonists like Dickkopf (Dkk) proteins and negative feedback loops (Clevers, 
Loh, and Nusse 2014; Clevers and Bevins 2013b). 
1.4 The Wnt signaling pathway  
Different molecular signaling pathways are involved in regulating and 
maintaining epithelial cell polarity in the intestinal tract. Notch, hippo, transforming 
growth factor- β (TGF- β)/bone morphogenetic protein (BMP), hedgehog and the 
Wnt pathway regulate cell fate and self-renewing processes in different tissues in the 
gut. The Wnt signaling pathway is highly conserved in all animals and regulates 
fundamental cellular interactions in multicellular organisms. β-catenin dependent 
Wnt signaling is indispensable for stem cell proliferation and maturation of Paneth 
cells. It maintains an undifferentiated state of the intestinal crypt progenitor cells and 
has a central role in regeneration and differentiation of the intestinal epithelium 
(Gregorieff et al. 2005; Korinek et al. 1998; Koslowski et al. 2009). Wnt factors, 
which are produced and secreted by epithelial cells at the bottom of the crypt 
(Crosnier, Stamataki, and Lewis 2006), generate a gradient of Wnt signals along the 
crypt–villus axis. Wnt signaling (figure 3) is activated by binding of ligands to the 
Wnt receptor complex on the cell surface, which includes either transmembrane co-
receptor Low-density lipoprotein receptor-related protein (LRP) 5 or 6, binding and 
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internalizing ligands in the process of receptor-mediated endocytosis, and their co-
receptor family Frizzled (Zhong et al. 2012). This leads to phosphorylation of the 
cytoplasmatic tail of LRP5 or LRP6, which enables the stabilisation of β-catenin in 
the cytoplasma. Subsequently, this main transducer of the canonical Wnt signaling 
translocates from the cytoplasma into the nucleus and forms complexes with 
transcription factors of the LEF/TCF family to activate target gene expression. The 
stability of β-catenin is regulated by phosphorylation, ubiquitination and 
subsequently degradation by a cytoplasmatic deconstruction complex consisting of 
the protein Axin, adenomatous polyposis coli (APC), the kinases glycogen synthase 
kinase-3 alpha/beta (GSK-3) and casein kinase-1 (CK1). In case of degradation, CK1 
and GSK3β phosphorylate threonine and serine residues in the amino terminal 
region of β-catenin (Kitagawa et al. 1999; Behari 2010). 
The transcription factor TCF-1 (also known as TCF-7) belongs together with 
LEF-1, TCF-3 (TCF-7L1) and TCF-4 (TCF-7L2) to a family of DNA binding proteins 
(van Beest et al. 2000). TCF-1, best known for its crucial role in thymus development 
(F. J. T. Staal, Luis, and Tiemessen 2008), requires the interaction with β– catenin, 
which provides a transactivation domain, to become an active transcription factor 
(Behrens et al. 1996; van de Wetering et al. 1997). It has been described that TCF-1 
regulates proliferation of epithelial cells (Gregorieff et al. 2005). Through alternate 
promoter usage, different TCF-1 isoforms are generated. These isoforms can be sub-
grouped into dominant negative isoforms, lacking the N-terminal β-catenin 
interaction domain and active isoforms, which are able to transactivate target genes 
(Van de Wetering et al. 1996).  
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Figure	3:	The	Wnt	signaling	pathway	in	the	Paneth	cell	
Interaction	of	Wnt	proteins	with	receptors	of	the	LRP	and	Frizzled	family	leads	to	pathway	activation.	
This	 results	 in	 intracellular	 stabilisation	 of	 β-catenin	 due	 to	 decreased	 β-	 catenin	 degradation	
because	of	an	 inhibition	of	 a	β-catenin	deconstruction	complex.	 Stabilization	enables	β-	 catenin	 to	
enter	 the	 nucleus	 and	 interact	 with	 transcription	 factors	 of	 the	 Lef/TCF	 family.	 Target	 genes	 like	
human	 defensins	 5	 and	 6	 as	 well	 as	 other	 critical	 components	 of	 the	 complex	 Paneth	 cell	 gene	
program	get	activated	(figure	modified	from	Beisner,	Teltschik	et	al.,	2014,	AJPGI).	
 
Different model systems showed that disruption of β-catenin dependent Wnt 
signaling compromises Paneth cell differentiation (Korinek et al. 1998; Andreu et al. 
2005, 2008). LRP5 knockout mice show normal development but have metabolic 
abnormalities and low bone mass (Kato et al. 2002; Magoori et al. 2003). In 
comparison to the LRP5 knockout model the depletion of the LRP6 gene is lethal 
(Pinson et al. 2000). Mice embryos with a double knockout in the LRP5 and 6 genes 
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die much earlier than LRP6 knockout mice, to be specific, during gastrulation (Kelly, 
Pinson, and Skarnes 2004). These studies show that LRP6 is more crucial in 
embryogenesis than LRP5, but they also show that LRP5 and 6 have some functional 
redundancy. Studies from our group revealed that a functional mutation, a non-
synonymous single nucleotide polymorphism (SNP) (rs2302685; Ile1062Val), in the 
LRP6 gene is associated with early onset of Crohn´s disease. This SNP was former 
linked to increased fracture risk (van Meurs et al. 2006) and to an increased risk of 
myocardial infarction (Xu et al. 2014). This further strengthens the role of Wnt 
signaling in the pathogenesis of Crohn´s disease and further showed us the necessity 
to analyse the co- exressed receptor LRP5.  
1.5 Crohn´s disease  
Crohn´s disease (CD) is named after Dr. Burrill B. Crohn, who first described 
the disease in 1932 together with his colleagues Dr. Leon Ginzburg and Dr. Gordon D. 
Oppenheimer. The disease is an inflammatory disease of the gastrointestinal tract 
and belongs together with other diseases, namely ulcerative colitis (UC) and colitis 
indeterminata, to the group of inflammatory bowel diseases (IBDs). CD affects about 
300 cases per 100000 people in Europe, with an annual incidence of 0.3-12.7 new 
cases per 100000 people (Preiß et al. 2009; Molodecky et al. 2012). The peak age-
specific incidence occurs between 15 and 34, so patients often are affected the whole 
working life. The outcome are not only direct costs for drugs, consultations, hospital 
stays or even surgeries, but also indirect costs for non-productive time or the inability 
to work arise (Kappelman et al. 2008).  
CD can affect any part of the gastrointestinal tract but most commonly it affects 
the ileum and the upper part of the colon. It can occur in a patchy pattern, which 
means that healthy parts are located between diseased areas. Often it results in 
strictures, microperforations and also fistulae. Histological manifestations are non-
necrotizing granulomas, transmural lymphoid aggregates and fissuring or 
microscopic skip lesions (Podolsky 2002). A distorted epithelial structure, infiltration 
of plasma cells and lymphocytes, crypt abscesses, and lymphoid aggregates are 
characteristics to distinguish between IBD and other inflammations in the 
gastrointestinal tract (Le Berre et al. 1995). Typical symptoms are persistent diarrhea, 
rectal bleeding, pain and cramps in the abdomen and urgent needs for a bowel 
movement. Problems can also occur extra-intestinal and become manifested in 
symptoms like axial and peripheral arthritis, Erythema nodosum and growth 
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retardation in children. Medication and dietetic treatment can however weaken the 
symptoms and thereby improve quality of live. If cortisone, which attenuates the 
inflammation, is ineffective, immunosuppressant drugs like Azathioprine and 6-
Mercaptopurine can dampen the immune response and thereby weaken the 
symptoms. Side effects of these drugs are often massive and patients are more prone 
to develop serious infections due to the weak immune defense (Lémann et al. 2006; 
Kübler et al. 2009). No curative medication is available so patients suffer from the 
disease lifelong. 
The location of chronic inflammation is used to subcategorize disease subtypes. 
It can affect only the small intestine, which is categorized as L1, only the colon (L3) or 
both locations together (L2). Additional to an initial L1, L2 or L3 disease location, the 
upper GI tract can also be involved (L4). But not only the location is defining in CD, 
also the progression status can be used for classification; inflammatory or B1 is the 
weakest state, followed by B2 (stenotic) and a penetrating course (B3) with intestinal 
fistulas. Different from the location, the progression status can change over time. 
This makes it more likely that the mechanisms causing CD might be location-specific 
and therefore different in colonic and ileal CD (Silverberg et al. 2005; Louis et al. 
2001; Jakobsen et al. 2014; Gasche and Grundtner 2005).  
The pathogenesis of CD is not completely understood. Today, much data 
demonstrates that the immune system and also genetic predispositions as well as 
environmental factors like the gastrointestinal microbiota, stress, and diet are crucial 
in the development of IBD (Wehkamp et al. 2008; Hill and Artis 2010) and the 
normal gut microbiota plays an important causative role in the disease (Ostaff, 
Stange, and Wehkamp 2013).  
1.5.1 Large intestinal Crohn’s disease  
Colonic CD is associated with reduced antimicrobial activity against certain 
strains of gut bacteria (Nuding et al. 2007). The mechanisms behind this reduction of 
antimicrobial defence are poorly understood, but it is believed that a lack of β-
defensin induction could account for this disease pattern (Wehkamp et al. 2008). The 
production and secretion of human β-defensin 2 (hBD-2) needs to be induced by 
pathogens but also by probiotic bacteria. This induction is mediated via the “nuclear 
factor kappa-light-chain enhancer of activated B cells” (NF-κB) and activator protein 
1 (AP-1) (Wehkamp et al. 2003). Especially the inducible hBD-2 is decreased in 
colonic CD as compared to ulcerative colitis. Impaired upregulation of hBD-3 and 
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hBD-4 could additionally contribute to impaired defence (Nuding et al. 2007; 
Fahlgren et al. 2003; Wehkamp et al. 2003). Other antimicrobials like Elafin, LL37 
and SLP1 can be reduced in colonic CD and thereby account for disease (Schmid et al. 
2007; Wehkamp et al. 2008). A lack of hBD-1, which is, in comparison to hBD-2, 
constitutively and widely expressed as one of the most prominent defensins (Bjoern O 
Schroeder et al. 2011), leads to decreased microbial activity in the colonic mucosa 
resulting in increased mucosal adherence of bacteria but also fungi or viruses 
(Swidsinski et al. 2002). This lack of hBD-1 can partly be explained by a functional 
SNP in the promoter of the hBD-1 gene, which seems to be predisposing for colonic 
CD (Kocsis et al. 2008; Peyrin-Biroulet et al. 2010). Other regulatory factors can also 
influence the expression of this important defence molecule. There are data available 
showing that the nuclear receptor PPARγ seems to be important for the maintenance 
of a constitutive epithelial expression of β-defensins in the colon, including hBD-1 in 
humans and mDefB10 in mice. Despite of its high expression and wide distribution, 
hBD-1 was long believed to be a very weak antimicrobial. This was due to the fact that 
defensins were studied under aerobic conditions. Schroeder et al. from our group 
could show that activation of hBD-1 depends on a reduction of its disulphide bonds. 
This happens under anaerobic conditions in the colon and hBD-1 thereby becomes a 
very potent bactericidal substance with killing capacity against fungi and bacteria 
(Schroeder et al. 2011).  
1.5.2 Small intestinal Crohn’s disease  
In comparison to ulcerative colitis but also to colonic CD, development of ileal 
CD is linked to diminished expression of other, specific, antimicrobial peptides; more 
precisely both Paneth cell α-defensins HD-5 and HD-6 are reduced (Wehkamp et al. 
2005). The secretion of these two antimicrobials seems to be linked to the 
Nucleotide- binding oligomerization domain containing molecule (NOD) 2 (also 
known as CARD15) receptor. As a peptidoglycan receptor it is important for 
recognising and reacting against invading pathogens by activation of NF-κB and 
thereby making it responsive to bacterial lipopolysaccharides (Hugot et al. 2001; 
Ogura et al. 2001). It could be shown that a mutation in this receptor, which is 
predominantly found in antimicrobial peptide- producing Paneth cells (Lala et al. 
2003) is linked to decreased HD-5 and -6 levels (Wehkamp et al. 2004; Wehkamp et 
al. 2005; Armbruster, Stange, and Wehkamp 2017). Studying these connections in 
mouse models is challenging due to variability in experimental setup (Shanahan et al. 
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2014). Along with this, disturbances in the processing of defensins, to be specific, the 
processing of the α-defensin HD-5 precursor via trypsin and other proteases, 
potentially increase the risk to develop CD by leading to lowered levels of functional 
peptides and thereby to a reduced antimicrobial defence (Elphick, Liddell, and 
Mahida 2008). Disturbed differentiation of PCs and an affected amount and 
distribution of these cells, can compromise production and secretion of defensins. T 
cell transcription factor 4 (TCF-4, TCF7L2), which is an important factor in the Wnt 
signaling pathway, is in turn important for PC differentiation and is reduced in ileal 
CD patients. This negatively affects PC differentiation and leads to decreased levels of 
HD-5 and -6 (Wehkamp et al. 2007). Also mutations in the TCF-4 promoter region 
have been associated with ileal CD (Koslowski et al. 2009). In comparison to the 
decreased expression of HD-5 and -6, which is by the way independent of 
inflammation and specific for small intestinal CD (Bevins, Stange, and Wehkamp 
2009), the expression of other PC products is unchanged (Kübler et al. 2009; 
Wehkamp et al. 2002). Other genetic variants in the autophagy-associated gene 
ATG16L1, which is important for PC biology are also specifically linked to ileal CD 
(Cadwell et al. 2008; Deuring et al. 2014). Wnt signaling, which is crucial for 
epithelial differentiation and production of AMPs in the PC, is disturbed in ileal 
Crohn´s disease (Koslowski et al. 2012; Wehkamp et al. 2007); a mutation in the 
LRP6 gene is associated with early onset Crohn´s disease (Koslowski et al. 2012). 
LRP6 and LRP5 are co-expressed receptors, often acting together and are both 
needed to respond to some Wnt signals (Goel et al. 2012). To elucidate if LRP5 is 
therefore another important factor in the development of CD, SNPs in this gene were 
analysed. For this analysis SNPs which were already described to be linked to other 
diseases like osteoporosis, increased fracture risk (Urano et al. 2009; Korvala et al. 
2012; Xiong et al. 2007) and also familial exudative vitreoretinopathy were selected 
(Jiao et al. 2004). Furthermore coding SNPs were chosen, which could influence the 
structure or function of the gene and SNPs in putative regulatory regions. Tag SNPs, 
which should cover the major haplotypes were additionally analysed. 
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1.6 Aim of the work/ Hypothesis 
Ileal Crohn´s disease (CD) is characterized by inflammations of the intestinal 
mucosa. The patients suffer from diarrhea, abdominal pain, fever, bleeding, 
tiredness, anal fissures and weight loss. The disease is not lethal but the life quality of 
the patients is strongly affected. CD is not curable because neither medical nor 
surgical methods lead to a cure. In light of this knowledge, it seems crucial to find 
therapies to improve the quality of live or even find a cure for the patients. 
Accountable for the persistent inflammations is a diminished production of the 
Paneth cell products HD-5 and -6, enabling the microbial challenge to overpower the 
weakened innate defense allowing the gut flora to enter the epithelium. Various data 
from our group showed that deficiencies of those two defensins are linked to 
impairments in the Wnt signaling pathway (Beisner et al. 2014b; Koslowski et al. 
2009; Wehkamp et al. 2007). Although it is clear, that Crohn´s disease is a 
multifactorial disease, involving environmental (e.g. microbes, nutrition), genetic 
(SNPs), and likely also epigenetic (miRNAs, methylation, acetylation) factors, many 
details and potent other factors are unclear. Despite the findings made, it is known 
that the underlying genetics are more important in disease etiology of CD than in 
ulcerative colitis (Ellinghaus et al. 2015).  
The Wnt signaling pathway regulates fundamental cellular interactions in 
multicellular organisms. β- catenin dependent Wnt signaling is indispensable for 
stem cell proliferation and maturation of Paneth cells. It maintains an 
undifferentiated state of the intestinal crypt progenitor cells and has a central role in 
regeneration and differentiation of the intestinal epithelium (Gregorieff et al. 2005; 
Korinek et al. 1998; Koslowski et al. 2009). The pathway has to be very tightly 
regulated and even small disturbances can dramatically change the mucosal barrier. 
To better understand the relations between Wnt signaling and diminished 
antimicrobial host barrier further factors of the Wnt signaling were analysed.  
The already described mutations in the Wnt pathway alone cannot explain HD-
5 and -6 deficiencies (Koslowski et al. 2009,  2012) so there is need to reveal further 
genetic factors involved. A SNP in the Wnt pathway receptor LRP6 was former linked 
to early onset of Crohns disease (Koslowski et al. 2012). To further elucidate the role 
of LRP6, IHC methods could clarify the location of this upstream component and 
mRNA data could reveal possible expression differences in patients and healthy 
controls.  
INTRODUCTION	 27	
 
 
As a co-expressed receptor of LRP6, LRP5 is also an interesting upstream 
component. Both receptors are co-expressed and have partly overlapping functions. 
Genetic analyses could reveal if, like for LRP6, a genetic association for small 
intestinal CD might exist. MRNA analyses of the subgroups might clarify possible 
expression changes. In order to consider possible LRP5 effects on HD-5 and -6 
expression, overexpression experiments in cell culture could be conducted to show 
effects on target genes HD-5 and -6. 
Transcription factors of the TCF family are important components of the Wnt 
target gene regulation and maintain proliferation of small intestinal stem cells and 
Paneth cell differentiation. The mentioned lower HD-5 and -6 levels are partly caused 
by TCF-4 (Wehkamp et al. 2007; Koslowski et al. 2012). This work could help to 
better understand TCF-1 in Paneth cell gene regulation and its role in CD. 
Immunohistochemical methods may confirm the location of TCF-1 in the small 
intestine. Furthermore mRNA expression experiments will be conducted and a TCF-1 
knock out mouse model will be analysed. 
Trying to better understand the mechanisms causing impairments in the 
antimicrobial defense, animal models can help to study and understand the role of 
defensins in vivo. For this reason two different liver cirrhosis rat models will be 
analysed to better understand the role of defensins and other antimicrobial peptides 
in vivo. From former studies it is known that patients with liver cirrhosis suffer from 
severe infections and sepsis caused by bacteria originating from the normal gut flora 
(Wiest and Garcia-Tsao 2005; Steffen, Berg, and Deitch 1988). This case is 
comparable with the situation in CD. In both diseases commensals play a central role 
in the disease pathogenesis. Expression analyzes of different Paneth cell and non-
Paneth cell products could explain if the situation is similar to the one observed in 
ileal CD patients and shed light on the role of defensins and other AMPs in vivo. 
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2. MATERIAL AND METHODS 
2.1 Material  
2.1.1 Patient samples 
All healthy controls and patients included in the studies gave their written and 
informed consent after the study purpose, sample procedure, and potential 
adjunctive risks were clarified. The ethics committees of the Medical University 
Vienna, Austria, the University Hospital Tübingen, Germany and the University of 
Leuven, Belgium approved all studies. Subgrouping of included patient samples was 
done according to provided phenotype data, which was based on clinical, radiological, 
endoscopic and histopathological diagnoses at the respective IBD centres. Following 
the Vienna classification the patients were sub-grouped into three subgroups: 
patients who suffer from ileal disease only (L1), patients who suffer from colonic 
disease (L2) and patients that have ileocolonic disease (L3). 
2.1.1.1 Samples for mRNA expression analysis 
Tissue samples used for mRNA analysis were either part of the Stuttgart cohort 
or the Norwegian cohort. The Stuttgart cohort has been continuously collected at the 
Robert-Bosch Hospital, Stuttgart since 2001. Included patients and healthy controls 
were endoscoped for diagnostic reasons. Additional biopsies for study purposes were 
collected from the ileum, coecum, sigma and the rectum and immediately shock 
frozen and stored in liquid nitrogen. The Norwegian cohort comprises 36 pediatric 
patients with CD and 29 non-IBD controls (< 18 years (median age in the CD group: 
13.8 years, in the Non-IBD group: 12.2 years)) (all based in the catchment area). 
Sample collection that took place from May 2005 and December 2007 was part of a 
larger study in Inflammatory Bowel South-Eastern Norway (IBSEN-II) and 
investigated immunological, genetic and environmental factors, which can all 
contribute to the pathogenesis of IBD. Several biopsies were taken from different 
segments during endoscopy for histological evaluation. Histopathological analysis of 
an expert pathologist (Lars Gustav Lyckander) confirmed IBD diagnosis according to 
the Porto criteria. As Non-IBD controls served children with no evidence of IBD or 
mucosal inflammation (with final diagnoses of irritable bowel syndrome or recurrent 
abdominal pain). Terminal ileum and colon ascendens biopsies were obtained from 
36 patients with CD and from 29 non-IBD controls. If possible, biopsies were taken 
from non-inflamed mucosa but also from inflamed mucosa of IBD patients. 
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Altogether 15 small intestinal biopsies and 4 colonic biopsies were macroscopically 
inflamed. A pathologist performed histological grading of the taken biopsies. The 
degree of inflammation was determined differentiating between normal mucosa 
(score 0), no active inflammation (score 1), mild active inflammation (score 2), 
moderate active inflammation (score 3), and severe active inflammation staining 
(score 4). Classifying the patients with CD according to disease behaviour 30 
pediatric CD patients with a non-stricturing and non-penetrating disease type (B1) 
and 6 with stricturing behavior (B2) were available.   
2.1.1.2 Samples used in genetic analysis 
To analyse a potential association of genetic variants in the LRP5 gene, the 
distribution of 45 SNPs in patients with CD, UC and unrelated healthy controls were 
evaluated. The analyses comprised 3 Caucasian DNA cohorts (Vienna, Stuttgart and 
Leuven). DNA was isolated at the respective centres from whole blood via standard 
procedures and provided as either liquid or dried samples. Phenotyping data, which 
was collected in our institute, was used to classify and group the patients. To exclude 
effects due to differences between subgroups, subgrouping was performed according 
to criteria like age, gender, age of onset of disease, behaviour and involvement of 
small intestine (L1), colon (L2) or both (L3) and additional involvement of the upper 
gastrointestinal tract (L4). 
The Vienna and Leuven cohorts have been previously studied by our group and 
are described in more detail in Koslowski et al., 2012 . The Vienna cohort consists of 
~700 IBD patients (~200 ileal CD) which are compared to ~925 healthy blood donor 
controls from Stuttgart. The Leuven cohort consists of ~650 samples (300 controls 
and 350 IBD patients, including about 200 ileal CD cases). The DNA cohort from 
Stuttgart has been collected as part of a biobank assembly and measured ~500 
samples. These included 148 control patients, who underwent routine endoscopy, 163 
ileal CD (75 L1. 88 L3), 140 UC and 37 colonic CD patients. 
2.1.2 Animal models 
2.1.2.1 Tcf-1 knockout mice 
Tcf-1 knockout and wild type littermate mice with a C57BL6 background were 
kindly provided by the group of Prof. Staal from the Utrecht University, Netherlands. 
The knockout was described previously (Verbeek et al. 1995). The mice were kept in 
the Utrecht University shared animal facility according to government regulations. 
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Tissue samples from the proximal, middle and distal part of the small intestine from 
Tcf-1 -/- (n=6), +/- mice (n=6) and control Tcf-1 +/+ mice (n=6) was available.  
2.1.2.2 Rat models 
Liver cirrhosis and portal vain ligation rat model were kindly provided by the 
group of Prof. Wiest from the University Hospital Regensburg, Germany.  
All experimental procedures in this study were conducted according to the 
American Physiological Society principles for the care and use of laboratory animals 
and the local ethical committee approved the study. Tissue samples from the 
proximal, middle and distal part of the small intestine from rats with portal vain 
ligation (n=6) and healthy control mice (n=6) was analysed.  
2.1.2.2.1 Prehepatic portal hypertension rat model  
Induction of prehepatic portal hypertension (PVL): In order to examine 
whether the changes in antimicrobial peptide expression could be related to the 
phenomenon of portal hypertension per se the PVL model was chosen. This model is 
known to lack hepatic parenchymal cell damage as well as Kupffer cell dysfunction. 
Importantly, this PVL animal model is characterized by a high rate of bacterial 
translocation (BT) to mesenteric lymph nodes (MLN) at 2 days after PVL whereas in 
the chronic phase (two and more weeks after PVL) no BT is observed. Portal 
hypertension was induced surgically in aseptic conditions as it has been described 
before (Lopez-Talavera et al. 1996). Briefly, the rats (n=6) were anaesthetized with 
ketamine hydrochloride (Ketalar, 100 mg/kg body wt; Parke- Davis, Avon, CT, USA). 
After a midline abdominal incision, the portal vein was cleared from surrounding 
tissue. A ligature (silk gut 3-0) was placed around a 20-gauge blunt-tipped needle 
lying alongside the portal vein. Subsequent removal of the needle yielded a calibrated 
stenosis of the portal vein. In sham-operated rats, the same operation was performed 
with the exception that after isolating the portal vein no ligature was placed. After the 
operation, the animals were housed in plastic cages and allowed free access to rat 
food and water. All studies were performed in 12-18 h fasted animals 2 days after 
surgery. Tissue samples from the proximal, middle and distal part of the small 
intestine from rats with portal vain ligation (n=6) and healthy control mice (n=6) 
were analysed.  
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2.1.2.2.2 CCl4-induced liver cirrhosis rat model  
Cirrhosis was induced in male pathogen free CD rats (Charles River, 50-80 g 
initial weight) by inhalation of CCl4 along with phenobarbital (0.35 g/l) in the 
drinking water, as previously described (Wiest et al. 2003). CCl4 administration was 
started three times a week over one minute and increased every other week by one 
minute to a maximum of 5 minutes, depending on the animal’s change in body 
weight. After 12 to 16 weeks this approach induces micronodular liver cirrhosis with 
ascites. Seven days prior to experimental procedures application of CCl4 as well as 
phenobarbital was stopped. Only cirrhotic animals with decompensation of liver 
function and thus presence of ascites were used. Phenobarbital-treated age- and sex-
matched rats were used as control group. Tissue samples from the proximal, middle 
and distal part of the small intestine from rats with portal vain ligation (n=6) and 
healthy control mice (n=6) were analysed.  
2.1.2.2.3 Assessment of bacterial translocation 
Experiments were performed under strict sterile conditions. Ketamine 
hydrochloride (Ketalar, 100 mg/kg body weight) was used as anesthesia. Rats were 
shaved and the skin was disinfected with alcohol. After midline laparotomy, MLNs 
draining lymph from the terminal ileum, coecum, and ascending colon were 
subsequently dissected, removed, and weighed (E400D scale from Ohaus Corp., 
Florham Park, NJ; accurate to ++ 0.01 g). Liver and spleen tissue were also removed 
and weighed. MLNs, liver and spleen samples were diluted in phosphate-buffered 
saline (0.1 ml per 0.1 g), homogenized and 100 µl of suspension was cultured on 
MacConkey, Mueller-Hinton and whole blood agar for 48 hours. Bacterial growth was 
considered as evidence of BT to MLNs. To exclude bacteremia, 3 ml of blood was 
withdrawn from the vena cava inferior and inoculated into aerobic and anaerobic 
Bactec culture bottles, which were incubated at 35 °C; the growth value (measuring 
the bacterial CO2 production) was continuously monitored for at least 7 days. No 
bacterial growth was observed; confirming that this model of CCl4- induced liver 
cirrhosis does not present spontaneous bacteremia.  
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2.1.2.2.4 Histological examation 
Cross sections of the distal ileum, coecum and colon were fixed in 10% 
buffered formalin and stained with haematoxylin-eosin. To quantify the histological 
damage in intestinal tissue, a previously described scoring system was applied 
(Teltschik et al. 2012). Both the degree of inflammatory infiltrate and mucosal 
architecture were independently graded from 0 to 4 and the mean score was noted 
(figure 22). Histological analysis was performed in a blinded fashion. 
2.1.3 Consumables 
Table	1:	Consumables		
Antibodies	 	
Biotinylated	anti-rabbit	Ig	G	antibody	(goat)	 Vector,	Burlingame,	CA,	USA	
Horse-radish-peroxidase	 -labelled	 secondary	
antibody	
DAKO,	Glostrup,	Denmark	
LRP6	antibody	 ABGENT,	San	Diego,CA,	USA	
TCF-1	antibody	 Cell	signaling,	Danvers,	MA,	USA	
Chemicals	 	
3’-Diaminobenzidine	tetrahydrochloride	 DAKO,	Glostrup,	Denmark	
100bp	and	1kb	ladder		 Invitrogen	 Corporation,	 Carlsbad,	 CA,	
USA	
Agarose	(NEEO	ultra	quality)	 CARL	ROTH	GMBH	+	CO.	KG,	Karlsruhe,	
Germany	
Ampicillin	 Sigma-Aldrich	 Chemie	 GmbH,	
Steinheim,	Germany	
Bromophenol	blue	 Merck	KgaA,	Darmstadt,	Germany	
Chloroform	 CARL	ROTH	GMBH	+	CO.	KG,	Karlsruhe,	
Germany	
Cytoseal	 Thomas	Scientific,	Swedesboro,	NJ,	USA	
DMEM	(Dulbecco's	Modified	Eagle	Medium)	 Gibco,	Invitrogen,	Karlsruhe,	Germany	
Diethylpyrocarbonate	(DEPC)	 CARL	ROTH	GMBH	+	CO.	KG,	Karlsruhe,	
Germany	
Dimethylformamide	 CARL	ROTH	GMBH	+	CO.	KG,	Karlsruhe,	
Germany	
Dinatrium	salt	dihydrate	(EDTA)	 CARL	ROTH	GMBH	+	CO.	KG,	Karlsruhe,	
Germany	
EcoRI	time	saving	high	fidelity	restriction	enzyme/	
buffers	
New	 England	 Biolabs	 (NEB),	 Ipswich,	
MA,	USA	
EDTA	 CARL	ROTH	GMBH	+	CO.	KG,	Karlsruhe,	
Germany	
Ethanol	 CARL	ROTH	GMBH	+	CO.	KG,	Karlsruhe,	
Germany	
Ethidium	bromide		 Sigma-Aldrich	 Chemie	 GmbH,	
Steinheim,	Germany	
Ficoll	 Sigma-Aldrich	 Chemie	 GmbH,	
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Steinheim,	Germany	
Formaldehyde	 Sigma-Aldrich	 Chemie	 GmbH,	
Steinheim,	Germany	
Formamide	 Sigma-Aldrich	Chemie	GmbH,	
Steinheim,	Germany	
FuGENE	6	reagent	 Roche	 Diagnostics	 Deutschland	 GmbH,	
Mannheim,	Germany	
HCl	 CARL	ROTH	GMBH	+	CO.	KG,	Karlsruhe,	
Germany	
Isopropyl	alcohol	 CARL	ROTH	GMBH	+	CO.	KG,	Karlsruhe,	
Germany	
Ketamine	hydrochloride		 Parke-	Davis,	Avon,	CT,	USA	
Li	Chrosolv	water	 Merck	KgaA,	Darmstadt,	Germany	
Luria	Broth	medium	for	cultivation	in	falcons	 Sigma-Aldrich	 Chemie	 GmbH,	
Steinheim,	Germany	
Luria-Agar	for	plates	 Sigma-Aldrich	 Chemie	 GmbH,	
Steinheim,	Germany	
Lysis	buffer		 Promega	 Corporation,	 Madison,	 WI,	
USA	
MOPS	(C7H15NO4S)	 CARL	ROTH	GMBH	+	CO.	KG,	Karlsruhe,	
Germany	
NEO-CLEAR®	 Merck	KgaA,	Darmstadt,	Germany	
PBS	buffer	 Gibco,	Invitrogen,	Karlsruhe,	Germany	
Peroxidase	blocking	solution	 DAKO,	Glostrup,	Denmark	
Schaedler	broth	 Becton	Dickinson,	Sparks,	MD,	USA	
Sodium	actete	 CARL	ROTH	GMBH	+	CO.	KG,	Karlsruhe,	
Germany	
Sodium	hydroxide	(NaOH)	 Merck	KgaA,	Darmstadt,	Germany	
Sucrose	 CARL	ROTH	GMBH	+	CO.	KG,	Karlsruhe,	
Germany	
Sterile	nuclease	free	water	 Delta	Select,	Dreieich,	Germany	
Stop&Glow	 Promega	 Corporation,	 Madison,	 WI,	
USA	
Tris	 CARL	ROTH	GMBH	+	CO.	KG,	Karlsruhe,	
Germany	
Tris/EDTA	buffer	pH	9		 DAKO,	Glostrup,	Denmark	
TRIzol™		 Invitrogen	 Corporation,	 Carlsbad,	 CA,	
USA	
Tween	80	 Merck	KgaA,	Darmstadt,	Germany	
Unspecific	serum	from	a	pig	 Slaughterhouse,	Stuttgart	
X-Gal	 CARL	ROTH	GMBH	+	CO.	KG,	Karlsruhe,	
Germany	
Xylene	cyanol	 Merck	KgaA,	Darmstadt,	Germany	
Consumables	 	
50	ml	Centrifuge	Tube	 Corning	Incorporated,	Corning,	NY,	USA	
8-channel	pipettes	 Eppendorf	AG,	Hamburg,	Germany	
Anaero	GenTM	sachet	 Oxoid	Limited,	Hampshire,	UK	
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Anaerobe	indicator	 Oxoid	Limited,	Hampshire,	UK	
Columbia	blood	agar	Plates	 Becton	 Dickinson,	 Franklin	 Lakes,	 NJ,	
USA	
Cryo	tubes	 Nunc/Thermo	 Electron	 LED	 GmbH,	
Langenselbold,	Germany	
Cover	slip	 R.	 Langenbrinck,	 Emmendingen,	
Germany	
Eppendorf	tubes	(1.5.	2	ml,	Safe	look	tubes)	 Eppendorf	AG,	Hamburg,	Germany	
Genetic	analyzer	tubes	and	septa		 Applied	Biosystems,	Carlsbad,	CA,	USA	
Indicator	paper	 Macherey-Nagel	 GmbH	 &	 Co.	 KG,	
Düren,	Germany	
LightCycler®	480	Multiwell	Plates	96		 Roche	 Diagnostics	 Deutschland	 GmbH,	
Mannheim,	Germany	
Luminometer	tubes	 Sarstedt	 AG	 &	 Co.,	 Nümbrecht,	
Germany	
Multiflex	Round	Tips	 Sorenson,	Salt	Lake	City,	UT,	USA	
Object	plate	 R.	 Langenbrinck,	 Emmendingen,	
Germany	
Petri	dish	 Greiner	 Bio-One,	 Frickenhausen,	
Germany	
Pipet	tips:	epT.I.P.S	(different	sizes)	 Eppendorf	AG,	Hamburg,	Germany	
Pipet	tips:	Multiguard,	Barrier	Tips	(different	sizes)	 Sorenson,	Salt	Lake	City,	UT,	USA	
Pestle	 CARL	ROTH	GMBH	+	CO.	KG,	Karlsruhe,	
Germany	
RNase	AWAY®	 CARL	ROTH	GMBH	+	CO.	KG,	Karlsruhe,	
Germany	
RNase	free	reaction	tubes	 CARL	ROTH	GMBH	+	CO.	KG,	Karlsruhe,	
Germany	
safe	seal	tips	 Biozym	 Scientific	 GmbH,	 Hessisch	
Oldendorf,	Germany	
Scalpel	 Feather	Safety	Razor	Co,	Osaka,	Japan	
SpectroCHIP®	arrays	 Sequenom	 Industrial	 Genomics,	 San	
Diego,	CA	,	USA	
Ultrafiltration	NucleoFast®	96	PCR	manifolds	 Macherey-Nagel	 GmbH	 &	 Co.	 KG,	
Düren,	Germany	
Kits	and	Enzymes	 	
Avidin-biotin-blocking	Kit	 Linaris,	Dossenheim,	Germany	
Agilent	RNA	600	nano	Kit	 Agilent,	Santa	Clara,	CA,	USA	
AMV	Reverse	Transcription	System	Kit	 Promega	 Corporation,	 Madison,	 WI,	
USA	
Big	Dye	Terminator	V.1.1	Cycle	Sequencing	Kit	 Applied	Biosystems,	Van	Allen	Way,	CA,	
USA	
Dako	 REAL™	 EnVision™	 Detection	 System,	
Peroxidase/DAB+,	Rabbit/Mouse	
Dako,	Glostrup,	Denmark	
DharmaFECT®	Duo	Transfection	Reagent	 ThermoScientific,	Waltham,	MA,	USA	
Dual	Luciferase	Reporter	Assay	System	 Promega	 Corporation,	 Madison,	 WI,	
USA	
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EcoRI	 time	 saving	high	 fidelity	 restriction	enzyme	
and	buffers		
New	England	Biolabs,	Ipswich,	MA,	USA	
EnVision™+	System	Kit	 DakoCytomation,	Glostrup,	Denmark	
HotStarTaq®	PCR	Kit	 Qiagen	GmbH,	Hilden,	Germany	
iPLEX™	Gold	assay	for	SNP	Genotyping	 Sequenom	 Industrial	 Genomics,	 San	
Diego,	CA,	USA	
LightCycler®	480	SYBR	Green	I	Master		 Roche	 Diagnostics	 Deutschland	 GmbH,	
Mannheim,	Germany	
QIAamp	DNA	Blood	Mini	Kit		 Qiagen	GmbH,	Hilden,	Germany	
QIAprep	Spin	Miniprep	Kit	 Qiagen	GmbH,	Hilden,	Germany	
QIAquik	PCR	Purification	Kit	 Qiagen	GmbH,	Hilden,	Germany	
RNeasy	Mini	Kit	 Qiagen	GmbH,	Hilden,	Germany	
TOPO	TA	Cloning	Kit	 Invitrogen	 Corporation,	 Carlsbad,	 CA,	
USA	
Laboratory	equipment	 	
ABI	Prism™	310	Sequencer	 Applied	Biosystems,	Carlsbad,	CA,	USA	
Bio	Photometer	 Eppendorf	AG,	Hamburg,	Germany	
Centrifuge	5415D		 Eppendorf	AG,	Hamburg,	Germany	
CL-	GS6R	Beckman	Coulter	Centrifuge	 Beckman	Coulter,	Inc.,	Brea,	CA,	USA	
Compact	Analyzer	 Sequenom	 Industrial	 Genomics,	 San	
Diego,	CA,	USA	
Consort	Electrophoresis	Power	Supply	 Sigma-Aldrich	 Chemie	 GmbH,	
Steinheim,	Germany	
Electrophoresis	chamber	B1A		 Peqlab,	PEQLAB	Biotechnologie	GMBH,	
Erlangen,	Germany	
Gradient	cycler	 MJ	Research	now	Bio-Rad	Laboratories,	
Hercules,	CA,	USA	
Leica	DM	4000	B	microscope		 Leica	Microsystems,	Wetzlar,	Germany	
LightCycler®	480	Real-Time	PCR-System	 Roche	 Diagnostics	 Deutschland,	
Mannheim,	Germany	
Liquid	nitrogen	tank	 Messer	 Industriegase	 GMBH,	 Bad	
Soden,	Germany	
Luminometer	AutoLumat	Plus	 Berthold	 technologies,	 Bad	 Wildbad,	
Germany	
MassARRAY®	Nanodispenser		 Sequenom	 Industrial	 Genomics,	 San	
Diego,	CA,	USA	
MassARRAY®	Compact	Analyzer	 Sequenom	 Industrial	 Genomics,	 San	
Diego,	CA,	USA	
NanoDropTM	2000	 NanoDrop,	Wilmington,	DE,	USA	
PTC-225	Peltier	Thermal	Cycler	 MJ	Research	now	Bio-Rad	Laboratories,	
Hercules,	CA,	USA	
UV	 table	 and	 camera	 for	 the	 documentation	 of	
electrophoresis	gels	
Cybertech,	Berlin,	Germany	
Veriti	384well	PCR	Thermal	cycler	 Applied	Biosystems,	Carlsbad,	CA,	USA	
Video	Monitor	WV-	BM	900	 Panasonic,	Secaucus,	New	Jersey,	USA	
Software	 	
Cell	Quest	Software	 Becton	 Dickinson,	 Franklin	 Lakes,	 NJ,	
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USA	
Geneious	pro	V.4.8.5	 Biomatters	Ltd,	Auckland,	New	Zealand	
GraphPad	Prism	Ver.	4.0	 GraphPad	 Software,	 Inc.,	 La	 Jolla,	 CA,	
USA	
Haploview	 Broad	Institute,	Cambridge,	MA,	USA	
Leica	Application	Suite	V4	 Leica	Microsystems,	Wetzlar,	Germany	
Light	Cycler	Software	V.3.5	 Roche	 Diagnostics	 Deutschland	 GmbH,	
Mannheim,	Germany	
Primer3	(freely	available	software)	 Steve	 Rozen	 and	 Helen	 J.	 Skaletsky	
(2000)	(http://primer3.wi.mit.edu/)	
Sequenom	software	SpectroTYPER	 Sequenom	 Industrial	 Genomics,	 San	
Diego,	CA,	USA	
Test	 for	 deviation	 from	 Hardy-Weinberg	
equilibrium/	association	(freely	available	software)	
Helmholtz	 Institute	 Munich	
(http://ihg.gsf.de/cgi-bin/hw/hwa1.pl)	
2.1.4 Media and buffers 
50x TAE buffer 
Used for the preparation of electrophoresis gels/ while electrophoresis in chambers. 
242 g Tris 
57 ml glacial acetic acid 
100 ml 0.5M EDTA (pH 8.0) 
add 1 l nuclease free H2O 
 
6x sample buffer  
Used for gel electrophoresis 
40 g sucrose 
0.25 g bromophenol blue or xylene cyanol 
50 ml H2O (aqua dest.) 
 
Haemalm: 
Needed for counterstaining of nuclei. 
1 g C16H14O6 (Haematoxylin)  
1 l H2O (aqua dest.) 
0.2 g NaJO3 (Natrium iodate) 
50 g KAl(SO4)2 (Potassium alum) 
50 g C2H3Cl3O2 (Chloral hydrate) 
1 g C6H8O7 (Citric acid)    
Stirring for 14 days on a magnetic mixer  
 
LB-medium 
Used for bacteria breeding. 
20 g lysogeny (Luria) broth 
500 ml H2O (aqua dest.)  
0.5 ml ampicillin solution 
LB-medium for agar plates 
Used for plating bacteria and selection of bacteria colonies carrying the desired 
plasmids. 
40 g luria agar 
1 l H2O (aqua dest.)  
Autoclaving and subsequent cooling down to 60°C 
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1 ml ampicillin solution (100 mg ampicillin/1ml Millipore H2O) 
Before utilization for plating: treating of the hardened LB with 200 µl X-Gal solution  
(40 mg/ml dimethylformamide) for blue-white selection. 
 
Phloxine staining solution: 
Used for staining of Paneth cells. 
0.5 g Phloxine B 
0.5 g of CaCl2 (Calcium chloride) 
100 ml H2O (aqua dest.) 
 
Washing buffer: 
Used for washing steps in immunohistochemical staining.  
0.15 M NaCl (Sodium chloride) in 5mM Tris-buffer+ 0.1% Tween 80, pH 7.6 
For 2 l: 
NaCl  M= 58.44 g/mol 
Set: 0.15 M NaCl ! 17.532 g  
Tris M= 121.14 g/mol 
Set: 0.15 M Tris ! 121.14/1000x2x5 = 1.2114 g 
0.1% Tween 80 ! 2 ml  
Fill up to 2 l, adjust pH with HCl (Hydrochloric acid) 
Store at 4°C  
 
Primer and plasmids: 
Primers are listed in table 2. The plasmids used as standards for calculating mRNA 
copy numbers were constructed using the PCR2.1-TOPO vector further described 
under 2.2.2.3 and the PCR products generated with the listed primers (table 2). 
 
	
Table	2:	forward	and	reverse	primer	used	for	qPCR	and	sequencing	
Primers	were	designed	with	freely	available	Primer3	software	(http://primer3.wi.mit.edu/).	
Gene	 Sense	5´-3´	 Antisense	5´-3´	 Product	size	(bp)	
HUMAN	 		 		 		
β-actin		 GCC	AAC	CGC	GAG	AAG	ATG	A	 CAT	CAC	GAT	GCC	AGT	GGT	A	 120	
LRP-5	 ACA	ACG	GCA	GGA	CGT	GTA	AG	 GTC	CAG	CGA	GAT	CCT	CCG	TA	 82	
LRP-6	 TGC	CAT	TGC	CAT	AGA	TTA	C	 CCA	TTG	AGC	CTT	GTC	ACT	TC	 219	
TCF-1	iso	1	 ACG	AGC	TGC	TGG	CCT	TC	 GTG	GGT	AAT	GCA	TGA	GCA	GA	 336	
TCF-1	 CTC	ATA	AGT	TGG	ACC	AGA	GGA	AG	 GGC	GGA	CTG	AAT	GCT	GAA	AGA	 429	
HD-5	 	GCC	ATC	CTT	GCT	GCC	ATT	C	 	AGA	TTT	CAC	ACA	CCC	CGG	AGA	 	241	
HD-6	 	CCT	CAC	CAT	CCT	CAC	TGC	TGT	TC	 	CCA	TGA	CAG	TGC	AGG	TCC	CAT	A	 	266	
MOUSE	 		 		 		
β-actin	 GCT	GAG	AGG	GAA	ATC	GTG	CGT	G	 CCA	GGG	AGG	AAG	AGG	ATG	CGG	 100	
Defa24	 CAA	GAG	GCT	GCA	AAG	GAA	GAG	AAC	 TGG	TCT	CCA	TGT	TCA	GCG	ACA	GC	 93	
Defa21	 CCA	GGG	GAA	GAT	GAC	CAG	GCT	G	 TGC	AGC	GAC	GAT	TTC	TAC	AAA	GGC	 112	
CRS-1C	 CAC	CAC	CCA	AGC	TCC	AAA	TAC	ACA	G	 ATC	GTG	AGG	ACC	AAA	AGC	AAA	TGG	 92	
Lysozyme	 GCC	AAG	GTC	TAC	AAT	CGT	TGT	GAG	TTG	 CAG	TCA	GCC	AGC	TTG	ACA	CCA	CG	 86	
TCF-1	 CCA	GGA	CTC	ACC	CTC	GT	 TTC	TGT	GCC	TAG	CAA	CCA	A	 220	
Reg3γ	 TTC	CTG	TCC	TCC	ATG	ATC	AAA	A	 CAT	CCA	CCT	CTG	TTG	GGT	TCA	 101	
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RAT	 		 		 		
rβ-actin		 GCT	GAG	AGG	GAA	ATC	GTG	CGT	G	 CCA	GGG	AGG	AAG	AGG	ATG	CGG	 100	
cryptdin	5		 GAC	CAG	GTT	GTT	TCT	GTC	TCC	ATT	G	 TGA	GGC	TTC	CGT	ATC	TCT	TGT	TGC	 152	
cryptdin	7		 AGC	AAC	CAT	CAG	ATG	AGG	ACC	AGG	 ACC	TTG	AGC	ACA	GAA	CGC	AGT	GG	 158	
rHIP/PAP	3		 CCA	AGA	ACC	CAA	CAG	AGG	TGG	ATG	 GGT	CCC	ACA	GTG	ACT	TCC	AGA	GAC	AG	 106	
r-lysozyme		 CAA	GCC	ATA	CAA	TGT	GCG	AAG	AGA	G	 TGT	TGG	TTT	GAG	GGG	AAA	GCA	AG	 220	
rBD1		 TCT	GGA	CCC	TGA	CTT	CAC	CGA	C	 TCT	TCA	AAC	CAC	TGT	CAA	CTC	CTG	C	 246	
rBD2		 TTT	CTC	CTG	GTG	CTG	CTG	TCG	C	 CCA	CAA	GTG	CCA	ATC	TGT	CGA	AAA	C	 131	
rCRAMP		 TGC	CTC	TAA	CCG	TTT	CCC	AGA	CC	 TGC	TCA	GGT	AAC	TGC	TGT	GAT	GCC	 214	
rNP3		 TTT	GGA	GGG	GAT	AAA	GGC	 	TCA	GCA	ACA	GAG	TCG	GTA	 147	
SEQUENCING	 		 		 		
T7	 TAA	TAC	GAC	TCA	CTA	TAG	GG	 		 		
M13	 CAG	GAA	ACA	GCT	ATG	ACC	 		 		
LRP5	tf	
plasmide	1	 CTC	GTT	CCG	GCA	GAA	GGT	 		 		
LRP5	tf	
plasmide	2	 ATG	GGC	CTC	ATG	TAC	TGG	AC	 		 		
LRP5	tf	
plasmide	3	 CGA	GTG	TGC	CAA	CTT	GGA	T	 		 		
LRP5	tf	
plasmide	4	 CAC	AGG	ATC	TCC	CTC	GAG	AC	 		 		
LRP5	tf	
plasmide	5	 CTG	CGC	CTC	ACA	CTA	CAC	C	 		 		
LRP5	tf	
plasmide	6	 GAA	CGT	CAA	AGC	CAT	CGA	CT	 		 		
LRP5	tf	
plasmide	7	 CTG	GAG	GAC	GCC	AAC	ATC	 		 		
LRP5	tf	
plasmide	8	 AGA	CTG	TCA	GGA	CCGC	TCA	G	 		 		
 
2.2 Methods  
2.2.1 Staining methods 
2.2.1.1 Immunohistochemistry 
LRP6 immunohistochemical staining was performed using the two-step 
immunoperoxidase EnVision technique. Human small intestinal tissue was fixed in 
buffered formalin and embedded in paraffin. Embedded tissue was cut in 3 µm 
sections, dewaxed with NEO-CLEAR® for 30 min and rehydrated in a graded alcohol 
series (100%-96%-70% (each step for one minute)) and subsequently rinsed in water. 
Slides were heated for 30 minutes in a steam cooker for antigen retrieval (pH 9) using 
a Tris/EDTA buffer pH 9, washed in water and endogenous peroxidase was blocked 
with peroxidase blocking solution. Subsequently slides were incubated for 1 hour with 
the primary anti-LRP6 antibody diluted 1:100 in TBST (20 mM Tris-Base (pH 7.4), 
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0.14 M NaCl, 0.1% Tween 20). Slides were washed in washing buffer and water and 
the horse-radish-peroxidase -labelled secondary antibody visualized the LPR6 
protein. The secondary antibody was detected with 3’-diaminobenzidine 
tetrahydrochloride. Slides were washed with washing buffer and water and 
counterstained with hematoxylin (10 sec). Afterwards they were exposed to ascending 
alcohol series (70%- 96%- 100% (each step for one minute)) and mounted with 
Cytoseal. Sections were evaluated by light microscopy. 
2.2.1.2 Avidin-Biotin-Complex (ABC) method:  
Immunohistochemistry was performed using the EnVision™+ System Kit. 
Human small intestinal tissue was fixed in buffered formalin and embedded in 
paraffin. Embedded tissue was cut in 3 µm sections, dewaxed with NEO-CLEAR® for 
30 min and rehydrated in a graded alcohol series (100%-96%-70% (each step one 
minute)) and subsequently rinsed in water. Endogenous peroxidase was blocked with 
peroxidase blocking solution. Unspecific reactions were blocked with unspecific 
serum from a pig (purchased directly from the slaughterhouse, Stuttgart). After every 
blocking step slides were rinsed with water. Slides were subjected to antigen retrieval 
in a steam cooker using a Tris/EDTA buffer pH 9. Slides were rinsed in washing 
buffer and subsequently in water. Endogenous biotin was blocked with an avidin-
biotin-blocking-kit and subsequently rinsed with washing buffer and water. As 
primary antibody, the monoclonal TCF-1 antibody was used in a dilution 1:100 and 
incubated over night. Slides were rinsed with washing buffer and water and the 
biotinylated secondary antibody was incubated for 30 min. Slides were rinsed in 
washing buffer and water and ABC complex was incubated for 30 min. Subsequently 
slides were washed and DAB staining was performed (10 min). Slides were rinsed in 
water for 5 min. Counterstaining was performed with hematoxylin (10 sec). Slides 
were exposed to ascending alcohol series (70%- 96%- 100%) and mounted with 
Cytoseal. Sections were evaluated by light microscopy. 
2.2.1.3 Phloxine-tartrazine Staining 
Phloxine-tartrazine staining solution should not be older than two weeks. 
Human small intestinal tissue was fixed in buffered formalin and embedded in 
paraffin. Embedded tissue was cut in 3 µm sections, dewaxed with NEO-CLEAR® for 
30 min and rehydrated in a graded alcohol series (100%-96%-70% (each step for one 
minute)) and subsequently rinsed in water. Slides were incubated with Haemalm for 
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5 min to stain the nuclei, after a 5 min wash in water the slides were incubated with 
the phloxine staining solution for 30 min. Slides were shortly washed in water 
(phloxine is water soluble) and then washed in 2-ethoxyethanol. Stripping was 
performed for 10 to 15 min in tartrazine (2.5 g of tartrazine in 100 ml in NEO-
CLEAR®). Slides were rinsed and mounted with Cytoseal and sections were 
evaluated by light microscopy. Paneth cells appear in red/pink. 
2.2.2 Molecular biological methods 
2.2.2.1 RNA isolation, quantitative and qualitative analysis of isolated 
RNA, cDNA synthesis and real-time PCR 
Because RNA is very sensitive to enzymatic or spontaneous hydrolysis, all RNA 
handling steps were performed with RNase-free materials. It is recommended to 
clean the workplace with isopropyl alcohol and RNase-away. RNA isolation was 
performed according to the manufacturer’s protocol with the principle of acidic 
phenol/ chloroform partitioning of RNA into an aqueous supernatant: Frozen 
biopsies were pestled in liquid nitrogen and lysed in 100µl TRIzol™. TRIzol™ 
contains guanidinium isothiocyanate as a powerful protein denaturant for the 
inactivation of RNases.  
After incubation for 10 min at RT, 200 µl of chloroform was added to the 
tissue- TRIzol™ mix. After another incubation for 3 min at RT and centrifugation 
(4°C and 11.6 rpm) 3 phases could be defined: one colour-less aqueous top phase 
containing RNA, a middle, grey DNA interphase and a red, organic, phenol-
chloroform phase at the bottom containing lipids and proteins. The RNA containing 
phase was transferred into a Dolphin Eppendorf tube. Using 99.7% isopropyl alcohol 
RNA was precipitated, washed with 75% ethanol, dried and subsequently dissolved in 
25µl 0.1% DEPC aqua dest., and stored at –80°C. Concentration of RNA was 
determined photometric with NanoDrop 2000 spectrophotometer and a quality 
check was performed with Agilent RNA 600 Nano kit and the Agilent 2100 
bioanalyzer according to the manufacturer’s protocol. 
RNA isolated from cell culture experiments was extracted with the RNeasy 
Mini Kit according to the manufacture’s protocol. Briefly cells were washed and lysed 
with RLT buffer. Subsequently the homogenate was centrifuged in the QIAshredder 
columns. To provide ideal binding conditions, ethanol was added to the lysate. The 
lysate was then loaded onto an RNeasy silica membrane and centrifuged. A DNase 
digestion step with DNase1-RDD buffer mix was performed. After a washing step 
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with RPE buffer RNA was eluted with RNase-free H2O and stored at -80°C.  
Total RNA was transcribed into cDNA with oligo (dT) primers and AMV- 
reverse transcriptase (RT) according to the manufacturer’s protocol. Briefly 1 µg of 
total RNA was diluted to achieve a volume of 9.75 µl and incubated for 10 min at 70°C 
to linearize possible double strands. After adding 10.75 µl of a mix containing 
reaction agents according to the manual, the reaction was cycled for 15 min at 42°C 
and then for 5 min 95°C in a thermocycler PTC-200. Nuclease-free water was added 
to achieve an end volume of 100 µl. cDNA was stored at -20°C and used for the 
analysis with quantitative real time polymerase chain reaction (qRT-PCR) in the 
LightCycler 480 using primers, listed in table 2 for the different gene products and 
normalised to the house-keeping gene β-actin.  
The real-time PCR relies on the same principles, like a common PCR, but it 
enables quantification of the PCR product with the help of a fluorescent dye. The 
LightCycler480 system uses SybrGreen, which can intercalate with double-stranded 
DNA and therefore quantify the amount of new synthesised DNA via the increase of 
emitted fluorescence. So it is possible to continuously monitor cycle by cycle 
accumulation of the fluorescently labelled PCR product. cDNA corresponding to 10 
ng of RNA served as a template in a 10 ml reaction containing 4 mM MgCl2. 0.5 mM 
of each primer and LightCycler-FastStart DNA Master SYBR Green I mix. Samples 
were loaded into 96-well plates and incubated in the LightCycler 480 with different 
cycle programs, depending on the individual melting temperature of the used primer 
pairs (see below). Quantification of the single PCR products and analysis of the 
standard curves obtained for each primer set (1 ng to 10-7 ng, in 1:10 dilution steps of 
DNA) was performed using LightCycler Software.  
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Table	3:	Run	templates	for	LightCycler480	 
denaturation	 amplification	 melting	 products	
95	 95-60-72	 95-65-95	 rBD1,	rCrypt5,	rCrypt7,	rHIP/PAP3,	lysozyme,	rNP3,	rBD1,		
10	min	 1s	-	10s	-	∞	 1s	-	10s	-	∞	 rBD2,	rβ-actin,	rCRAMP,	rRELM,	rPSP,	β-actin,	mReg3y	
96	 96-62-72	 95-60-95	 mTCF-1,	m-lysozyme,	mβ-actin,	mCRS-1c,	LRP6	
5	min	 10s	-	5s	-	15s	 1s	-	15s	-	∞	 		
97	 96-64-72	 95-62-95	 LRP5	
5	min	 10s	-	5s	-	15s	 1s	-	15s	-	∞	 		
96	 96-60-72	 95-58-95	 TCF-1	
5	min	 10s	-	5s	-	15s	 1s	-	15s	-	∞	 		
96	 96-58-72	 95-56-95	 panCrypt	
5	min	 10s	-	5s	-	15s	 1s	-	15s	-	∞	 		
97	 96-64-72	 95-62-99	 mDef21,	mDefa24	
5	min	 10s	-	5s	-	15s	 1s	-	15s	-	∞	 		
99	 99-62-72	 99-60-99	 TCF-1	isoform	1	
5	min	 10s	-	5s	-	15s	 1s	-	15s	-	∞	 		
95	 95-66-72	 95-65-95	 HD-5,	HD-6	
5	min	 10s	-	5s	-	10s	 1s	-	15s	-	∞	 		
 
2.2.2.2 DNA analysis from whole blood 
Whole blood DNA from healthy controls and patients with IBD was isolated 
according to the manufacturer's protocol using the DNA blood purification kit 
(Qiagen GmbH Germany, 40724 Hilden, Germany). 
2.2.2.3 Plasmid construction and restriction enzyme digestion 
To evaluate expression levels of mRNA isolated from patient samples, plasmids 
to create standard curves were constructed. For amplification the primers listed in 
table 2 and HotStarTag DNA Polymerase according to manufacturer's protocol were 
used. cDNA samples from healthy control patients served as template. Product size 
and quality was confirmed with an agarose gel (1% agarose in 1x TAE buffer, 2 drops 
ethidium bromide), purified with the QIAquick PCR Purification Kit and 
concentration and quality was checked with the Agilent RNA 600 nano kit and the 
Agilent 2100 bioanalyzer. Subsequently the PCR product was incorporated in a 
PCR2.1-TOPO vector and the construct was transformed in TOP 10 E. coli cells 
described in the manufactures protocol (TOPO TA Cloning kits). Transformation 
solution was plated on LB ampicillin agarose plates. To identify clones carrying the 
inserted plasmid, plates were coated with 40 µl X-Gal solution (40 mg X-Gal/ml N,N-
dimethylformamide). After over night incubation (37°C) blue (due to vector religation 
44	 MATERIAL	AND	METHODS	
 
 
the β-Galactosidase could convert the X-Gal) and white colonies (due to DNA 
insertion in the vector enzymatic degradation of X-Gal was impossible) were visible. 
White colonies were picked and incubated in 5 ml LB medium (with ampicillin (1 
µl/ml)) over night (37°C). Isolation of plasmid DNA was performed using the 
QIAprep spin Miniprep kit according to manufactures protocol: cells were lysed and 
DNA was denatured with basic buffer. After adding neutralization buffer the DNA 
was centrifuged to eliminate the remaining cellular parts. To achieve higher purity, 
the DNA bound in the column was washed twice and subsequently eluted with 
nuclease-free H2O. Concentration was determined with the Spectrophotometer 
NanoDropTM 2000. To confirm the correct plasmid size, the plasmids were digested 
with the restriction enzyme EcoRI: 500 ng plasmid DNA and 2 µl NEB buffer was 
filled up to a volume of 17 µl with nuclease-free H2O and incubated (1 h, 37°C). 
Subsequently xylen-cyanol buffer was added and an agarose gel (1% agarose in 1x 
TAE buffer, 2 drops ethidium bromide) was used to visualise the plasmid sizes. 
Plasmids showing the right size were sequenced. 
2.2.2.4 Primer 
Primer used for the construction of plasmid standards, sequencing and real-
time PCRs were designed using freely available Primer3 online software and are 
purchased from Eurofins MWG Operon (Ebersberg, Germany). Primers used for 
genotying are designed using the LRP5 reference sequence NT 033903, listed in the 
SNPdb (NCBI) and the specialized MassARRAY® Assay Design Software. These 
primers were purchased from Metabion International AG. All primers are listed in 
table 2. 
2.2.2.5 Sequencing of plasmid standards and the LRP5 cell culture 
overexpression plasmid 
Constructed plasmids were sequenced with the ABI Prism™ 310 Sequencer 
and the BigDye Terminator v1.1 Cycle Sequencing Kit to confirm the correctness of 
the sequences. The ABI sequencer works with the chain termination method (Sanger 
et al., 1977). Sequencing PCR was performed according to the manufacturer’s 
protocol. Primers T7 and M13 (sequences listed in table 2) which are binding 5´ of 
the LRP5 insert, in the insert and 3´ of the insert were used for sequencing of plasmid 
standards. For cell culture overexpression plasmids, the according primers were used 
(see table 2). DNA was precipitated, washed and solved in nuclease-free H2O. After 
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electrophoresis the chromatograms were analysed with the Geneious software 
(Biomatters, Auckland, New Zealand) and compared to reference sequences available 
at the NCBI (US National Library of Medicine National Institutes of Health) database 
homepage. 
 
Sequencing PCR 
96°C  1 min 
96°C  10 sec 
50°C  5 sec  24 cycles 
60°C  4 min 
12°C  10 min 
	
	
Table	4:	pipetting	scheme	for	sequencing	reaction	
Ready	Reaction	Premix	1.1	 2	µl	
Big	Dye	Sequencing	Buffer	 1	µl	
Primer	forward	or	reverse	(3.2pmol)	 1	µl	
DNA	template	 x	µl	(50	ng)	
Nuclease-free	H2O	 fill	up	to	10	µl	
 
2.2.2.6 Genetic analysis  
2.2.2.6.1 SNP selection in the candidate gene LRP5 
Our group could formerly show that a rare variant of a coding single nucleotide 
polymorphism (SNP, figure 4) in the LRP6 gene is associated with early onset of ileal 
CD (Koslowski et al. 2012). In the present study focus was on its highly homogous co-
expressed receptor LRP5 as a potential new factor in the development of ileal CD. 
Criteria for including SNPs were already described associations with other diseases 
(e.g. osteoporosis, increased fracture risk and familial exudative vitreoretinopathy), 
which were found in the NCBI database (SNPdb), coding SNPs which could influence 
protein stability and function and to further analyse the gene SNPs in the 3´- and 5´-
region of the LRP5 gene were included. Additionally it was tried to cover the major 
haplotypes with Tag SNPs, which should predict the values of the remaining SNPs. A 
haplotype describes a collectively inherited and transmitted group of alleles. They can 
be used to discriminate between cases and controls in association studies and are 
necessary for linkage analysis. Location of Tag SNPs is primarily based on the 
principle of linkage disequilibrium (LD).  If two SNPs are in LD there is a strong 
correlation between the alleles of these SNPs. LD describes the fact that two alleles in 
one population located at two or more gene loci occur non-randomly more often or 
less frequently as expected due to their individual allele frequency (Abdallah et al. 
46	 MATERIAL	AND	METHODS	
 
 
2003). Two statistical measures are used to describe the level of LD: D´ (deviation) is 
the difference between the observed and the expected frequency of one haplotype. LD 
intensity can be tested with D´: D´= 0 if the loci are in linkage equilibrium. If the loci 
are in linkage disequilibrium, then D´≠ 0. The correlation between two loci is 
described with r2. r2 = 0 indicates that two loci are in complete linkage equilibrium 
and r2= 1  that the two loci are in complete linkage disequilibrium (Slatkin 2008). For 
selecting Tag SNPs the Tag-SNP picker function of the International HapMap Project 
homepage was used. This “Tagger” software, which is online available was developed 
by Paul de Bakker at the Center for Human Genetic Research of Massachusetts 
General Hospital, the Harvard Medical School and the Broad Institute (USA). Tag 
SNP selection was based on the CEU genotyping data which is freely available online 
on the HapMap homepage (www.hapmap.org), since all included study samples 
where patients and controls with a Caucasian background. Criteria additionally used 
for the SNP selection were a minor allele frequency cut off of 0.15 and an r2 cut off of 
0.8.  
To ensure similar GC contents, the primer sequences were adjusted with 
preceding 5’ ACG TTG GAT G 3’ sequences. The manufacturer purified the primers by 
HPLC, desalted and scaled them at 0.04 µmol. 
 
Figure	4:	Single	nucleotide	polymorphism	(SNP):	
Schematic	 illustration	of	2	DNA	strains	with	differing	base	pairs:	 Left	 side:	 the	major	allele	has	A/T	
and	at	the	same	position	the	other	strand	(right	side)	is	carrying	the	SNP	and	has	C/G.	SNPs	can	be	
synonymous	 (non	 coding,	 silent)	 and	 therefore	 lie	 outside	 a	 coding	 exon	 or	 non-synonymous	 and	
therefore	 resulting	 in	 a	 different	 amino	 acid	 after	 translation	 and	 lie	 inside	 a	 coding	 gene	 region	
(exon).	If	a	SNP,	which	is	lying	in	a	coding	region	leads	to	a	deletion	or	insertion	of	a	single	nucleotide	
it	 can	cause	a	 frame	shift	and	 thereby	alter	 the	 transcription	of	 the	affected	gene	 (Teltschik	et	al.,	
unpublished).	
 
2 µl DNA was pipetted in 384 well plates and dried overnight. Mastermix was 
mixed containing all needed primers and pipetted in a 96-well plate. 5 µl of the 
mastermix was added to the dried DNA and materials from the Sequenom iPLEX® 
Gold Kit were used according to the manufacturer’s protocol. ~ 100bp fragments 
including the particular SNP were assembled with a Multiplex-PCR using the 
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HotStarTaqTM Master Mix according to the manufacturer’s protocol and verified via 
gel electrophoresis. To verify the quality of the PCR products control samples were 
verified on a 3% agarose gel. The next step was a shrimp alkaline phosphatase (SAP) 
cleaning step to inactivate not incorporated remaining dNTPs. Patient samples were 
treated with the reaction mix and subsequently exposed to SAP reaction (table 6). 
Primer elongation (PEX reaction) was performed (for PCR conditions see below). The 
assay was designed in a way that the same conditions could be used for all primers, 
which are specifically designed and incorporated in a single termination mix 
(MassEXTEND®). This allows the detection of differences in mass at a single 
nucleotide level. 
Patients from Leuven, Vienna and Stuttgart via MALDI TOF MS (matrix 
assisted laser desorption/ionisation time of flight mass spectrometry) were 
genotyped. This method enables analysis of single base polymorphisms (SNPs) in the 
genome (Griffin, Tang, and Smith 1997; Ross et al. 1998). A first primer elongation 
step was performed. For that step an extension primer was used which bound directly 
in front of the examined SNP in the PCR product. The reaction itself was carried out 
with three dideoxynucleotides which cannot be elongated after insertion and one 
deoxynucleotide (Sanger, Nicklen, and Coulson 1977). Because of the use of this 
reaction mix every extension primer can be elongated for one or two bases. Allele- 
specific DNA fragments with different lengths were generated.  
 To eliminate cationic molecules, which could disturb the MALDI TOF MS 
reaction a PEX reaction clean- up step with 6 mg Resin (Sequenom Industrial 
Genomics, San Diego, CA, USA) was performed. Nucleic acids show high affinity to 
alkaline and alkaline earth metal ions. Without this clean-up step additional signals 
would occur and disturb the MALDI TOF MS reaction. After adding 15 µl nuclease-
free H2O the plates were closed and shaken for 20 min subsequently they were 
centrifuged for 20 min (1300 rpm) and then spotted on SpectroCHIP® arrays 
utilizing the MassARRAY® Nanodispenser and analysed in the MALDI TOF MS 
mass spectrometer which can detect the masses and therefore the correlating 
genotype in real time. Analysis of the results, which were automatically loaded in a 
special database, was performed with the Sequenom software, which can 
automatically translate the masses of the single products into genotypes. 
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Table	5:	Multiplex	PCR	reagents		
(DNA	was	previously	dried	in	384	well	plates	and	primers	for	each	assay	were	previously	mixed)	
Reagent	 Amount	per	well	
HotStarTaq	Master	Mix	 4	μl	
Primer	for	(100.0	μM)	 0.005	μl	each	
Primer	rev	(100.0	μM)	 0.005	μl	each	
MgCl2	(25mM)		 0.3	μl	
DNA	(dried)	 ~	10ng	
Nuclease-free	H2O	 Add	5	μl	
	
Table	6:	Reagents	for	SAP	clean-	up	step	
Reagent	 	Amount	per	well	
Nuclease-	free	H2O			 1.53	μl	
SAP		 0.3	μl	
10	x	buffer	 0.17	μl	
	
Table	7:	Multiplex	PEX	reagents	mix	(primers	for	each	assay	were	previously	mixed)	
Reagent	 Amount	per	well	
iplex	buffer	 0.2	μl	
iplex	termination	mix	0.2	μl	 0.2	μl	
Pex	Primer	(500.0	μM)	 0.0112	μl	each	
iplex	enzyme	 0.041	μl	
Nuclease-	free	H2O			 Add	2	μl	
 
Thermocycler conditions for each reaction for preparation of PCR constructs for 
MALDI-TOF MS (MassARRAY® Compact System (Sequenom, San Diego, CA, USA)) 
 
Multiplex- PCR 
Initiation  95°C 15 min 
Denaturation 95°C 30 sec 
Annealing  56°C 60 sec         45 cycles 
Elongation  72°C 60 sec     
Final elongation 72°C 10 min 
Cooling  12°C ∞ 
SAP clean- up step 
1. Incubation  37°C 20 min 
2. Incubation 85°C 10 min 
Cooling  12°C ∞ 
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PEX reaction 
Initiation  95°C 4 min 
Denaturation 99°C 30 sec              
Annealing  52°C 30 sec      56 cycles 
Elongation  72°C 30 sec    
Final elongation 72°C 2 min 
Cooling  12°C ∞ 
2.2.3 Cell culture 
2.2.3.1 Co-transfection 
To analyse LRP5 and 6 effects on their potential target genes HD-5 and HD-6 
cell culture experiments in HEK-293 cells were performed. A dominant negative and 
an active form of LRP6, which was co-transfected with either 1kb of the HD-5 or the 
HD-6 promoter was used. Béatrice Romagnolo and Pauline Andreu kindly provided 
the HD-5 and HD-6 luciferase reporter constructs which were described previously 
(Andreu et al. 2005). LRP5 and LRP6 expression plasmids were generously provided 
by Xi He and Mikhail V. Semenov (described previously (Tamai et al. 2004; Zeng et 
al. 2005)). The Wnt responsive TopFlash luciferase reporter construct was originally 
designed at the Hans Clevers lab. It contains multiple repeated copies of wild-type 
TCF/LEF-binding sites and can be induced via β-catenin-mediated transcriptional 
activation (Korinek et al. 1997; van de Wetering et al. 1997). It was gratefully received 
from Vladimir Korinek.  
85000 HEK-293 cells were seeded in 24-well plates and grown for 24 hours. 
Subsequently cells were transfected with 200 ng of either the full-length LRP5 
expressing vector, the full length LRP6 expression vector or a non-functioning 
dominant negative (dn) LRP6 expressing vector variant, or an empty vector as 
control, together with 200 ng of a TopFlash luciferase or HD-5 or HD-6 promoter 
construct and 50 ng of a Renilla luciferase expressing vector in each well, using the 
FuGENE 6 reagent according to the manufacturer’s protocol. Cells were incubated for 
at 37°C for 48 h.  
50	 MATERIAL	AND	METHODS	
 
 
2.2.3.2. siRNA and co-transfection experiments 
 To reveal possible effects of the overexpression of LRP5, which could be 
covered by the stronger signaling activity of LRP6, LRP6 siRNA to knockdown the 
activity of intracellular LRP6 was used and LRP5 was overexpressed. 
DharmaFECT® Duo Transfection Reagent which is designed for siRNA and 
plasmid co-transfection was used. 80000 HEK-293 cells were seeded in 24-well 
plates and grown for 24 hours. Subsequently cells were transfected with 75 ng of 
either the full-length LRP5 expressing vector or an empty vector as control, together 
with 375 ng of a TopFlash luciferase or HD-5 promoter construct and 50 ng of a 
Renilla luciferase expressing vector and 25 µl LRP6 siRNA (2 µM), a negative control 
siRNA (2 µM) or serum-free medium per well, using the DharmaFECT® reagent 
according to the manufacturer’s protocol. Cells were incubated at 37°C for 48 h. 
Knockdown of LRP6 was confirmed by analysing mRNA expression levels of LRP6 
with quantitative real-time PCR. Levels were at about 50 % lower than the expression 
levels in cells transfected with negative control siRNA or in control cells. One day 
post-transfection, cells were additionally stimulated with Wnt1 or Wnt3a to increase 
the induction activity of LRP5 (2.2.3.3). 
2.2.3.3 Stimulation with either Wnt3a or Wnt1  
Wnt3a and Wnt1, which are two ligands of LRP5, were used to stimulate and 
therefore increase the activity (signal transduction) of LRP5, this was previously 
shown by (Bhat et al. 2007). 24 h post transfection, the cells were stimulated with 
either Wnt3a or Wnt1: medium was removed and 500 µl of DMEM medium and 4.2 
µl Wnt3a (100 ng/µl) or 1 µl Wnt1 (100 ng/µl) or 4.2 µl control medium (PBS+BSA) 
was added. Cells were incubated at 37°C for 24 h. 
2.2.3.4 Dual Luciferase Reporter Assay 
48 h post transfection, medium was removed from the wells, cells were washed 
with PBS buffer, and 100 ml passive cell lysis buffer diluted 1:5 in H2O aqua dest. was 
added. Plates were shaken for 15 min and subsequently cells were resuspended by 
pipetting the cells up and down. 40 µl of the lysate was added to the luminometer 
tubes. LarII and Stop&Glow was added to the cell lysates according to the 
manufacturer’s protocol and the luciferase activity was measured via the Dual 
Luciferase Reporter Assay with the luminometer AutoLumat Plus according to the 
manufacture’s protocol. Firefly luciferase activity was assessed and normalized to the 
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corresponding studied promoter constructs. Increased activity of β-catenin 
dependent Wnt signaling in response to the overexpression of LRP5 or LRP6 
constructs transactivates HD-5 or HD-6 promoter activity in the used HEK-293 cells. 
Values shown represent the average of triple determinations with the standard error 
of mean (SEM) indicated by error bars. Using the respective activity of the co-
transfected Renilla luciferase, it was possible to normalize based on the transfection 
efficiencies. Three or more independent experiments were performed and 
transfections were carried out in triplicates.  
2.2.4 Determination of antimicrobial activity with fluorescence activated 
cell sorting 
Antimicrobial activity of defensins and other antimicrobial peptides can be 
assessed by fluorescence activated cell sorting (FACS). Antimicrobial activity from rat 
tissue was analysed as described before with modifications (Jan Wehkamp et al. 
2007. 4; Nuding et al. 2006; Teltschik et al. 2012). Frozen tissue samples were 
pulverized with a pestle in liquid nitrogen and proteins were extracted under gentle 
agitation for 90 min in 60% acetonitrile + 1% trifluoroacetic acid. The acid soluble 
proteins in the supernatant were dried under vacuum and resuspended in 0.01% 
acetic acid. Mid-logarithmic growth phase suspensions of Escherichia coli K12 and 
Enterococcus faecalis ATCC 29212 were grown aerobically at 37 °C, whereas 
Bacteroides fragilis ATCC 25285 and Bifidobacterium adolescentis Ni3, 29c were 
cultured anaerobically (Anaero Gen; Oxoid Limited, Hampshire, UK). Escherichia 
coli K12, Enterococcus faecalis ATCC 29212, Bacteroides fragilis ATCC 25285 
purchased from ATCC Bacteriology Collection and Bifidobacterium adolescentis Ni3, 
29c isolated from stool of a child with disturbed small intestinal microbiota.  
To verify that the acetic acid per se has no bactericidal effect, 10 µl bacteria 
suspension and the according volume of 0.01% acetic acid as negative/living control 
was used. Additionally pH-controls (pH 5, pH 4, pH 3, pH 2, pH 1 (60 % acetonitrile 
+ 1% TFA in 0.01% acetic acid in increasing concentration) were used to exclude 
bactericidal effects due to acid- or acetonitrile remnants. As a positive control 
bacteria incubated with human β-defensin 3 (15 µg/ml bacteria suspension) were 
used.  
Aerobic bacteria (Escherichia coli K12 and Enterococcus faecalis ATCC 29212) 
were incubated over night (37°C) on blood agar plates (Becton Dickinson, Sparks, 
MD, USA).  The following day the optical density of the bacteria suspension was 
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tailored to OD600 = 0.05 with Schaedler broth 1:6 diluted in sterile H2O (Becton 
Dickinson, Sparks, MD, USA). Subsequently bacteria were incubated for 1.5 h at 37°C 
until their growth reached OD600 = 0.1 (logarithmic growth). Anaerobic bacteria 
(Bifidobacterium adolescentis Ni3, 29c and Bacteroides fragilis ATCC 25285) were 
incubated in an anaerobic jar (Anaero Gen; Oxoid Limited, Hampshire, UK) over 
night (37°C) on blood agar plates. The following day they were diluted in Schaedler 
broth (1:6 diluted in sterile H2O) and incubated for 48 h in the anaerobic jar at 37°C. 
This culture was then directly used (OD600= 0.1).  
Bacteria suspensions were diluted 1:10 with Schaedler broth (1:6 diluted with 
sterile H2O) and incubated for 90 min at 37°C with the according protein mix. 1.5 µl 
DiBAC4(3) (1:50 in sterile H2O) was added incubated for 5 min and centrifuged (5 
min, 7000 rpm). The supernatants were discarded and the pellets were resuspended 
in 100 µl FACS- Flow and then added to 200 µl of FACS-Flow in FACS tubes. 
Measurements were performed with the FACSCaliburTM cytometer (Becton 
Dickinson, Sparks, MD, USA). 30000-100000 events were analysed for every sample 
with the “Cell Quest“ software. 
2.3 Statistics  
Data were analysed with GraphPad Prism 5. The values were tested for normal 
distribution (D’Agostino-Pearson test). Statistical analysis of real-time qPCR and 
antimicrobial assays were performed nonparametrically or parametrically (in case of 
normal distribution) by using the Wilcoxon U test, Mann-Whitney, or t test. 
Differences were considered significant at p < 0.05; values represent the mean of 
normalized data ± SEM. mRNA levels were normalized to β-actin and interpreted 
with the GraphPad Prism software. 
The freely available Finetti based software (http://ihg.gsf.de/cgi-
bin/hw/hwa1.pl) which uses log the likelihood ratio chi square test, was used to test 
whether the SNPs are in the Hardy- Weinberg equilibrium. The same software was 
used to test for associations in subgroups (like age of onset, gender, location of 
disease) and controls in one cohort. Here the confidence intervals (CI) and odds 
ratios (OR) were calculated and Pearson's goodness-of-fit chi square tests were 
performed. Haplotypes and linkage disequilibria were calculated with Haploview.
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3. RESULTS 
3.1 Low-density lipoprotein receptor-related protein 6 (LRP6) 
 
Parts of these results have previously been published in: 
 
Association of a functional variant in the Wnt co-receptor LRP6 with 
early onset ileal Crohn's disease. 
Koslowski MJ, Teltschik Z, Beisner J, Schaeffeler E, Wang G, Kübler I, Gersemann M, 
Cooney R, Jewell D, Reinisch W, Vermeire S, Rutgeerts P, Schwab M, Stange EF, 
Wehkamp J. PLoS Genet. 2012;8(2):e1002523. doi: 10.1371/journal.pgen.1002523. 
Epub 2012 Feb 23. 
 
Author contributions: 
Conceived and designed the experiments: MJK JW. Performed the experiments: MJK 
ZT MG GW IK JB. Analyzed the data: MJK ZT JB JW. Contributed 
reagents/materials/analysis tools: ES MG IK RC DJ WR SV PR MS EFS. Wrote the 
paper: MJK EFS JW. Recruiting and phenotyping of patients and controls in the 
association study: RC DJ WR SV PR. Obtained plasmids and performed pretests: 
GW. Involved in discussion of methods and data: JB ES MS. 
 
 
As described previously the antimicrobial peptides HD-5 and HD-6 are 
reduced in ileal CD. Paneth cells in the small intestinal crypts exclusively produce 
these two defensins. Recently the β-catenin dependent Wnt transcription factor TCF-
4 (TCF7L2) has been linked to an impairment in antimicrobial PC defense (Jan 
Wehkamp et al. 2007). To elucidate whether other upstream factors of the Wnt 
pathway could be involved in the regulation of PC defensins, it was now focused on 
LRP6. This co-receptor is expressed in the small intestinal epithelium (Zhong et al. 
2012) and stabilises β-catenin which, after entering the nucleus (G. Liu et al. 2003; 
Semënov et al. 2001) binds to factors of the (Lef)/TCF family to activate target gene 
promoters including the HD-5 and -6 promoters (Giese, Amsterdam, and Grosschedl 
1991; van Beest et al. 2000). 
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3.1.1 IHC staining shows LRP6 expression at the bottom of the crypts 
Immunohistochemical (IHC) staining was performed using an antibody, which 
is directed against the C-terminal part of LRP6 or more precisely against the amino 
acids 1538- 1568 (figure 5). IHC staining revealed expression of LRP6 in the whole 
human small intestinal epithelium and therefore also in Paneth cells. This expression 
is consistent with former results from Zhong et al. and shows that LRP6 is expressed 
at the bottom of the crypt where Wnt signaling is important to regulate expression of 
its target genes, for example α- defensins. 
 
Figure	5:	Immunohistochemical	staining	of	LRP6	in	the	epithelium	of	human	small	intestinal	tissue	
(Teltschik	et	al.,	unpublished)	
 
3.1.2 Cell culture 
3.1.2.1 Transcriptional regulation of HD -5 and -6 seems dependent on 
LRP6 
Overexpression of LRP6 with a plasmid expressing the active form of LRP6 
transactivates the human α-defensins HD-5 and -6 promoter in human embryonic 
kidney cells (HEK-293 cells). As seen in IHC staining experiments, the LRP6 protein 
is widely expressed in the human small intestinal epithelium (figure 5). 
Overexpression of LRP6 and co-transfection with TopFlash, that can be induced via 
β-catenin-mediated transcriptional activation, indicates an activation of β-catenin 
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dependent Wnt signaling as described before (Zeng et al. 2008; He et al. 2004). 
Overexpression of LRP6 and co-transfection with either HD-5 or -6 reporter plasmid 
leads to an induction of luciferase reporter activity (figure 6). In comparison, no 
effect was observed when using a non-functional variant of the LRP6 plasmid, which 
lacks the cytoplasmic part that is necessary for signal transduction or using an empty 
vector without the LRP6 insert as control. This shows that LRP6 is involved in HD-5 
and -6 expression. Experiments were performed at least three times and transfections 
were carried out in triplicates. The values used are average with SEM indicated by 
error bars. 
Figure	 6:	 Increased	 activity	 of	 β-catenin	 dependent	 Wnt	 signaling	 via	 overexpression	 of	 LRP6	
transactivates	 human	 α-defensin	 5	 (HD-5,	 graph	 A)	 and	 α-defensin	 6	 (HD-6,	 graph	 B)	 promoter	
activity	in	HEK-293	cells:	Overexpression	of	LRP6	in	HEK-293	cells	leads	to	an	activation	of	β-catenin	
dependent	Wnt	signaling	as	monitored	by	TopFlash	activity	(graph	A,	right	panel	and	graph	B,	right	
panel).	 The	 transcriptional	 activity	 of	 a	 luciferase	 reporter	 under	 the	 control	 of	 either	 a	 1kb	HD-5	
promoter	or	a	1kb	HD-6	promoter	was	also	 increased	after	LRP6	mediated	activation	of	Wnt.	Both	
effects	were	 not	 seen	when	 a	 non-functional	 version	 of	 the	 LRP6	 co-receptor	 (dnLRP6)	was	 used.	
Values	are	the	average	of	triple	determinations	with	the	SEM	indicated	by	error	bars,	*	p	<	0.05,	**	p	
<	0.01	(Teltschik	et	al.,	unpublished).	
 
3.2. Low-density lipoprotein receptor-related protein 5 (LRP5) 
As mentioned and shown above, the canonical Wnt pathway receptor LRP6 has 
been linked to ileal Crohn´s disease (CD) and, directly impacts on the expression of 
Paneth cell alpha-defensins. Besides that, canonical Wnt also influences gut mucosal 
proliferation and small intestinal Paneth cell maturation. Because of the important 
role of LRP6 in regulating Wnt target genes the co-expressed receptor LRP5 was 
analysed. Both receptors are co-expressed and have overlapping functions while also 
56	 RESULTS	
 
 
taking on context dependent and specific roles. Therefore LRP5 mRNA expression in 
patients was studied, the co-receptors functional impact on Paneth cell defensins was 
analysed, and the distribution of SNPs were studied to see whether a genetic 
association with the ileal subtype of CD might exist. 
3.2.1 mRNA data  
LRP5 is constitutively expressed at the cell surface (Joiner et al. 2013) and is 
also involved in β-catenin dependent Wnt signal transduction. To examine if this 
receptor is also changed in Crohn’s disease, differences in LRP5 mRNA expression 
were analysed by quantitative real- time PCR in the Stuttgart cohort. This comprises 
controls and patients suffering from L1, L2 and L3 CD. Additionally a pediatric cohort 
from Norway comprising controls and L1, L2 and L3 CD patients was studied.  
3.2.1.1 LRP5 expression in the ileal CD is slightly decreased  
The Stuttgart cohort comprises 28 healthy controls and 72 CD patients. The 
samples were sub-grouped according to the disease state and patients/controls with 
mutations in the pattern recognition receptor NOD2 as well as patients with a 
neoterminal ileum were excluded. MRNA levels of patients with solely ileal Crohn’s 
disease (L1), Crohn’s disease of the small intestine and the colon (L3) and patients 
with solely colonic involvement of disease (L2) in comparison to healthy controls 
were analysed. L1 patients showed slightly but not significantly decreased levels of 
LRP5 mRNA in comparison to controls and to patients suffering from L2 CD (figure 
7, lower panel). No differences between inflamed and not inflamed tissue was 
observed (figure 7, upper panel). To confirm the observed effects, LRP5 expression 
was analysed in the cohort from Norway. This cohort consists of pediatric patients, 
where the genetic influence might be more pronounced. LRP5 mRNA expression 
levels in the mucosa of 32 non-IBD control children in comparison to children 
suffering from Crohn’s disease (n=28) was analysed. Again, a small but not 
significant, decrease of LRP5 mRNA levels was observed in the ileal CD group (L1, 
n=2). Also no significant differences were observed in the colonic CD group (L2, n=5) 
and in ileocolonic disease (L1+L3, n=23), (figure 8). 
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Figure	7:	LRP5	mRNA	expression	in	the	ileum	of	Crohn´s	disease	patients	from	Stuttgart.		
Slight	but	not	significant	decrease	of	LRP5	mRNA	expression	was	observed	in	patients	suffering	from	
ileal	 Crohn’s	 disease	 (L1)	 in	 comparison	 to	 the	 healthy	 control	 group	 and	 patients	 suffering	 from	
colonic	Crohn’s	disease	(L2,	 lower	panel).	No	differences	were	seen	between	inflamed	samples	and	
non-inflamed	samples	(upper	panel),	(Teltschik	et	al.,	unpublished).	
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Figure	8:	LRP5	expression	 in	 the	 ileal	mucosa	of	pediatric	Crohn’s	disease	patients	 from	Norway.	
No	 significant	differences	of	 LRP5	mRNA	expression	were	observed	 in	patients	 suffering	 from	 ileal	
Crohn’s	 disease	 (L1,	 n=2)	 in	 comparison	 to	 a	 healthy	 non-IBD	 control	 group	 (n=32)	 and	 patients	
suffering	from	colonic	Crohn’s	disease	(L3,	n=21),	(Teltschik	et	al.,	unpublished).	
 
3.2.1.2 HD-5 expression is significantly decreased in ileal  and ileocolonic 
CD 
As previously described, the regulation of α- defensin 5 (HD-5) is linked to the 
Wnt signaling pathway (Wehkamp et al. 2007; Koslowski et al. 2012; Beisner et al. 
2014). 
Measuring the mRNA expression revealed significantly decreased levels of HD-5 in 
patients with ileal CD (L1, p=0.0023) and patients with colonic CD (L3, p=0.0277), as 
well as in ileocolonic disease (L1+L3, p=0.0029) in comparison to L2 CD patients and 
healthy controls (figure 9). This decrease was independent of inflammation (data not 
shown). As LRP5 expression was not significantly chanced, this significant decrease 
of HD-5 indicates a mechanism not depending on LRP5 expression. Similar to the 
effects seen in the Stuttgart cohort, in the Norwegian cohort levels of HD-5 were 
significantly decreased in children suffering from ileocolonic Crohn’s disease (L1+L3, 
p=0.0298, L3, p=0.0347) in comparison to children suffering from solely colonic 
disease (L2) and a non-IBD control group (data not shown) (Perminow et al. 2010). 
Due to the fact that LRP5 mRNA levels are unchanged, this mechanism also seems to 
be independent from LRP5 expression.  
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Figure	 9:	 Expression	 of	 human	 α-defensin	 5	 (HD-5)	 in	 the	 ileal	 mucosa	 of	 CD	 patients	 from	
Stuttgart.	MRNA	expression	of	HD-5	is	significantly	decreased	in	patients	suffering	from	ileal	Crohn’s	
disease	(L1)	as	well	as	in	patients	with	colonic	and	ileal	involvement	of	disease	(L3),*	p	<0.05,	**	p	<	
0.01	(Teltschik	et	al.,	unpublished).	
 
3.2.1.3 LRP5 mRNA expression seems to be unchanged in colonic 
biopsies 
  Additionally the expression of LRP5 in mRNA isolated from colonic mucosal 
tissue from the Stuttgart cohort was analysed. No significant differences between 
patients with any subgroup of Crohn’s disease and the control group were detected 
(figure 10). Again, also in the pediatric cohort from Norway the colonic tissue was 
analysed. Although no significant differences in LRP5 mRNA expression between 
patients with any subgroup of Crohn’s disease and the control group (figure 11) was 
seen, a slight decrease in expression in all CD subgroups comparable to the slight 
decrease of LRP5 expression in the ileum in L1 patients was observed. 
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Figure	10:	LRP5	mRNA	expression	in	the	colon	of	Crohn´s	disease	patients	from	Stuttgart.	
No	significant	differences	 in	LRP5	mRNA	expression	 in	patients	 suffering	 from	 ileal	Crohn’s	disease	
(L1)	in	comparison	to	the	healthy	control	group	and	patients	suffering	from	colonic	Crohn’s	disease	
(L2),	(Teltschik	et	al.,	unpublished).	
 
 
Figure	11:	LRP5	expression	in	the	colon	of	pediatric	Crohn´s	disease	patients	from	Norway.		
LRP5	is	not	significantly	decreased	in	colonic	tissue	of	patients	suffering	from	ileal	or	colonic	Crohn’s	
disease	(L1	n=2,	L2	n=5,	L3	n=20)	in	comparison	to	a	healthy	non-IBD	control	group	(n=32),	(Teltschik	
et	al.,	unpublished).	
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3.2.2 LRP5 overexpression experiments in HEK-293 cells 
To elucidate the function of LRP5 relating to its role in the activation of Wnt 
target genes HD-5 and HD-6, overexpression experiments in HEK-293 cells were 
performed. LRP6 and LRP5 have overlapping but also distinct functions and LRP6 is 
thought of having a stronger role in the activation of Wnt target genes (MacDonald et 
al. 2011). As shown above, LRP6 overexpression leads to activation of HD-5/-6. 
Therefore the LRP6 gene was knocked down with siRNA to study the role of LRP5 
alone. Experiments were performed at least three times and transfections were 
carried out in triplicates. The displayed values represents averages with SEM 
indicated by error bars. 
3.2.2.1 In vitro β-catenin dependent Wnt HD-5 target gene promoter 
activation seems to be independent of LRP5 expression levels. 
To elucidate the role of LRP5 in vitro, human embryonic kidney cells (HEK-
293 cells) were transfected with a LRP5 overexpression plasmid, harbouring the 
active form of LRP5. This overexpression was however not sufficient to transactivate 
the co-transfected HD-5 (figure 12, upper panel) or HD-6 (data not shown) promoter 
when compared to an empty plasmid or medium controls.  
3.2.2.1.1 Additional stimulation with Wnt1 does not induce HD-5 
promoter activity 
To counteract a potentially low activity of LRP5 in comparison to LRP6, 
additional stimulation with Wnt1 was performed, which is a ligand known to interact 
with the LRPs (Bhat et al. 2007). Furthermore, intracellular LRP6 was also knocked-
down with siRNA to avoid effects, which might allow a strong LRP6 function to level 
out any LRP5 mediated changes in activity (figure 12, lower panel). No significant 
induction of HD-5 promoter activity was observed after overexpression and 
additional Wnt1 stimulation of LRP5 and parallel knockdown of intracellular LRP6 in 
HEK-293 cells in comparison to cells transfected with a negative control siRNA and 
to unstimulated cells and also to a non-targeting control siRNA (figure 12, lower 
panel).  
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Figure	12:	No	significant	transactivation	of	the	HD-5	promoter	activity	via	overexpression	of	LRP5	
transfection	plasmid	and	either	no	stimulation	or	stimulation	with	 the	LRP5	 ligand	Wnt1	 in	HEK-
293	 cells:	 The	 transcriptional	 activity	 of	 a	 luciferase	 reporter	 under	 the	 control	 of	 a	 1kb	 HD-5	
promoter	was	not	significantly	increased	after	LRP5	mediated	activation	of	β-catenin	dependent	Wnt	
signaling.	Knockdown	of	LRP6	to	reveal	effects	of	LRP5	which,	could	be	overlain	by	LRP6,	only	very	
slightly	increased	the	effects	of	LRP5	overexpression.	Values	are	the	average	of	triple	determinations	
with	the	SEM	indicated	by	error	bars	(Teltschik	et	al.,	unpublished).	
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3.2.2.1 In vitro β-catenin dependent Wnt TopFlash target gene promoter 
activation seems to be independent of LRP5 expression levels. 
To test whether overexpression of LRP5 per se leads to stronger Wnt signaling 
activity, HEK-293 cells were transfected with the active LRP5 expression plasmid and 
the TopFlash plasmid, a luciferase reporter that contains multiple repeated copies of 
wild-type TCF/LEF-binding sites. TopFlash can consequently very effectively be 
induced via β-catenin-mediated transcriptional activation. LRP6 expression was 
knocked-down with siRNA and LRP5 signaling activity was either not stimulated, 
stimulated with Wnt1 or Wnt3a, which has also been shown to increase LRP5 activity 
before (Grumolato et al. 2010). Although slight upregulation after Wnt3a stimulation 
was observed, no significant transactivation of β-catenin dependent Wnt signaling via 
overexpression of LRP5 transfection plasmid and either no stimulation, stimulation 
by the LRP5 ligand Wnt1 or Wnt3a was observed (figure 13).  
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Figure	13:	No	significant	transactivation	of	β-catenin	dependent	Wnt	signaling	via	overexpression	
of	LRP5	transfection	plasmid	and	either	no	stimulation,	stimulation	with	the	LRP5	ligand	wnt1	or	
wnt3a	 in	 HEK-293	 cells:	 Overexpression	 of	 LRP5	 in	 HEK-293	 cells	 leads	 to	 an	 slightly	 but	 not	
significant	 activated	 β-catenin	 dependent	 Wnt	 signaling	 as	 monitored	 by	 TopFlash	 activity.	
Knockdown	of	LRP6	to	reveal	effects	of	LRP5,	which	could	be	overlaid	by	LRP6	did	not	or	only	very	
slightly	 (for	 stimulation	 with	 wnt3a)	 increased	 the	 effects	 of	 LRP5	 overexpression.	 Values	 are	 the	
average	of	triple	determinations	with	the	SEM	indicated	by	error	bars	(Teltschik	et	al.,	unpublished).	
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3.2.3 Genetic analysis of the candidate gene LRP5 
As described (M. J. Koslowski et al. 2012) mutations in the LRP6 gene are 
associated with early onset Crohn´s disease. LRP6 and LRP5 are co-expressed 
receptors which often act together and are both needed to respond to some Wnt 
signals (Goel et al. 2012). Although a direct influence of LRP5 on HD- and -6 was not 
detected on mRNA level, Wnt is important for normal epithelial homeostasis (Fevr et 
al. 2007), which is disturbed in CD. Therefore a potential genetic association of LRP5 
to Crohn´s disease was investigated. 45 SNPs in the LRP5 gene (figure 14) in three 
cohorts (Leuven, Stuttgart, Vienna) were analysed. The analysis included exonic, 
coding SNPs, which lead to an amino acid change (indicated in red), exonic 
synonymous SNPs, which do not lead to an amino acid change (indicated in green) 
and intronic SNPs, which are indicated in blue based on selection criteria as listed in 
“methods”.  
 
Figure	14:	Schematic	representation	of	the	human	LRP5	gene,	indicating	the	relative	location	of	the	
analysed	 single	 nucleotide	 polymorphisms	 (SNPs)	 that	 belong	 to	 five	 haploblocks	 (see	 figure	 15),	
(Teltschik	et	al.,	unpublished).	
 
The samples were sub-grouped according to gender, age, age of onset of 
disease (A1: 16 years or younger, A2: 17–40 years and A3: >40 years), behaviour of 
disease and involvement of either small intestine (L1), colon (L2), both small 
intestine and colon (L3) and additional involvement of the upper gastrointestinal 
tract (L4). Analysis of single cohorts showed very significant differences in the 
disease group in comparison to controls, as described below. But analysis of all three 
cohorts compensated the obvious differences between the analysed groups. This is 
due to often observed reversed results in one cohort in comparison to another (see 
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table 8). Table 8 shows three SNPs as examples. SNP1´s (examples in green) minor 
allele frequency (MAF) in the Leuven cohort is 7.87% in the control group and 14.71% 
in the group with patients suffering from early onset of disease. In the Vienna cohort 
it is 13.94% in the control group and 4.17% on the early onset group, so the results are 
reversed in the two different cohorts. In the third cohort (Stuttgart) the trend is the 
same than in the Vienna cohort, but the MAFs are much lower. SNP2 (examples in 
orange) has a MAF of 29.55% in the Leuven control group and a MAF of 36.41% in 
the ileal CD group. The Vienna control group has a MAF of 41.63% in comparison to 
30.81% for patients suffering from ileal CD and in the Stuttgart cohort 29.14% MAF 
in the control group and 30.56% in the ileal CD group. These examples show very 
nicely the problems analysing the different cohorts due to the uneven distribution of 
the analysed SNPs in the different cohorts. This highlights a high level of 
heterogeneity in the population, which might be due to the fact that many SNPs 
might have some minor benefit or drawback or show associations with certain 
phenotypes, which cannot be accounted for. LRP5 deficiencies are indeed linked to 
many other disease for example increased fracture risk, osteoporosis (Urano et al. 
2009; Korvala et al. 2012; Xiong et al. 2007), and also familial exudative 
vitreoretinopathy (Jiao et al. 2004), but some SNPs are on the other hand also 
associated with higher bone mineral density (BMD). More data depending disease 
status and phenotype regarding BMD are not available, so it was not possible to 
exclude all the samples, which could lead to a bias in the analysis. For overall allele 
frequencies see appendix. 
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Table	8:	Exemplarily	the	minor	allele	frequencies	of	3	SNPs	to	demonstrate	the	observed	differences	
in	 the	 analysed	 cohorts	 (MAF:	 minor	 allele	 frequency,	 Divert:	 diverticulitis,	 C.	 Indet.:	 colitis	
indeterminata,	CD:	Crohn’s	disease).	
LEUVEN	 rs314756	 rs676318	 rs556442	 VIENNA	 rs314756	 rs676318	 rs556442	 STUTTGART	 rs314756	 rs676318	 rs556442	
MAFs	 SNP	1	 SNP	2	 SNP	3	 MAFs	 SNP	1	 SNP	2	 SNP	3	 MAFs	 SNP	1	 SNP	2	 SNP	3	
	 intronic	 intronic	 exonic		 	 intronic	 intronic	 exonic	 	 intronic	 intronic	 exonic	
Controls	 7.87%	 5.95%	 29.55%	 Controls	 13.94%	 9.24%	 41.63%	 Controls	 8.45%	 6.74%	 29.14%	
Divert.	 23.84%	 10.56%	 49.40%	 		 		 		 		 C.	indet.	 6.25%	 10.42%	 29.17%	
IBD	 9.26%	 8.49%	 32.47%	 IBD	 6.32%	 8.31%	 31.86%	 IBD	 8.38%	 6.13%	 32.49%	
UC	 12.50%	 5.49%	 24.73%	 UC	 6.99%	 10.33%	 35.16%	 UC	 7.30%	 6.67%	 33.46%	
		 		 		 		 		 		 		 		 		 		 		 		
CD	 8.18%	 9.49%	 35.09%	 CD	 5.85%	 6.90%	 29.54%	 CD	 9.14%	 5.76%	 31.82%	
male	 10.23%	 8.82%	 35.38%	 male	 5.04%	 8.62%	 29.57%	 male	 6.77%	 6.45%	 35.05%	
female	 8.53%	 8.81%	 31.37%	 female	 6.44%	 4.55%	 26.54%	 female	 11.34%	 5.32%	 29.90%	
A1	 14.71%	 11.76%	 35.29%	 A1	 4.17%	 6.25%	 27.08%	 A1	 3.03%	 1.52%	 25.76%	
A2	 8.03%	 8.99%	 31.25%	 A2	 5.66%	 6.97%	 29.85%	 A2	 9.92%	 6.47%	 34.02%	
A3	 11.64%	 4.79%	 30.67%	 A3	 8.62%	 6.90%	 29.31%	 A3	 17.39%	 11.36%	 39.13%	
B1	 7.14%	 11.43%	 36.96%	 B1	 3.30%	 6.31%	 27.18%	 B1	 6.34%	 7.14%	 31.94%	
B2	 7.02%	 12.07%	 31.03%	 B2	 12.50%	 3.13%	 25.00%	 B2	 13.64%	 5.56%	 29.10%	
B3	 8.47%	 7.69%	 34.32%	 B3	 5.09%	 8.41%	 33.33%	 B3	 5.77%	 8.00%	 39.42%	
L4*	 7.14%	 9.52%	 38.10%	 L4*	 3.97%	 13.71%	 30.65%	 L4*	 4.55%	 13.64%	 54.55%	
		 		 		 		 		 		 		 		 		 		 		 		
ileal	CD	 8.80%	 9.95%	 36.41%	 ileal	CD	 5.39%	 6.44%	 30.81%	 ileal	CD	 10.06%	 5.88%	 30.56%	
male	 9.68%	 9.68%	 39.13%	 male	 4.35%	 8.33%	 32.39%	 male	 7.69%	 6.67%	 33.13%	
female	 8.13%	 10.16%	 34.40%	 female	 6.00%	 3.50%	 26.02%	 female	 12.34%	 5.41%	 29.49%	
A1	 14.00%	 18.00%	 48.00%	 A1	 5.26%	 5.26%	 26.32%	 A1	 3.85%	 1.92%	 27.78%	
A2	 7.88%	 8.90%	 34.25%	 A2	 5.99%	 6.44%	 31.90%	 A2	 10.50%	 6.84%	 33.82%	
A3	 8.75%	 10.00%	 40.24%	 A3	 10.00%	 7.50%	 37.50%	 A3	 20.59%	 9.38%	 35.29%	
B1	 10.23%	 14.77%	 46.51%	 B1	 2.24%	 6.82%	 32.03%	 B1	 6.12%	 4.17%	 26.00%	
B2	 7.55%	 12.96%	 32.41%	 B2	 10.23%	 3.41%	 25.00%	 B2	 14.17%	 6.14%	 28.69%	
B3	 8.80%	 7.01%	 34.40%	 B3	 5.43%	 6.59%	 32.02%	 B3	 7.89%	 9.72%	 39.74%	
L4*	 7.14%	 9.52%	 38.10%	 L4*	 3.97%	 13.71%	 30.65%	 L4*	 4.55%	 13.64%	 54.55%	
 
3.2.3.1 Haplotypes 
To see whether a certain combination of SNP variants might predispose to CD, 
haplotype blocks and linkage disequilibria were calculated with Haploview. Analysis 
of haplotypes for the 45 analysed SNPs in the three cohorts revealed 5 haploblocks 
(figure 15). Neither allele combination within these blocks was however significantly 
associated with small intestinal CD as the differences between patients who suffer 
from ileal CD and a healthy control group were not significant (table 9). Association 
of haploblocks in haplotype analysis for all cohorts are listed in table 10.  
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Figure	 15:	 Haplotype	 blocks	 and	 linkage	 disequilibria	 were	 calculated	 with	 Haploview.	 Five	
haploblocks	 were	 found.	 But	 no	 significant	 differences	 between	 patients	 who	 suffer	 from	 ileal	
Crohn’s	disease	and	a	healthy	control	group	were	found.	D’	and	LOD	(log	of	the	likelihood	odds	ratio)	
values	were	used	for	selection	of	LD	colour	scheme	in	the	discovery	phase.	None	of	the	five	blocks	
found	in	LRP5	was	significant	(Teltschik	et	al.,	unpublished).	
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Table	9:	Association	of	haploblocks	in	haplotype	analysis	for	all	cohorts		
(cases	and	controls	in	ileal	CD)	
haplotype	 frequency	
case	|	control	
ratios	
chi	
square	 p-value	
BLOCK	1	 		 		 		 	
CCT	 0.357	 0.349	|	0.359	 0.279	 0.5975	
CCG	 0.312	 0.311	|	0.312	 0.003	 0.9593	
TCG	 0.194	 0.207	|	0.189	 1.263	 0.2612	
CTT	 0.131	 0.127	|	0.133	 0.221	 0.6384	
BLOCK	2		
ATT	 0.587	 0.602	|	0.582	 0.984	 0.3212	
ACG	 0.210	 0.197	|	0.215	 1.150	 0.2836	
ATG	 0.121	 0.132	|	0.116	 1.448	 0.2289	
GCG	 0.081	 0.069	|	0.085	 2.253	 0.1334	
BLOCK	3	
AGG	 0.605	 0.610	|	0.604	 0.088	 0.7673	
GAG	 0.157	 0.160	|	0.156	 0.072	 0.7882	
GGA	 0.150	 0.157	|	0.148	 0.381	 0.537	
GGG	 0.085	 0.071	|	0.091	 3.084	 0.0791	
BLOCK	4		
CTA	 0.670	 0.690	|	0.662	 2.249	 0.1337	
CGG	 0.168	 0.165	|	0.169	 0.076	 0.783	
TGG	 0.149	 0.136	|	0.154	 1.580	 0.2087	
BLOCK	5			
TAACT	 0.649	 0.667	|	0.642	 1.701	 0.1921	
TGCTA	 0.136	 0.115	|	0.144	 4.134	 0.042	
TACTA	 0.126	 0.137	|	0.121	 1.339	 0.2472	
CAACA	 0.082	 0.073	|	0.085	 1.306	 0.2532	
 
Table	10:	Association	of	SNPs	in	cases	and	controls	for	all	cohorts	in	ileal	CD	
SNP	number	 					rs	number	 assoc.	allele	
case	|	control	
ratios	 chi-square	 p-value	
1	 rs2137328	 T	 0.209	|	0.192	 1.086	 0.2973	
2	 rs11606508	 C	 0.869	|	0.863	 0.2	 0.6551	
5	 rs4988300	 G	 0.521	|	0.504	 0.778	 0.3777	
6	 rs634008	 T	 0.544	|	0.531	 0.437	 0.5088	
8	 rs314756	 A	 0.931	|	0.913	 2.653	 0.1034	
9	 rs312781	 T	 0.733	|	0.701	 3.131	 0.0768	
13	 rs312788	 T	 0.602	|	0.587	 0.546	 0.4601	
15	 rs638051	 A	 0.613	|	0.601	 0.381	 0.537	
17	 rs4988319	 A	 0.157	|	0.147	 0.52	 0.4707	
18	 rs4988320	 A	 0.157	|	0.147	 0.535	 0.4645	
24	 rs2306862	 C	 0.863	|	0.848	 1.087	 0.2972	
28	 rs2472415	 T	 0.049	|	0.029	 6.008	 0.0142	
30	 rs599083	 T	 0.701	|	0.681	 1.098	 0.2947	
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32	 rs17149104	 T	 0.019	|	0.017	 0.261	 0.6098	
33	 rs556442	 A	 0.689	|	0.661	 2.14	 0.1435	
39	 rs1127291	 T	 0.015	|	0.009	 2.246	 0.134	
40	 rs676318	 T	 0.925	|	0.916	 0.614	 0.4332	
41	 rs3867143	 A	 0.887	|	0.855	 4.916	 0.0266	
43	 rs12294029	 A	 0.748	|	0.733	 0.671	 0.4127	
44	 rs7126340	 C	 0.750	|	0.738	 0.429	 0.5124	
45	 rs12226585	 T	 0.669	|	0.646	 1.444	 0.2295	
 
3.3 T cell transcription factor 1 (TCF-1) 
 
Parts of these results have previously been published in: 
 
Intestinal Stem Cells in GI Physiology and Disease TCF-1-mediated Wnt 
signaling regulates Paneth cell innate immune defense effectors HD-5 
and -6: implications for Crohn’s disease 
Julia Beisner, Zora Teltschik, Maureen J. Ostaff, Machteld M. Tiemessen, Frank J. T. 
Staal, Guoxing Wang, Michael Gersemann, Gori Perminow, Morten H. Vatn, 
Matthias Schwab, Eduard F. Stange, Wehkamp. Am J Physiol Gastrointest Liver 
Physiol. 2014 Sep 1;307(5):G487-98. doi: 10.1152/ajpgi.00347.2013.Epub 2014 Jul 3. 
 
Author contributions: 
J.B., Z.T., M.J.O., G.W., E.F.S., and J.W. conception and design of research; J.B., 
Z.T., M.J.O., M.M.T., F.J.S., G.W., M.G., and G.P. performed experiments; J.B., Z.T., 
M.J.O., M.G., and J.W. analyzed data; J.B., Z.T., M.J.O., M.H.V., M.S., E.F.S., and 
J.W. interpreted results of experiments; J.B., Z.T., and M.J.O. prepared figures; J.B. 
and J.W. drafted manuscript; J.B., Z.T., M.J.O., M.M.T., F.J.S., G.P., M.H.V., M.S., 
E.F.S., and J.W. edited and revised manuscript; J.B., Z.T., M.J.O., M.M.T., F.J.S., 
G.W., M.G., G.P., M.H.V., M.S., E.F.S., and J.W. approved final version of 
manuscript. 
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3.3.1 IHC staining reveals TCF-1 expression at the bottom of the crypts 
Since our group could previously show that a decrease of Paneth cell α-
defensins in patients with ileal CD is partially caused by impaired TCF-4 function 
(Jan Wehkamp et al. 2007; M. J. Koslowski et al. 2009),  TCF-1 (also known as TCF-
7) as another Wnt factor was analysed in the same context. TCF-1 protein in the small 
intestine was immunohistochemical stained to determine the expression pattern. The 
used antibody only detects the active isoform and not the inactive isoforms lacking 
the amino-terminal β-catenin binding domain. The active isoform is expressed 
predominantly at the bottom of the intestinal crypts in small intestinal cells (figure 
16, left panel). This is the side where also the α-defensin producing Paneth cells are 
located. A corresponding section was phloxine-tartrazine stained; this shows the 
secretory granules in Paneth cells in pink (figure 16, right panel). As clearly seen, cells 
expressing the active TCF-1 colocalize with the stained Paneth cells. According to the 
important role of Wnt epithelial proliferation active TCF-1 was also detected above 
Paneth cells in epithelial progenitor cells as well as in some infiltrating gut 
lymphocytes. 
 
 
 
Figure	16:	 Immunohistochemical	staining	of	the	active	TCF-1	 isoform	in	small	 intestinal	crypts	(left	
panel)	 and	 phloxine	 tartrazine	 staining	 of	 human	 Paneth	 cell	 granules	 in	 the	 consecutive	 section	
(right	panel),	(Beisner,	Teltschik	et	al.,	2014).	
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3.3.2 TCF-1 expression is significantly decreased in ileal  and ileocolonic 
CD 
To study differences in mRNA expression of the transcription factor TCF-1 and 
its active isoform 1 it was performed quantitative real-time PCR in the Stuttgart 
cohort, comprising controls and patients suffering from L1, L2 and L3 Crohn’s 
disease and a pediatric cohort from Norway comprising non-IBD controls and 
children suffering from L1, L2 and L3 CD.  
In the Stuttgart cohort the expression of TCF-1 in the ileal mucosa tissue is 
significantly decreased in patients with ileal Crohn’s disease (L1) as well as in patients 
with ileocolonic involvement of disease (L3) in comparison to patients with colonic 
CD (L3) and to the healthy control group (figure 17, A). In the Norwegian cohort, 
similar effects were detected. TCF-1 mRNA expression in biopsies isolated from the 
small intestine was significantly reduced (p=0.0007) in patients suffering from CD 
with ileal involvement (L1 and L3) in comparison to non-IBD controls and to patients 
suffering solely from colonic disease (figure 18, A). The latter showed only very 
slightly decreased levels of TCF-1.  
In the Stuttgart cohort the mRNA expression of TCF-1 does not show any 
significant differences in the analysed groups in colonic mucosa tissue (figure 17, B).  
The TCF-1 gene can generate full-length activating isoforms as well as 
dominant negative isoforms by alternative promoter usage. A real-time PCR assay 
was used, which only detects the active TCF-1 mRNA isoform 1 containing the β-
catenin binding domain and found similar results then for general TCF-1. Patients 
with ileal and ileocolonic CD had significantly decreased levels of TCF-1 isoform 1 in 
the small intestine in comparison to colonic CD patients and to the control group 
(figure 17, C). Also the active TCF-1 isoform 1 mRNA in the Norwegian cohort was 
significantly reduced (p=0.0008) in L1 and L3 CD patients in comparison to the non-
IBD control group and children suffering from colonic CD (figure 18, B). Again, the 
expression in the colonic biopsies revealed no significant differences, despite similar 
trends in the Stuttgart cohort (figure 17, D).   
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Figure	 17:	TCF-1	 and	 active	 TCF-1	 isoform	 expression	 in	 the	 ileal	 and	 colonic	mucosa	 of	 healthy	
controls	and	patients	with	Crohn’s	disease	from	Stuttgart.	TCF-1	(A,	B)	and	active	TCF-1	isoform	(C,	
D)	 mRNA	 expression	 were	 quantified	 by	 LightCycler	 real-time	 reverse	 transcriptase	 PCR	 in	 small	
intestinal	and	colonic	biopsies	 from	a	control	group	(n=27),	Crohn’s	disease	(CD)	patients	with	 ileal	
(L1,	n=14),	colonic	(L2,	n=19)	and	ileocolonic	phenotype	(L3,	n=26)	at	diagnosis,*	p	<0.05,	**	p	<	0.01	
(Beisner,	Teltschik	et	al.,	2014).		
 
 
Figure	18:	Expression	of	TCF-1	in	the	ileal	mucosa	of	paediatric	CD	patients	from	Norway.		
Paediatric	patients	with	 ileal	Crohn’s	disease	 (L1	+	 L3,	n=22)	 show	significantly	decreased	 levels	of	
TCF-1	(p=0.0007)	(A)	and	active	TCF-1	isoform	1	(B)	in	comparison	to	patients	suffering	from	colonic	
Crohn’s	disease	(L2,	n=6)	and	non-IBD	controls	(n=29),	**	p	<	0.01	(Beisner,	Teltschik	et	al.,	2014).		
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3.3.3 TCF-1 knockout mice 
To further study the functional role of TCF-1 in vivo, mRNA expression levels 
of different defensins, extracted from the middle part of the small intestine (jejunum) 
of TCF-1 knockout mice (with a C57BL6 background) were analysed by quantitative 
real- time PCR. To confirm the TCF-1 knockout TCF-1 expression on mRNA level was 
analysed. In heterozygous knockout mice the levels of TCF-1 were 2-fold lower than 
in wild type mice, in homozygous knockout mice the levels of TCF-1 were only very 
low residual, non-functional levels of TCF-1 detectable (data not shown). This is 
consistent with former data and relates to the fact that the knockout only affects parts 
of the gene as described in (F. J. Staal et al. 2001).  
Further the expression of Defa21, which is a C57BL6 strain specific analogue to 
cryptdin 4 was measured (Shanahan, Tanabe, and Ouellette 2011). Heterozygous 
knockout mice show slightly reduced levels of this cryptdin in comparison to wild 
type mice, homozygous TCF-1 knockout mice showed even stronger, significantly 
reduced expression (figure 19, A). Additionally the expression of Defa24, lysozyme 
and cryptdin-related sequence-1C (CRS-1C) showed similar but not significant trends 
(figure 19, B, C, D). Analysis of the proximal and the distal part of the small intestine 
did not consistently show the same trends. To get a better overview of all cryptdins, a 
pan cryptdin assay (Shanahan et al. 2010) was performed to asses total cryptdin 
mRNA levels in the duodenum, the jejunum and the ileum of TCF-1 knockout mice. 
Pan cryptdin expression in the jejunum was significantly decreased in homozygous 
TCF-1 knockout mice in comparison to wild type mice (figure 20, A, B, C). These 
results are corresponding to the mentioned results for defa21. Further the expression 
of Reg3γ, the mouse analogue to the human Reg3α, which is one of the best-studied 
bactericidal lectins was analysed. In the duodenum in the jejunum, but not in the 
ileum, significantly increased expression in the TCF-1 knockout mice was found 
(figure 20, D, E, F).  
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Figure	19:		Expression	of	Paneth	cell	gene	products	in	the	small	intestine	of	Tcf-1	1	+/+,	+/-	and	-/-	
mice.	mRNA	expression	levels	of	defa24	(A),	defa21	(B),	lysozyme	(C)	and	cryptdin-related-sequence	
1c	(CRS1C)	were	quantified	by	LightCycler	real-time	reverse	transcriptase	PCR	 in	the	middle	part	of	
small	 intestinal	mouse	tissues	of	Tcf-1	+/+	(n=6),	+/-	(n=6)	and	-/-	mice	(n=6)	.	**	p	<	0.01	(Beisner,	
Teltschik	et	al.,	2014).	
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Figure	 20:	 Expression	 of	 total	 Paneth	 cell	 α-defensins	 (pan	 cryptdin)	 and	 Reg3γ	 in	 the	 small	
intestine	of	of	Tcf-1	+/+,	+/-	and	 -/-	mice.	mRNA	expression	 levels	of	 total	 cryptdins	 (A,	B,	C)	 and	
Reg3γ	(D,	E,	F)	in	the	tissue	from	the	duodenum,	jejunum	and	ileum	from	Tcf-1	+/+,	+/-	and	-/-	mice	
(each	n=6),	*	p	<	0.05	(Beisner,	Teltschik	et	al.,	2014)	.	
	
3.4 Functional relevance of antimicrobial defence regarding bacterial 
translocation in two animal models  
 
Parts of these results have previously been published in: 
 
Intestinal bacterial translocation in rats with cirrhosis is related to 
compromised Paneth cell antimicrobial host defense. 
Teltschik Z1, Wiest R, Beisner J, Nuding S, Hofmann C, Schoelmerich J, Bevins CL, 
Stange EF, Wehkamp J. Hepatology. 2012 Apr;55(4):1154-63. doi: 
10.1002/hep.24789. Epub 2012 Feb 15. 
 
Author contributions: 
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Since the study of antimicrobial function in the human in vivo situation 
provides various challenges and proves to be rather limited to descriptive data, it was  
aimed to further investigate the role of defensins and other antimicrobials in animal 
models. One event that is linked to impaired barrier function and therefore 
potentially to changes in antimicrobial defence, is the translocation of bacteria over 
the gastrointestinal mucosa. Mucosal adherent bacteria are seen in IBD and are likely 
linked to defective expression of antimicrobial peptides (Y. Liu et al. 1995; Darfeuille-
Michaud et al. 2004; Swidsinski et al. 2005). In liver cirrhosis, another devastating 
gastrointestinal disorder, bacterial translocation (BT) has been implicated as a 
pathogenesis-promoting event. If and how antimicrobial defense at the intestinal 
barrier plays into a gut liver axis regarding bacterial translocation and the onset or 
maintenance of cirrhosis has yet to be studied. 
3.4.1 Rats with liver cirrhosis and rats with portal vein ligation 
To better understand the mechanisms, which could lead to deficiencies in 
antimicrobial defence in the intestine, two different rat models were analysed. From 
former studies it is known that patients with liver cirrhosis (LC) suffer from severe 
inflammations and sepsis, which is mostly caused by bacteria originating from the 
normal gut microbiota (Wiest and Garcia-Tsao 2005; Steffen, Berg, and Deitch 1988). 
The liver cirrhosis rat model comprised rats with a CCl4 induced liver cirrhosis. The 
portal vein ligation (PVL) model comprised rats with a portal vein ligation, imitating 
the congestion of blood, which is typically observed in liver cirrhosis due to destroyed 
liver tissue, but without the cirrhosis. This model was used to exclude the possibility 
that the observed changes in the LC model are only due to liver cirrhosis- induced 
portal hypertension.  
3.4.1.1 Rat model with liver cirrhosis 
Rats in this model were exposed to CCl4 (inhalation) along with phenobarbital 
in the drinking water (Wiest et al. 2003). After 12 to 16 weeks this approach induces 
micronodular liver cirrhosis with ascites.  
3.4.1.2 Intestinal bacterial translocation in a rat liver cirrhosis model 
BT was visualized with green fluorescent protein (GFP) labelled E. coli. To 
obtain this labelled E. coli a clinical isolate was transformed with a high-copy plasmid 
pCU18-GFP, carrying a modified gfp-gene. 108 labelled E. coli were administered to 
the rats and six hours later MLN and ascites fluid were harvested and cultured. GFP- 
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marked E. coli bacteria were found along the gastrointestinal (GI) tract in the stool 
but also in mesenteric lymph nodes, indicating a translocation of these bacteria 
(figure 21, C). This work was performed in cooperation with Rainer Wiest from the 
University Hospital Regensburg. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
Figure	 21:	 Representative	 bacteria	 culture	 of	 mesenteric	 lymph	 nodes	 (MLN)	 from	 rats	 with	
cirrhosis	and	ascites.	A:	Animal	without	bacterial	translocation	(BT):	sterile	plates	after	48	hours	of	
incubation.	 B:	 Animal	with	 BT:	 endogenous	 commensal	 E.	 coli	 on	 each	 culture	 plate.	 From	 left	 to	
right:	Mueller-Hinton,	MacConkey,	and	whole	blood	agar	plates.	C:	Separate	experiment	in	an	ascitic	
rat	with	cirrhosis	that	was	administered	a	high	amounts	of	Green	Fluorescent	Protein-marked	E.	colis	
harvested	after	6	hours.	Fluorescent	E.	colis	can	be	seen	not	only	 in	high	density	along	the	GI	tract	
but	 also	 in	 cultures	 obtained	 from	MLNs	 as	 well	 as	 in	 ascites.	 This	 experiment	 was	 performed	 in	
cooperation	with	Rainer	Wiest	from	the	University	Hospital	Regensburg	(Teltschik	et	al.,	2012).	
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3.4.1.3 Increased bacterial translocation in LC can not be explained by 
intestinal inflammation  
Intestinal tissue from cirrhotic rats with and without BT and healthy controls 
were scored to investigate whether the expression changes of antimicrobial and related 
peptides might be due to a secondary effect of inflammation. As shown before (Saitoh 
et al. 1999), liver cirrhosis was associated with intestinal inflammation (figure 22) but 
without striking differences between the cirrhosis groups with and without BT. No 
significant differences between both cirrhotic groups were observed throughout the 
different tissues in the ileum, coecum and colon (figure 22).  
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Figure	 22:	 Inflammation	 score	 in	 rats	 with	 liver	 cirrhosis	 without	 (LC-)	 and	 with	 bacterial	
translocation	(LC+).	Cross	sections	of	 the	 ileum,	coecum	and	colon	were	haematoxilyn-eosin	stained	
and	 the	 histological	 damage	 was	 scored.	 The	 degree	 of	 inflammatory	 infiltrate	 and	 the	 mucosal	
architecture	were	graded	from	0	to	4.	No	significant	differences	between	the	groups	were	observed	
(Teltschik	et	al.,	2012).	
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3.4.1.4 Expression of some Paneth cell products in LC rats is decreased 
Expression levels of different antimicrobial peptides and related products were 
analysed with quantitative real-time PCR in different parts of the intestine from rats 
with LC and BT, rats with LC without BT and healthy controls. Reduced expression of 
Paneth cell defensins was found to be associated with BT throughout the whole 
intestinal tract (figure 23). Especially cryptdin 5 and 7 expression was significantly 
decreased in rats suffering from LC and BT. These changes were most pronounced in 
the proximal (crypt 5 p = 0.02; crypt 7 p=0.008) and distal ileum (crypt 5 p=0.02; 
crypt7 p=0.01). Expression of these two defensins was almost undetectable in the 
coecum and the colon from LC rats with BT in comparison to LC rats without BT; 
these latter exhibit even increased levels of cryptdin 5 and 7 in comparison to the 
healthy control group, whereas lysozyme was significantly upregulated in the BT 
group in comparison to controls. The hepatocarcinoma–intestine–
pancreas/pancreatic–associated protein 3 (HIP/PAP3), a member of the Reg family 
of AMPs expressed in Paneth cells, showed a diverse picture with also almost 
undetectable expression in the coecum and colon of LC+BT rats.  
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Figure	23:	Expression	of	Paneth	cell	antimicrobial	peptides	in	liver	cirrhosis	without	(LC-BT)	and	with	
bacterial	 translocation	 (LC+BT).	 Expression	 of	 cryptdin	 5,	 cryptdin	 7,	 hepatocarcinoma-intestine-
pancreas/	 pancreatic-associated	 protein	 3	 (HIP/PAP3)	 and	 lysozyme	 in	 proximal	 and	 distal	 small	
intestine,	 coecum	and	colon	of	 controls,	 LC-BT	group	and	LC+BT	group	 (n=15)	was	assessed	by	 real-
time	qPCR.	Means	(+/-	SEM)	of	transcript	copies	are	shown	per	1000	copies	β-actin,	*	p	<	0.05,	**	p	<	
0.01,	***	p	<	0.001	(Teltschik	et	al.,	2012).	
 
3.4.1.5 Expression of different non-Paneth cell products in rats with liver 
cirrhosis 
Measuring the expression levels of the non-Paneth cell antimicrobials β-
defensin 1 (BD1), β-defensin 2 (BD2), CRAMP, which is the rat analogue to 
cathelicidin and Neutrophil protein 3 (NP3), revealed much lower overall expression, 
similar to what was observed for the Paneth cell products (figure 24). BD1, which is 
produced by normal enterocytes, was upregulated in the proximal and distal small 
intestine and in the coecum of rats with LC+BT. The observed up-regulation was 
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most pronounced in the proximal ileum (p=0.006). The CRAMP expression in the 
coecum of rats with liver cirrhosis is significantly decreased (p=0.0027), this effect is 
even stronger in the subgroup with BT (p=0.0002). 
Figure	24:	Expression	of	non-Paneth	cell	antimicrobial	peptides	in	liver	cirrhosis	without	(LC-BT)	and	
with	 bacterial	 translocation	 (LC+BT).	 Expression	 of	 β-defensin	 1	 (BD1),	 β-defensin	 2	 (BD2),	 the	 rat	
analogue	 to	 cathelicidin	 (CRAMP)	 and	 the	 neutrophil	 protein	 (NP3)	 in	 the	 proximal	 and	 distal	 small	
intestine,	 coecum,	and	colon	of	 the	controls,	 LC-BT	group,	and	LC+BT	group	 (n=15)	was	assessed	by	
real-time	 qPCR.	 Means	 (6SEM)	 of	 transcript	 copies	 are	 shown	 per	 1000	 copies	 β-actin,	 *p<0.05,	
**p<0.01,	***p<0.001	(adapted	from	Teltschik	et	al.,	2012).	
3.4.1.6 Antimicrobial activity in rats with liver cirrhosis and controls 
shows significant differences  
As already published as a part of my diploma thesis: “Gestörte Defensinabwehr 
als mögliche Ursache einer bakteriellen Translokation bei Leberzirrhose” at the 
University of Hohenheim in 2009, the mucosal antimicrobial activity (% of killed 
bacteria) in rats with liver cirrhosis with bacterial translocation (LC+BT) against 
different commensal bacteria is reduced in the distal small intestine. In the normally 
sterile proximal intestine, the functional antimicrobial activity in rats with cirrhosis 
against Enterococcus faecalis ATCC 29212 and Bacteroides fragilis ATCC 25285 was 
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comparable to that of controls but approximately doubled against E. coli K12 and 
Bifidobacterium adolescentis Ni3, 29c, with no difference between BT and non-BT 
(figure 25). However, in the distal ileum diminished activity against E. coli and 
Enterococcus faecalis was found in the rats with cirrhosis with BT compared with non-
BT. A similar effect was detected in the coecum against Bacteroides fragilis and in the 
colon against Bifidobacterium adolescentis. 
 
Figure	25:	Antimicrobial	activity	(%	of	killed	bacteria)	in	rats	with	liver	cirrhosis	without	(LC-BT)	and	
with	bacterial	translocation	(LC+BT)*.	Data	are	based	on	protein	extracts	from	controls,	LC-BT	group	
and	LC+BT	group	(n=15)	against	E.	coli	K12,	B.	adolescentis	Ni3,	29c,	B.	fragilis	ATCC	25285,	E.	faecalis	
ATCC	29212.	*	p	<	0.05,**	p	<	0.01,	***	p	<	0.001	(Teltschik	et	al.,	2012).	
*	these	data	are	already	published	as	part	of	my	diploma	thesis:	“Gestörte	Defensinabwehr	als	mögliche	Ursache	
einer	bakteriellen	Translokation	bei	Leberzirrhose”	at	the	University	of	Hohenheim	in	2009.	
3.4.2 Portal vein ligation rat model 
The portal vein ligation (PVL) model was chosen in order to examine whether 
the changes in antimicrobial peptide expression could be related to the phenomenon 
of portal hypertension per se. This model is known to lack hepatic parenchymal cell 
damage as well as Kupffer cell dysfunction. Importantly, this PVL animal model is 
characterized by a high rate of bacterial translocation to mesenteric lymph nodes 
(Neugebauer et al. 2008). Portal hypertension was induced surgically in aseptic 
conditions as it has been described before (Lopez-Talavera et al. 1996).  
RESULTS	 85	
 
 
 
3.4.2.1 mRNA expression of 4 antimicrobial peptides in PVL rats seems to 
be unchanged  
Measuring the expression levels of cryptdin 5, cryptdin 7, HIP/PAP3 and 
lysozyme in the proximal and distal small intestine, in the coecum and the colon of 
rats with portal vein ligation and in healthy control rats did not reveal significant 
differences in these two groups for all four measured products (figure 26). 
 
  
Figure	26:	Expression	of	Paneth	cell	antimicrobial	peptides	in	rats	with	portal	vein	ligation.		
Expression	 of	 cryptdin	 5,	 cryptdin	 7,	 hepatocarcinoma-intestine-pancreas/	 pancreatic-associated	
protein	3	(HIP/PAP3)	and	lysozyme	in	proximal	and	distal	small	intestine,	coecum	and	colon	of	controls	
(n=6)	and	rats	with	portal	hypertension	(PVL)	(n=6)	was	assessed	by	real-time	qPCR.	Means	(+/-	SEM)	
of	transcript	copies	are	shown	per	1000	copies	β-actin	(Teltschik	et	al.,	2012).	
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3.4.2.2 Antimicrobial activity in PVL rat intestine and controls seems to 
be unchanged  
Measuring the antimicrobial activity against the same strains used for 
measuring the antimicrobial activity in rats with liver cirrhosis revealed slightly up-
regulated activity against E. coli K12 in the proximal and distal ileum and the coecum 
and against Bifidobacterium adolescentis Ni3, 29c in all parts of the intestine. No 
differences between controls and PVL rats were observed against Enterococcus 
faecalis ATCC 29212 and Bacteroides fragilis ATCC 25285 (figure 27). 
 
Figure	 27:	 Antimicrobial	 activity	 (%	 of	 killed	 bacteria)	 in	 rats	with	 portal	 hypertension.	 Data	 are	
based	on	protein	extracts	from	controls	(n=6)	and	rats	with	portal	hypertension	(PVL)	(n=6)	against	E.	
coli	 K12.	 B.	 adolescentis	 Ni3,	 29c,	 B.	 fragilis	 ATCC	 25285,	 E.	 faecalis	 ATCC	 29212	 (Teltschik	 et	 al,	
unpublished).	
 
These findings emphasize the specificity of the findings in rats with liver cirrhosis. 
Also, these data suggest that BT in acute vein ligation is caused by a different 
mechanism, which seems to be independent of the expression levels of some major 
AMPs.
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4. DISCUSSION  
In the recent years, the balance between our gut immune system and our gut 
microbiota has gained popularity in research regarding multiple diseases but also as a 
crucial part of human health in general. Today many questions remain unanswered 
when considering all the mechanisms involved in the maintenance of such a 
beneficial homeostasis. The aim of this study was to shed light on some of these 
critical homeostasis-promoting functions. A particular emphasis was placed on the 
host side, but the microbial side was also considered and studied in functional 
models. One disorder at the forefront of disturbed host microbe interaction is 
Crohn´s disease, which also involves defects in the Wnt signaling pathway (Beisner et 
al. 2014; Koslowski et al. 2012; Wehkamp et al. 2007). Other factors of this important 
pathway were studied to generate new findings, which help to explain what enables 
commensal microbiota to enter the mucosa and cause inflammations. As described 
previously, AMPs, which are in part regulated by the Wnt signaling pathway influence 
the intestinal microbiota (Salzman et al. 2003, 2010), and a disbalance in this system 
can disturb the homeostasis thereby becoming a predisposing factor in the 
pathogenesis of CD (Ostaff, Stange, and Wehkamp 2013). It was able to show that 
LRP6, an important Wnt co-receptor directly regulates Paneth cell HD-5 and HD-6 
expression levels (Koslowski et al. 2012b), while LRP5 on the other hand is neither 
changed on the transcriptional expression level in patients, nor functionally involved 
in the regulation of these important α-defensins in vitro. Finally, this second Wnt co-
receptor, while displaying a great heterogeneity in multiple studied populations, 
showed no genetic association with any subgroup of CD. TCF-1 on the other hand, 
which is also directly linked to HD-5 and HD-6 expression, displays reduced mRNA 
in ileal CD patients. A knockout of this important Wnt transcription factor is 
furthermore linked to lower levels of mouse Paneth cell cryptdins in vivo (Beisner et 
al. 2014). 
Studying antimicrobial function in humans is limited more or less to 
descriptive data. Alternatives are animal models. For analysing the function and role 
of antimicrobial peptides a liver cirrhosis rat model was chosen. In severe liver 
cirrhosis, another disastrous gastrointestinal disorder, bacterial translocation 
through the gastrointestinal mucosa to mesenteric lymph nodes is common and a 
pathogenesis-promoting event (Wiest, Lawson, and Geuking 2014). This could be due 
to impairments in barrier function, and therefore due to changes in antimicrobial 
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defense. Mucosal adherent bacteria are seen in IBD, which has been linked to 
defective expression of antimicrobial peptides (Perminow et al. 2010). It was tried to 
elucidate if and how antimicrobial defense at the intestinal barrier plays into a gut 
liver axis under regard of bacterial translocation and the onset or maintenance of 
cirrhosis. In this context, it was possible to show that indeed, differences in the 
expression of Paneth cell defensins and other AMPs are linked to bacterial 
translocation events (Teltschik et al. 2012). These results, as well as the above 
mentioned data on Wnt signaling factors in ileal CD will be discussed in further detail 
in the following chapters. 
4.1 Low-density lipoprotein receptor-related protein 6 (LRP6) 
The analysis on the functional role of Wnt in ileal CD´s pathogenesis was 
started with studies on LRP6. To confirm that this important Wnt co-receptor is 
expressed at the bottom of crypts, where the Paneth cells are located, 
immunohistochemical staining of human small intestinal tissue slices was performed. 
LRP6 could be detected in the whole epithelium suggesting an expression also at the 
bottom of the crypt where active Wnt signaling is important for the α-defensin 
expression. To get an idea whether this expression can translate into a functional 
involvement, in vitro experiments using a HEK-293 cell line were performed. 
Unfortunately, no small intestinal cell line exists, and colonic cell lines are unsuitable 
for studying Wnt related mechanisms, since the exclusively descend from cancer 
tissue, which harbors mutations that constitutively increase Wnt signaling activity 
(Teltschik et al. 2012). HEK-293 cells on the other hand originate from human 
embryonic kidney cells and harbor no Wnt affecting mutations. It is therefore often 
the cell line of choice when studying this pathway. The problem using this cell line is 
that tissue-specific properties and interactions are ignored.  
LRP6 overexpression in HEK-293 cells showed promoter transactivation of the 
target genes HD-5 and HD-6, confirming a direct role of LRP6 in regulating both 
these Paneth cell α-defensins. Transfection with a TopFlash luciferase reporter 
construct, which is an artificial promoter that is very responsive to Wnt signaling 
because it contains multiple repeated copies of wild-type TCF/LEF-binding sites 
(Korinek et al. 1997; van de Wetering et al. 1997), showed corresponding effects. This 
β-catenin dependent induction of Wnt signaling by LRP6 overexpression is consistent 
with former findings (MacDonald et al. 2011). These results show the importance of 
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LRP6 in mediating β- catenin dependant Wnt signaling and highlights it’s importance 
in regulating α- defensin expression. 
4.2 Low-density lipoprotein receptor-related protein 5 (LRP5) 
Because LRP6 holds a critical role in mediating regulation of α-defensins (M. 
J. Koslowski et al. 2012) it was hypothesized that the LRP6 homologue LRP5 is also 
involved in this regulation. Measuring mRNA levels in the Stuttgart cohort and a 
pediatric cohort from Norway revealed no significant differences between CD patients 
(in ileal and colonic subgroups) and a healthy control group. This leads to the 
conclusion that the observed decrease in human α-defensin 5 in patients with ileal 
CD (L1+L3) is not additionally due to changed expression levels in LRP5. If the 
receptor is however functionally involved in their regulation still remained to be 
answered. To further elucidate the functional role of LRP5, overexpression 
experiments with HD-5 or either HD-6 co-transfection in HEK-293 were performed. 
After overexpression of LRP5 and subsequent co-transfection with either a HD-5 or 
HD-6 promoter construct, Wnt signaling was stimulated with either Wnt1 or Wnt3a. 
To exclude effects due to LRP6 activity, LRP6 was knocked-down with siRNA. No 
significant induction of the HD-5 and HD-6 promoter activity was observed, also 
after stimulation with Wnt3a which was already described to increase LRP5 signaling 
activity before (Grumolato et al. 2010), indicating that LRP5 is not required to induce 
α-defensin expression. These results are consistent with data from MacDonald et al. 
(MacDonald et al. 2011). The group could show that the signaling capacity of LRP6 is 
much stronger than the LRP5 signaling capacity. But again, since LRP5 could have 
other important functions in maintaining epithelial integrity, it is not possible to 
exclude that it might nonetheless be involved in CD pathogenesis. The failed 
induction by Wnt3a and Wnt1 could also be due the used method. Although Wnt3a 
and Wnt1 are described to activate canonical Wnt pathway, many functions of the 
different Wnt ligands and which pathways they activate are still unknown 
(Dijksterhuis, Petersen, and Schulte 2014). The used artificial Wnt stimulants were 
not able to lead to a stable stimulation and it was not possible to observe stimulating 
effects at all. This could also be due to the fact that it seems very difficult to obtain 
pure biological active Wnts (Dijksterhuis, Petersen, and Schulte 2014). Cells 
stimulated with Wnt3a conditioned medium showed effects on Wnt signaling in HEK 
cells (Surmann-Schmitt et al. 2009).  
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A coding allele, the AIle1062Val SNP (rs2302685) in the LRP6 gene is 
associated with the development of early onset of small intestinal CD, arguing for the 
analysis of mutations in the LRP5 gene to elucidate whether CD patients, or a 
subgroup of CD patients, carry single nucleotide polymorphisms (SNPs) which could 
be predisposing in the development of CD. To investigate the potential role of LRP5 
in the pathogenesis of CD analysis of 45 SNPs (for detailed information, see figure 14) 
in the gene was performed. These SNPs, made up of exonic, coding (non-
synonymous) SNPs, exonic synonymous SNPs but also intronic SNPs, were analysed 
in three different European cohorts (Stuttgart, Vienna, Leuven). After sub-grouping 
the samples according to gender, age, age of onset of disease, behaviour of disease 
and location (L1, L2 and L3 and additional involvement of the upper GI-tract (L4)), 
the data set was analysed. Although significant differences in single cohorts were 
observed, overall analysis relativized the observed differences. This could be due to 
the fact the LRP5 gene seems to be very heterogeneous in the studied populations. An 
at least partial explanation for this observation could also be the essential role that 
the protein plays in skeletal homeostasis and some of the bone density related 
variability and diseases within populations seem to be for example linked to SNPs in 
LRP5 (Yi et al. 2013). Furthermore, familial exudative vitreoretinopathy has also 
been linked to mutations in this gene (Toomes et al. 2004). 
That SNPs associated with bone mineral density (BMD) variability, might not be 
under high selection pressure could be due to the fact that some of these SNPs could 
also have protecting abilities in other contexts. This is a possible explanation why the 
LRP5 gene seems to be so heterogeneously in regards to its SNP allele frequencies. 
The broad range of SNPs which are associated with different diseases or phenotype 
variability also make it hard to unmask potential effects in the IBD cohort since it is 
not possible to stratify the samples according to such possible confounders. Around 
15 SNPs in the LRP5 gene are associated with the development of familial exudative 
vitreoretinopathy, most of them influence the amount of produced LRP5 (Qin et al. 
2005; Toomes et al. 2004; Qin et al. 2008). Around 5 SNPs in the LRP5 gene are 
furthermore associated with juvenile primary osteoporosis. This leads to reduced 
signaling capacity of LRP5 which disrupts the regulation of BMD and causes early 
onset osteoporosis (Hartikka et al. 2005; Korvala et al. 2012). Osteoporosis-
pseudoglioma syndrome, which is associated with extremely low bone mineral 
density, is associated with more than 40 SNPs in the LRP5 gene. Patients suffering 
from this disease have multiple bone fractures and often form eye abnormalities. A 
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lot of the associated mutations obviate any production of LRP5 protein, others cause 
abnormal proteins not able to insert into their proper position and thereby disables 
them to perform their proper function (Ai et al. 2005; Gong et al. 2001; Levasseur, 
Lacombe and de Vernejoul 2005). Low BMD and osteoporosis is partly believed to be 
developed secondary due to medication and malabsorption caused by inflammation 
(Reinshagen 2008). But medication and inflammation can only explain parts of the 
observed effects and genetic predispositions predominantly in the Wnt pathway 
confer major risks (Ali et al. 2009). But not only low BMD is observed in patients 
with SNPs in the LRP5 gene, some SNPs are associated with increased bone mineral 
density. Persons with increased bone mineral density sometimes suffer from 
abnormal bone growth and skeletal architecture but can also be completely free of 
symptoms (Van Wesenbeeck et al. 2003; Boyden et al. 2002). Again, these examples 
suggest a high variability due to many SNPs in the gene, which can influence highly 
variable phenotypes within a population.  In the cohort it was not possible to stratify 
since the knowledge in the case history of the patients regarding other diseases, as 
well as their BMD was not available. Another, methodical, reason for the 
heterogeneous results in the three cohorts could be that the used cohorts are too 
small. Further experiments should be conducted in bigger cohorts.  
4.3 T cell transcription factor 1 (TCF-1, TCF7) 
Since it could be shown that the Wnt transcription factor TCF-4 shows 
aberrations in ileal CD patients and is furthermore important for the regulation of 
HD-5 and HD-6 (Wehkamp et al. 2007), it was decided to study TCF-1 in this context. 
Immunohistochemistry revealed expression of active TCF-1 in Paneth cells and also 
in Paneth cell progenitors above Paneth cells in the crypt. That active Wnt signaling is 
essential for the regulation of α-defensins in Paneth cells, as mentioned, is in line 
with former findings from our group (Wehkamp et al. 2007) and also with findings 
from Gregorieff et al., who could show that TCF-1 is also found to be expressed in 
epithelial cells in the crypt base (Gregorieff et al. 2005). In this context it makes 
complete sense that active TCF-1 is detected in α-defensin producing Paneth cells. 
Measuring the expression of TCF-1 and the active isoform 1 in the Stuttgart cohort 
showed significantly reduced levels of both in small intestinal biopsies from patients 
with ileal CD and also in patients with ileocolonic disease. Expression of TCF-1 and 
active TCF-1 isoform 1 were furthermore analysed in a second cohort from Norway 
comprising children with CD and a healthy control group. As in the Stuttgart cohort, 
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pediatric patients with ileal and ileocolonic disease showed significantly reduced 
expression levels of TCF-1 and active TCF-1 isoform 1 (Beisner et al. 2014). These 
findings further strengthen the finding that the Wnt signaling pathway has an 
important role in the pathogenesis of CD. To further study the role of TCF-1 in vivo, 
analysis of the mRNA levels of different cryptdins (mouse α-defensins) in a TCF-1 
knockout mouse model was performed. Analysing these cryptdins and also other 
Paneth cell products showed that, when TCF-1 is depleted, the levels of some 
cryptdins are slightly decreased (figure 19). These trends are weaker, but in line with 
former findings from our group, which showed that in TCF-4 heterozygous knockout 
mice, the levels of cryptdins are decreased (Wehkamp et al. 2007, 4). Paneth cell 
numbers are unchanged in TCF-1/TCF-3 double knockout mice (J. H. van Es et al. 
2012), indicating that the observed effects are not due to lower Paneth cell numbers 
in the TCF-1 knockout mice. Possible is that stronger effects due to TCF-1 depletion 
could be compensated by TCF-4, which has overlapping functions, resulting in lower 
effects. Another possibility is that in mice, other mechanisms or regulatory influences 
are important in these parts of the intestine. Neonatal TCF-4 knockout mice display a 
complete lack of intestinal crypts, which is also seen in conditional knockout of β-
catenin, resulting in completely blocked cell proliferation (van Es et al. 2012). 
Analysing the expression of total cryptdins with a pancryptdin assay in the 
duodenum, jejunum, and ileum of the same mice showed decreased cryptdin levels in 
the jejunum but not in the duodenum and the ileum. Interestingly, Reg3γ and 
lysozyme as two other Paneth cell products, not belonging to the group of cryptdins 
showed a different trend; lysozyme mRNA expression is similar to the observed 
trends in cryptdin expression whereas Reg3γ displays even higher expression in 
homozygous TCF-1 knockout mice (figure 20), prompting for an other regulation 
mechanism than cryptdins. In addition Reg3γ is also produced by enterocytes and 
lysozyme by macrophages and certain cells in the lamina propria (Bevins and 
Salzman 2011; Cash et al. 2006). This inconclusive data suggests slight effects on 
cryptdin expression in at least the jejunum of homozygous TCF-1 knockout mice. As 
mentioned before, Paneth cell number is likely unchanged in these mice suggesting 
another reason than Paneth cell number to be responsible for the observed effects.  
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4.4 Examination of the functional relevance of antimicrobial peptides in 
the intestine in two different animal models  
Animal models are a possibility to study aspects or answer questions when the 
options in humans are limited due to limited sample availability and ethical issues. 
Herein two different rat models were used to better understand the role of defensins 
and other antimicrobial peptides in vivo. Severe liver cirrhosis is linked to 
impairments in barrier function, which leads to bacterial translocation (BT) over the 
mucosa and to the mesenteric lymph nodes (Wiest, Lawson, and Geuking 2014). This 
situation is similar to the situation in inflammatory bowel diseases. In both, 
commensals of the gut play a central role in the pathogenesis of the disease. It is 
likely that a connection between the liver and the gut together with other unknown 
hepatic factors and antimicrobial peptides at the intestinal barrier could have impact 
on the mucosal immune system. The LC rat model comprised rats with a CCl4 induced 
liver cirrhosis. The second model was used to exclude the possibility that the 
observed changes in the LC model are only due to liver cirrhosis- induced portal 
hypertension. The portal vein ligation (PVL) model comprised rats with a portal vein 
ligation, imitating the congestion of blood, which is typically observed in liver 
cirrhosis due to destroyed liver tissue, but without the cirrhosis. Measuring the 
mRNA levels of different antimicrobial and related peptides revealed significantly 
decreased levels of cryptdin 5 and 7 in rats with liver cirrhosis and BT in comparison 
to rats with liver cirrhosis without BT and to healthy control rats. In PVL rats, no 
significant decreased levels were observed in comparison to controls, arguing for a 
mechanism, which seems to be independent of the portal hypertension as it was 
observed in both models. The mechanisms causing the BT in the PVL rats is indeed 
likely different, because in the PVL group, all animals develop BT short after vein 
ligation although the defensin expression is not significantly changed, whereas BT in 
the CCL4 model was clearly associated with reduced AMP levels along with decreased 
cryptdin mRNA levels in the LC+BT group, the antimicrobial activity of protein 
extracted from intestinal tissue is also decreased against different bacterial strains. 
Because inflammation is associated with liver cirrhosis, the inflammation state of the 
rats was additionally assessed and it could be shown that effects were not only a 
consequence of intestinal inflammation as the inflammation score did not correlate 
with the decrease in AMPs (Teltschik et al. 2012). The mechanisms, which could be 
critical for the observed decrease in Paneth cell cryptdins in the subgroup with liver 
cirrhosis and BT remain unclear but the decreased antimicrobial activity in these 
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animals are likely not mediated by a changed β-defensin (BD) expression. As 
mentioned, the picture is more diverse as for BD1, even a slight up-regulation in the 
LC+BT group was observed. The working group around Salzman et al. could show 
that Paneth cell defensins have the potential to inhibit BT in a transgenic mouse 
model (Salzman et al. 2003). Those findings support the data by indicating that the 
decrease in α-defensins or cryptdins could favour BT.  
That BT is only linked to a subgroup of rats with liver cirrhosis could possibly 
be explained by genetic predispositions. Especially because it is known that 
mutations in the NOD2 receptor, which has been linked to Paneth cell defensin 
expression (Bevins, Stange and Wehkamp 2009), and other genetic mechanisms are 
linked to bacterial peritonitis and even death in liver cirrhosis patients (Appenrodt et 
al. 2010; Bruns et al. 2012). As mentioned above, variants in this gene are linked to 
ileal Crohn´s disease and thereby to decreased antimicrobial peptide expression in 
the Paneth cells leading to a shift in the bacterial composition which could promote 
bacterial overgrowth and translocation (Wehkamp et al. 2004; Wehkamp et al. 
2005). In healthy individuals, the complex interplay between microbes and intestinal 
mucosal defence leads to a well-balanced cooperation of commensals and host 
defence against invading pathogens which also prevents inflammation (Hooper and 
Gordon 2001). Assuming that in predisposed animals liver cirrhosis favours the 
disruption of this balance because of a misbalanced production of α-defensins 
especially in the small intestine, these changes may lead to a disturbed microbial 
composition promoting BT (Morencos et al. 1996; Gupta et al. 2010; Natarajan et al. 
2006). To better understand the underling mechanisms it would be necessary to 
perform genetic analysis in LC rats.  
4.5 Conclusion 
Taken together, within this work it was possible to shed light on multiple 
mechanisms involved in balancing host microbe interactions at the intestinal barrier. 
It was able to further highlight the Wnt pathway as an important contributor to ileal 
CD. Amongst other mechanisms, Wnt signaling could be identified as a relevant 
factor in the transcriptional expression of the Paneth cell antimicrobial peptides HD-
5 and HD-6. Both these defensins are known to be crucial in maintaining a beneficial 
homeostasis towards microbiota at the small intestinal barrier. Furthermore, it could 
be demonstrated that bacterial translocation in a rat model of liver cirrhosis can be 
linked to lower levels of these defense mediators, but also other AMPs in the gut of 
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affected animals. While many of the underlying mechanisms in the complex and 
multifactorial inflammatory bowel disease Crohn’s disease are yet to be elucidated, 
identifying Wnt and it’s role in Paneth cell defects in patients, surely provides new 
possibilities to potentially one day develop curative therapy. 
The diminished HD-5 and -6 levels could provide a possible target for therapy; the 
administration of these two components could potentially restore the low levels. For a 
proper function, Wnt signaling must be tightly regulated. Interventions in this 
pathway could lead to an increased risk of developing cancer, because this pathway 
regulates cell growth and proliferation. Genesis of gastric cancer is in more than 70% 
associated with a gain in Wnt signalling (Ooi et al. 2009). Kaler et al. could show, that 
colorectal cancer is coupled with a gain of wnt signaling (Kaler et al. 2009). Therefore 
it requires more knowledge to use this promising working point. A better 
understanding of the homeostasis between bacteria and the human gut could as well 
provide new treatment targets. Further research is needed to gain more knowledge 
about the microbiota-gut-axis.  
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7. APPENDIX  
 
Primer used in Sequenom SNP genotyping assay: all Primers had a purification scale 
level of 0.04 µmol and were desalted. Primers were designed using SNPdb sequence 
information or Ensemble and subsequently Sequenom software (see methods part). 
Primers used in Mulitplex-PCRs for the amplification of sequences carrying the 
variation have the additional specification 1st-PCRP or 2nd-PCRP. PEX reaction 
primers were additionally named UEP_SEQ.  
 
 
1	 rs2137328	 2nd-PCRP	 ACGTTGGATGTCATCACGTTCTGGCAGTAG	
		 		 1st-PCRP	 ACGTTGGATGCTAGGATTACAGGCATGAGC	
		 		 UEP_SEQ	 GGTTGTGATAGAAGTTATTGTTTTG	   
2	 rs11606508	 2nd-PCRP	 ACGTTGGATGTCAAAGGCTTGTTTTCAGCG	
		 		 1st-PCRP	 ACGTTGGATGCAGAGTCCAGACATTTGTGC	
		 		 UEP_SEQ	 AAGCAACTGGATTTTTCTTAACC	   
3	 rs682429	 2nd-PCRP	 ACGTTGGATGAGGAGAAGAATCTCACCCAG	
		 		 1st-PCRP	 ACGTTGGATGAGACTGGGAGTTCCAACTTG	
		 		 UEP_SEQ	 cgaggacGGGCACAGAAGGGGCTC	   
4	 rs4988331	 2nd-PCRP	 ACGTTGGATGTTTCTCTCAGTGGCAAGAGC	
		 		 1st-PCRP	 ACGTTGGATGAGAGACAGAGAACAGTGTCC	
		 		 UEP_SEQ	 tagaCTGATGGGCCAGAGGTTC	   
5	 rs4988300	 2nd-PCRP	 ACGTTGGATGCAAAGGGTGGAACCTGATAG	
		 		 1st-PCRP	 ACGTTGGATGCCCACCTCATTGTCCTTTTC	   
		 		 UEP_SEQ	 gaAAAAGCATAAACGTGCAAG	   
6	 rs634008	 2nd-PCRP	 ACGTTGGATGCCTCTTCGTTCCATTTCCTC	   
		 		 1st-PCRP	 ACGTTGGATGTCCCAGGACCTCAGCACAAT	
		 		 UEP_SEQ	 aGTTCCATTTCCTCACAGTCT	   
7	 rs312778	 2nd-PCRP	 ACGTTGGATGAACCACACACCCAGCATAAC	
		 		 1st-PCRP	 ACGTTGGATGCCTAATGAGGCCACCTTTAC	
		 		 UEP_SEQ	 ccccAGCACCAGCGGAGAC	   
8	 rs314756	 2nd-PCRP	 ACGTTGGATGAGGAGATGGTCACAGCTAAG	
		 		 1st-PCRP	 ACGTTGGATGGCCTTTGACCCTGAGTTTTC	
		 		 UEP_SEQ	 ATCTCATCCCCTGCC	 		   
9	 rs312781	 2nd-PCRP	 ACGTTGGATGCCGTGCTGTCATCATCTTAG	
		 		 1st-PCRP	 ACGTTGGATGATTTGTGGCCTATGCCTTCC	
		 		 UEP_SEQ	 cccgaTGTCATCATCTTAGGTCTAC	   
10	 rs78219242	 2nd-PCRP	 ACGTTGGATGTTCCAGTTTTCCAAGGGAGC	
		 		 1st-PCRP	 ACGTTGGATGCCCCGTCTGGTTCAGGTAG	
		 		 UEP_SEQ	 gaAGCGAGGAGGCCATCA	   
11	 rs41494349	 2nd-PCRP	 ACGTTGGATGGAGATGACCACGTTCTGCAC	
		 		 1st-PCRP	 ACGTTGGATGTGTACTGGACAGACGTGAGC	
		 		 UEP_SEQ	 GTCTGGTTCAGGTAGGTC	   
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12	 rs643981	 2nd-PCRP	 ACGTTGGATGCTTGGGCTCATGCAAATTCG	
		 		 1st-PCRP	 ACGTTGGATGTCACGGGTAAACCCTGCTG	
		 		 UEP_SEQ	 TGCAAATTCGAGAGAGA	 		   
13	 rs312788	 2nd-PCRP	 ACGTTGGATGGCCTCAGTTTTCTCATCTGC	
		 		 1st-PCRP	 ACGTTGGATGCTGTGCATCTAGTGAGAACC	
		 		 UEP_SEQ	 tATTCCCACCTTCCCT	 	   
14	 rs121908673	 2nd-PCRP	 ACGTTGGATGCTCTCCGGGGACACTCTGT	
		 		 1st-PCRP	 ACGTTGGATGTCAGGATCTCCTTCCTCTTC	
		 		 UEP_SEQ	 GGACACTCTGTACTGGA	 		   
15	 rs638051	 2nd-PCRP	 ACGTTGGATGTTTGGGCAGTGGGCTTAGCG	
		 		 1st-PCRP	 ACGTTGGATGGACATAGCTCTGAGAGCCAC	
		 		 UEP_SEQ	 TGCCACTCGGGCCACAC	 		   
16	 CM053969	 2nd-PCRP	 ACGTTGGATGCCATTGCACCTGTCTCCACA	
		 		 1st-PCRP	 ACGTTGGATGATGTCGGTGAAGTCCGGCGT	
		 		 UEP_SEQ	 ggcgtACGGACCTACGGAGGATCT	   
17	 rs4988319	 2nd-PCRP	 ACGTTGGATGTCCAGGTCAATCTCCCTCTC	
		 		 1st-PCRP	 ACGTTGGATGTCGCACTGCACCCCGTGAT	
		 		 UEP_SEQ	 gccatGCCCCAGCCCCCGCC	   
18	 rs4988320	 2nd-PCRP	 ACGTTGGATGTGACCCCATGAGTCTGTCTG	
		 		 1st-PCRP	 ACGTTGGATGACATTTAGCCATGTGATGGG	
		 		 UEP_SEQ	 TGAGTCTGTCTGGTCTCTG	   
19	 rs491347	 2nd-PCRP	 ACGTTGGATGTGAGCCTGCAGAACTGTATG	
		 		 1st-PCRP	 ACGTTGGATGTTTCATCCTGTCCTGAGAGC	
		 		 UEP_SEQ	 gggtgAACAGGAAGGTTGAGTTAGG	   
20	 rs686921	 2nd-PCRP	 ACGTTGGATGAAACAAGACGGGTTCAATGC	
		 		 1st-PCRP	 ACGTTGGATGAGCGTCATTTATCCAGCACC	
		 		 UEP_SEQ	 TCAATGCCCAAGAGC	 	   
21	 rs545382	 2nd-PCRP	 ACGTTGGATGCAGTCCAGTAGATGAAGTCC	
		 		 1st-PCRP	 ACGTTGGATGATGTTGATGGGACGAAGAGG	
		 		 UEP_SEQ	 cccaCCCCAGCAGCGTGAACCC	   
22	 rs2277268	 2nd-PCRP	 ACGTTGGATGGTTGTTATTGGTCTCGAGGG	
		 		 1st-PCRP	 ACGTTGGATGTGAGTGACATGAAGACCTGC	
		 		 UEP_SEQ	 TGAAGACCAAGAAGGC	 	   
23	 rs4988321	 2nd-PCRP	 ACGTTGGATGTCTCCCTCGAGACCAATAAC	
		 		 1st-PCRP	 ACGTTGGATGCCAGTAGATGTGGTTGTTGG	
		 		 UEP_SEQ	 ggtTCGAGACCAATAACAACGAC	   
24	 rs2306862	 2nd-PCRP	 ACGTTGGATGTCCCTCCACACGAGGACTTG	
		 		 1st-PCRP	 ACGTTGGATGATGGGCAAGAACCTCTACTG	
		 		 UEP_SEQ	 cccggCCAGCCGCGCCACTTCGATTCT	   
25	 rs4988322	 2nd-PCRP	 ACGTTGGATGTGTGGAGGGACTTGGACAAC	
		 		 1st-PCRP	 ACGTTGGATGTACGAGGTGAACACAAGGAC	
		 		 UEP_SEQ	 ATCCCACCAAGGGGTAAG	   
26	 rs2242339	 2nd-PCRP	 ACGTTGGATGAACTTGCAGGCCACAGGGTA	
		 		 1st-PCRP	 ACGTTGGATGACATGATCGAGTCGTCCAAC	
		 		 UEP_SEQ	 ACGCCCGGCTGCCCC	 		   
27	 rs61370283	 2nd-PCRP	 ACGTTGGATGTGAGGAACGTCAAAGCCATC	
		 		 1st-PCRP	 ACGTTGGATGTTGGCTCGCTTGATGTTCTG	
		 		 UEP_SEQ	 AGCCATCGACTATGACCCA	   
APPENDIX	 117	
 
 
28	 rs2472415	 2nd-PCRP	 ACGTTGGATGAACTCCTGACCTCGTGATCC	
		 		 1st-PCRP	 ACGTTGGATGCCTAAGCAGCCTTCTTTTAC	
		 		 UEP_SEQ	 gggtCCAAAGTGCTAGGATACA	   
29	 rs61889560	 2nd-PCRP	 ACGTTGGATGACGACCTCAGCATCGACATC	
		 		 1st-PCRP	 ACGTTGGATGGTGGACGTTGATGGTATTGG	
		 		 UEP_SEQ	 acccCAGCATCGACATCTACAGCC	   
30	 rs599083	 2nd-PCRP	 ACGTTGGATGCCCATTGTGGTCGTATCTTG	
		 		 1st-PCRP	 ACGTTGGATGCAGAACCTCAGAATGTGAGC	
		 		 UEP_SEQ	 atttTGGTCGTATCTTGATCCTTCA	   
31	 rs554734	 2nd-PCRP	 ACGTTGGATGACAGGTCACAGCTCTCAATG	
		 		 1st-PCRP	 ACGTTGGATGTCTTCACCACCGGCCTCATC	
		 		 UEP_SEQ	 TGCCCAGTGTGTTGTC	 	   
32	 rs17149104	 2nd-PCRP	 ACGTTGGATGATGAGGCCGGTGGTGAAGAG	
		 		 1st-PCRP	 ACGTTGGATGACTTCACCAACATGCAGGAC	
		 		 UEP_SEQ	 ccccgAGAGGACCTCGCGCTCGGTGCC	   
33	 rs556442	 2nd-PCRP	 ACGTTGGATGTCTTCACCACCGGCCTCATC	
		 		 1st-PCRP	 ACGTTGGATGTCTCAATGCGCTTCAGGTCC	
		 		 UEP_SEQ	 TGTGGCCCTGGTGGT	 	   
34	 rs11607268	 2nd-PCRP	 ACGTTGGATGCACGTACAGAACTCCTCCAG	
		 		 1st-PCRP	 ACGTTGGATGATCGAGCGTGTGGAGAAGAC	
		 		 UEP_SEQ	 tCAGGCTGACTTCCTCCA	 		   
35	 rs12416761	 2nd-PCRP	 ACGTTGGATGAAGCAGAAGTTGAGAGGGAC	
		 		 1st-PCRP	 ACGTTGGATGAGCGATGGAGGATGTGCGG	
		 		 UEP_SEQ	 cttcGGCATCCCTGCTGTA	 		   
36	 rs12417014	 2nd-PCRP	 ACGTTGGATGGACAGAGGAGAACATCACAC	
		 		 1st-PCRP	 ACGTTGGATGTGAGTCCCTCTCAACTTCTG	
		 		 UEP_SEQ	 cccctCAAAACCCAGGCAATGGC	   
37	 rs3736228	 2nd-PCRP	 ACGTTGGATGTCTTGGCAGAGCCTTGACG	
		 		 1st-PCRP	 ACGTTGGATGAGACTGTCAGGACCGCTCA	
		 		 UEP_SEQ	 tCCTCACCGTCACAGTCC	 	   
38	 rs901824	 2nd-PCRP	 ACGTTGGATGTAGCACATCCCTGCTCCACT	
		 		 1st-PCRP	 ACGTTGGATGCCCTTCACAGGTAAGGAGC	
		 		 UEP_SEQ	 ttTGCCTCCTCCAGATC	 	   
39	 rs1127291	 2nd-PCRP	 ACGTTGGATGTCTACTCTTCAAACATTCCG	
		 		 1st-PCRP	 ACGTTGGATGGAACCCAATGGCCATGGAG	
		 		 UEP_SEQ	 AACATTCCGGCCACTG	 	   
40	 rs676318	 2nd-PCRP	 ACGTTGGATGTCATTTTTCACTGGGCCCTG	
		 		 1st-PCRP	 ACGTTGGATGACAGAGAGGTCAGATGGAAG	
		 		 UEP_SEQ	 GGGCTCTTCTGAACC	 	   
41	 rs3867143	 2nd-PCRP	 ACGTTGGATGAAGAAAGTCCATGTTGCCAG	
		 		 1st-PCRP	 ACGTTGGATGCCACATTTCTCGGGAACAAG	
		 		 UEP_SEQ	 ccttcCCAGTTTGGCTATTTCC	   
42	 rs2472429	 2nd-PCRP	 ACGTTGGATGGGTAACTTTGCTGTGGAGTC	
		 		 1st-PCRP	 ACGTTGGATGGATCCTTCAAGGCGTATGTG	
		 		 UEP_SEQ	 gggtcACTTTGCTGTGGAGTCTCACAT	   
43	 rs12294029	 2nd-PCRP	 ACGTTGGATGTGATACCCTGGCAAATACGG	
		 		 1st-PCRP	 ACGTTGGATGCACTTTGCAGATACTGTGTG	
		 		 UEP_SEQ	 gtGTTGCCATAAACCTTCAAT	   
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44	 rs7126340	 2nd-PCRP	 ACGTTGGATGGGGAAACCAATATATTCGTG	
		 		 1st-PCRP	 ACGTTGGATGGGTAAAGGCATACCTTGGAG	
		 		 UEP_SEQ	 cTGTGACATTTGCTTTTTTG	   
45	 rs12226585	 2nd-PCRP	 ACGTTGGATGCCTCCCACCTTGATTTCTTT	   
		 		 1st-PCRP	 ACGTTGGATGCTTACCCCCCACCAAAAAAA	
		 		 UEP_SEQ	 aggGATTTTCTGACATTTGACTATG	   
 
Overall alle frequencies all cohorts 
 
Leuven 
		 rs314756	 rs676318	 rs556442	 rs312788	 rs1127291	 rs638051	
		 SNP	1	 SNP	2	 SNP	3	 SNP	4	 SNP	5	 SNP	6	
		 intronic	 intronic	 exonic	V-->V	 intronic	 exonic	A-->V	 intronic	
LEUVEN	 		 		 		 		 		 		
MAFs	 		
	 	 	 	 	Controls	 7.87%	 5.95%	 29.55%	 33.94%	 0.40%	 33.40%	
Diverticulitis	 23.84%	 10.56%	 49.40%	 46.48%	 1.15%	 36.88%	
IBD	 9.26%	 8.49%	 32.47%	 42.66%	 1.76%	 37.63%	
UC	 12.50%	 5.49%	 24.73%	 40.22%	 1.10%	 32.45%	
		 		 		 		 		 		 		
CD	 8.18%	 9.49%	 35.09%	 43.49%	 1.98%	 39.36%	
male	 10.23%	 8.82%	 35.38%	 45.86%	 2.05%	 40.52%	
female	 8.53%	 8.81%	 31.37%	 40.53%	 1.64%	 35.71%	
A1	 14.71%	 11.76%	 35.29%	 48.53%	 4.41%	 33.82%	
A2	 8.03%	 8.99%	 31.25%	 42.52%	 1.37%	 39.96%	
A3	 11.64%	 4.79%	 30.67%	 41.67%	 2.05%	 33.33%	
B1	 7.14%	 11.43%	 36.96%	 42.14%	 2.14%	 35.71%	
B2	 7.02%	 12.07%	 31.03%	 39.29%	 1.72%	 35.83%	
B3	 8.47%	 7.69%	 34.32%	 46.05%	 1.67%	 43.03%	
L4*	 7.14%	 9.52%	 38.10%	 50.00%	 7.14%	 42.86%	
		 		 		 		 		 		 		
ileal	CD	 8.80%	 9.95%	 36.41%	 46.68%	 1.60%	 41.70%	
male	 9.68%	 9.68%	 39.13%	 48.90%	 2.13%	 44.74%	
female	 8.13%	 10.16%	 34.40%	 45.00%	 1.20%	 39.45%	
A1	 14.00%	 18.00%	 48.00%	 56.00%	 4.00%	 40.00%	
A2	 7.88%	 8.90%	 34.25%	 46.83%	 1.01%	 44.08%	
A3	 8.75%	 10.00%	 40.24%	 42.31%	 2.44%	 35.37%	
B1	 10.23%	 14.77%	 46.51%	 52.27%	 2.27%	 42.05%	
B2	 7.55%	 12.96%	 32.41%	 41.35%	 0.93%	 38.39%	
B3	 8.80%	 7.01%	 34.40%	 47.12%	 1.82%	 42.86%	
L4*	 7.14%	 9.52%	 38.10%	 50.00%	 7.14%	 42.86%	
*	the	same	
	 	 	 	 	 		
		 rs121908673	 rs3736228	 rs78219242	 rs61370283	 rs4988320	 rs4988319	
		 SNP	7	 SNP	8	 SNP	9	 SNP	10	 SNP	11	 SNP	12	
		 exonic	T-->I	 exon	A-->V	 exon	L-->R	 exon	L-->M	 intronic	 intronic	
LEUVEN	 		 		 		 		 		 		
MAFs	
	 	 	 	 	 	Controls	 0.00%	 13.75%	 0.00%	 0.00%	 11.02%	 14.46%	
Diverticulitis	 0.00%	 30.59%	 0.00%	 0.00%	 13.07%	 15.70%	
IBD	 0.00%	 16.21%	 0.00%	 0.00%	 15.42%	 15.62%	
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UC	 0.00%	 12.92%	 0.00%	 0.00%	 11.11%	 14.67%	
		 		 		 		 		 		 		
CD	
male	
0.00%	 17.27%	 0.00%	 0.00%	 16.85%	 15.93%	
0.00%	 16.37%	 0.00%	 0.00%	 17.37%	 15.98%	
female	 0.00%	 15.73%	 0.00%	 0.00%	 14.42%	 14.93%	
A1	 0.00%	 10.61%	 0.00%	 0.00%	 16.18%	 13.24%	
A2	 0.00%	 15.14%	 0.00%	 0.00%	 16.82%	 15.74%	
A3	 0.00%	 19.86%	 0.00%	 0.00%	 10.00%	 16.22%	
B1	 0.00%	 15.22%	 0.00%	 0.00%	 17.14%	 15.22%	
B2	 0.00%	 13.56%	 0.00%	 0.00%	 18.42%	 12.07%	
B3	 0.00%	 18.75%	 0.00%	 0.00%	 16.37%	 17.24%	
L4*	 0.00%	 20.00%	 0.00%	 0.00%	 14.29%	 23.81%	
		 		 		 		 		 		 		
ileal	CD	 0.00%	 18.04%	 0.00%	 0.00%	 18.08%	 17.06%	
male	 0.00%	 18.82%	 0.00%	 0.00%	 19.23%	 17.58%	
female	 0.00%	 17.46%	 0.00%	 0.00%	 17.21%	 16.67%	
A1	 0.00%	 14.58%	 0.00%	 0.00%	 22.00%	 16.00%	
A2	 0.00%	 17.67%	 0.00%	 0.00%	 18.40%	 18.06%	
A3	 0.00%	 21.25%	 0.00%	 0.00%	 15.38%	 15.00%	
B1	 0.00%	 17.44%	 0.00%	 0.00%	 20.45%	 18.60%	
B2	 0.00%	 14.55%	 0.00%	 0.00%	 19.81%	 12.96%	
B3	 0.00%	 19.09%	 0.00%	 0.00%	 16.67%	 17.45%	
L4*	 0.00%	 20.00%	 0.00%	 0.00%	 14.29%	 23.81%	
*	the	same	
	 	 	 	 	 		
	
	
		 rs7126340	 rs634008	 rs12294029	 rs4988300	 rs3867143	 rs11606508	
		 SNP	13	 SNP	14	 SNP	15	 SNP	16	 SNP	18	 SNP	20	
		
intronic	PPP6R3	
gene	(3´LRP5)	 intronic	
intronic	PPP6R3	
gene	(3´LRP5)	 intronic	 3´	intronic	 intronic	
LEUVEN	 		 		 		 		 		 		
MAFs	
	 	 	 	 	 	Controls	 24.21%	 40.12%	 24.31%	 42.94%	 15.23%	 11.86%	
Diverticulitis	 23.53%	 57.06%	 23.57%	 50.71%	 14.58%	 13.89%	
IBD	 25.98%	 47.16%	 26.29%	 50.27%	 14.67%	 13.15%	
UC	 19.66%	 44.02%	 20.33%	 46.15%	 13.07%	 11.67%	
		 		 		 		 		 		 		
CD	 28.07%	 48.20%	 28.26%	 51.64%	 15.21%	 13.64%	
male	 29.46%	 48.55%	 29.71%	 51.76%	 15.45%	 13.82%	
female	 23.28%	 46.46%	 23.70%	 49.76%	 13.93%	 13.33%	
A1	 22.06%	 50.00%	 22.06%	 51.47%	 7.58%	 11.76%	
A2	 23.47%	 46.14%	 24.08%	 50.23%	 13.98%	 14.91%	
A3	 32.14%	 45.89%	 31.76%	 49.32%	 21.32%	 8.22%	
B1	 27.86%	 47.14%	 27.86%	 52.86%	 15.44%	 20.00%	
B2	 21.43%	 41.38%	 20.69%	 43.97%	 8.93%	 7.89%	
B3	 28.95%	 50.00%	 29.83%	 53.81%	 16.67%	 11.76%	
L4*	 28.57%	 52.38%	 28.57%	 59.52%	 17.50%	 16.67%	
		 		 		 		 		 		 		
ileal	CD	 28.20%	 49.32%	 28.44%	 53.23%	 15.63%	 12.90%	
male	 32.42%	 47.87%	 32.98%	 52.15%	 15.93%	 13.83%	
female	 25.00%	 50.40%	 25.00%	 54.03%	 15.38%	 12.20%	
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A1	 26.00%	 50.00%	 26.00%	 52.00%	 12.00%	 12.00%	
A2	 27.27%	 49.66%	 27.55%	 54.45%	 14.64%	 14.63%	
A3	 35.53%	 46.34%	 35.37%	 48.78%	 22.37%	 7.50%	
B1	 29.55%	 52.27%	 29.55%	 59.09%	 16.67%	 20.45%	
B2	 21.15%	 42.59%	 20.37%	 45.37%	 9.62%	 8.49%	
B3	 29.33%	 50.45%	 30.28%	 54.63%	 16.99%	 10.55%	
L4*	 28.57%	 52.38%	 28.57%	 59.52%	 17.50%	 16.67%	
*	the	same	
	 	 	 	 	 		
		 rs61889560	 CM053969	 rs312781	 rs599083	 rs12226585	 rs2137328	
		 SNP	21	 SNP	22	 SNP	23	 SNP	24	 SNP	25	 SNP	26	
		 exonic	Q-->R	 exonic	S-->L	 intronic	 intronic	
intronic	PPP6R3	
gene	(3´LRP5)	
intronic	
upstream	5´	
LEUVEN	 		 		 		 		 		 		
MAFs	
	 	 	 	 	 	Controls	 1.38%	 0.00%	 26.19%	 27.27%	 30.68%	 41.55%	
Diverticulitis	 20.69%	 0.00%	 29.58%	 33.80%	 35.71%	 38.71%	
IBD	 2.93%	 0.00%	 30.03%	 31.67%	 35.79%	 37.66%	
UC	 4.26%	 0.00%	 29.89%	 23.63%	 26.37%	 40.91%	
		 		 		 		 		 		 		
CD	 2.48%	 0.00%	 30.07%	 34.39%	 38.91%	 36.54%	
male	 1.72%	 0.00%	 31.58%	 34.52%	 39.35%	 33.96%	
female	 3.69%	 0.00%	 28.54%	 30.58%	 33.73%	 39.64%	
A1	 0.00%	 0.00%	 35.29%	 33.33%	 33.82%	 32.93%	
A2	 3.13%	 0.00%	 28.54%	 30.75%	 34.17%	 39.34%	
A3	 1.33%	 0.00%	 33.11%	 31.08%	 38.36%	 37.89%	
B1	 0.71%	 0.00%	 27.14%	 35.00%	 40.00%	 35.87%	
B2	 3.33%	 0.00%	 23.73%	 31.25%	 35.34%	 47.37%	
B3	 2.87%	 0.00%	 34.32%	 34.21%	 38.56%	 33.00%	
L4*	 0.00%	 0.00%	 35.71%	 38.10%	 40.48%	 45.00%	
		 		 		 		 		 		 		
ileal	CD	 2.47%	 0.00%	 32.11%	 35.92%	 39.86%	 36.28%	
male	 1.05%	 0.00%	 34.41%	 39.13%	 43.48%	 33.91%	
female	 3.52%	 0.00%	 30.40%	 33.47%	 37.20%	 37.96%	
A1	 0.00%	 0.00%	 38.00%	 45.83%	 44.00%	 22.22%	
A2	 3.62%	 0.00%	 31.63%	 33.92%	 38.10%	 37.70%	
A3	 0.00%	 0.00%	 30.49%	 40.24%	 47.50%	 37.50%	
B1	 0.00%	 0.00%	 35.23%	 43.18%	 45.45%	 30.00%	
B2	 3.57%	 0.00%	 24.55%	 32.69%	 36.11%	 45.65%	
B3	 2.68%	 0.00%	 35.19%	 34.43%	 38.43%	 35.36%	
L4*	 0.00%	 0.00%	 35.71%	 38.10%	 40.48%	 45.00%	
*	the	same	
	 	 	 	 	 		
		 rs2306862	 rs17149104	 rs12416761	 rs2277268	 rs41494349	 rs491347	
		 SNP	27	 SNP	28	 SNP13	
SNP6					non-
coding	 SNP12	 SNP26	
		 exonic	N-->N	 exonic	D-->D	 LRP5	Int.	17	 LRP5	Ex.	9		
LRP5	Ex.	2	
missense	 LRP5	Int.	7	
LEUVEN	 		 		 		
	 	
		
MAFs	 		 		 		 		 		 		
Controls	 13.44%	 2.05%	 6.83%	 5.18%	 1.02%	 19.59%	
Diverticulitis	 14.79%	 2.14%	 6.82%	 4.76%	 1.14%	 24.14%	
IBD	 15.75%	 1.81%	 4.52%	 2.73%	 0.44%	 27.00%	
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UC	 12.37%	 0.57%	 4.35%	 2.91%	 0.56%	 19.44%	
		 		 		 		 		 		 		
CD	 16.91%	 2.21%	 4.58%	 2.66%	 0.40%	 29.76%	
male	 16.27%	 2.11%	 6.25%	 4.00%	 0.48%	 31.86%	
female	 15.17%	 1.92%	 3.40%	 1.74%	 0.34%	 28.28%	
A1	 10.29%	 4.41%	 5.00%	 5.00%	 2.50%	 37.50%	
A2	 15.37%	 1.40%	 5.14%	 2.66%	 0.28%	 28.45%	
A3	 19.44%	 2.08%	 3.00%	 2.04%	 0.00%	 32.98%	
B1	 17.14%	 2.14%	 3.17%	 0.00%	 0.00%	 33.87%	
B2	 12.07%	 1.72%	 5.17%	 4.31%	 0.00%	 25.42%	
B3	 17.83%	 1.74%	 5.56%	 3.54%	 0.84%	 27.88%	
L4*	 19.05%	 7.14%	 6.25%	 3.13%	 0.00%	 40.00%	
		 		 		 		 		 		 		
ileal	CD	 17.76%	 1.87%	 4.69%	 2.81%	 0.39%	 29.96%	
male	 18.68%	 2.75%	 6.59%	 4.55%	 0.00%	 32.22%	
female	 17.07%	 1.22%	 3.57%	 1.83%	 0.00%	 25.91%	
A1	 14.00%	 4.00%	 5.88%	 5.88%	 0.00%	 38.24%	
A2	 17.47%	 1.39%	 5.67%	 3.10%	 0.00%	 28.86%	
A3	 22.37%	 2.50%	 3.85%	 2.63%	 0.00%	 35.14%	
B1	 20.45%	 2.27%	 3.75%	 0.00%	 0.00%	 40.00%	
B2	 12.96%	 0.93%	 5.56%	 4.63%	 0.00%	 26.36%	
B3	 18.10%	 1.90%	 6.25%	 4.00%	 0.00%	 26.50%	
L4*	 19.05%	 7.14%	 6.25%	 3.13%	 0.00%	 40.00%	
*	the	same	
	 	 	 	 	 		
		 rs4988322	 rs4988331	 rs682429	 rs901824	 rs11607268	 rs12417014	
		 SNP11	 SNP20	 SNP23	 SNP8	 SNP38	 SNP	47	
		 LRP5	Int.	10	 LRP5	Int.	1	 LRP5	5´		 LRP5	Intron	20	 LRP5	E16	 LRP5	I17	
LEUVEN	 		 		 regulatory?	 		 missense	 intronic	
MAFs	 		 		 		 		 		 		
Controls	 7.53%	 8.47%	 36.67%	 6.99%	 0.00%	 4.34%	
Diverticulitis	 6.82%	 11.36%	 31.25%	 8.52%	
	
		
IBD	 4.40%	 7.65%	 30.35%	 3.44%	 0.00%	 4.47%	
UC	 5.00%	 6.11%	 32.22%	 3.45%	 0.00%	 4.32%	
		 		
	 	 	 	
		
CD	 4.18%	 8.20%	 29.68%	 3.43%	 0.00%	 4.51%	
male	 6.19%	 7.21%	 30.29%	 5.26%	 0.00%	 6.42%	
female	 2.74%	 8.90%	 29.25%	 2.17%	 0.00%	 3.18%	
A1	 5.00%	 12.50%	 30.95%	 5.00%	 0.00%	 8.70%	
A2	 4.57%	 8.05%	 30.29%	 3.13%	 0.00%	 4.60%	
A3	 3.00%	 8.00%	 27.55%	 4.26%	 0.00%	 3.92%	
B1	 2.42%	 8.87%	 27.78%	 0.88%	 0.00%	 5.47%	
B2	 5.08%	 8.62%	 32.20%	 4.46%	 0.00%	 4.92%	
B3	 5.13%	 8.55%	 29.74%	 3.27%	 0.00%	 4.82%	
L4*	 3.33%	 3.33%	 18.75%	 3.33%	 0.00%	 5.26%	
		 		
	 	 	 	
		
ileal	CD	 8.21%	 30.92%	 29.49%	 3.57%	 0.00%	 5.40%	
male	 6.52%	 7.14%	 30.77%	 5.42%	 0.00%	 7.14%	
female	 3.13%	 10.71%	 29.02%	 0.95%	 0.00%	 3.91%	
A1	 5.88%	 14.71%	 33.33%	 5.88%	 0.00%	 10.00%	
A2	 5.00%	 8.05%	 28.33%	 3.68%	 0.00%	 5.07%	
A3	 3.85%	 7.69%	 30.26%	 4.17%	 0.00%	 5.00%	
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B1	 2.56%	 10.26%	 26.25%	 1.43%	 0.00%	 6.98%	
B2	 5.45%	 9.26%	 31.82%	 4.81%	 0.00%	 5.26%	
B3	 5.77%	 8.17%	 28.64%	 3.19%	 0.00%	 5.50%	
L4*	 3.33%	 3.33%	 18.75%	 3.33%	 0.00%	 5.26%	
*	the	same	
	 	 	 	 	 		
		 SNP32	 SNP41	 SNP48		 SNP46	 SNP35	 SNP38	 SNP33	
		 LRP5	I11	 LRP5	 LRP5	E9	 LRP5	E8	 LRP5	I14	 LRP5	I2	 LRP5	I7	
LEUVEN	 intronic	 intronic	 		 non	coding	 intronic	 intronic	 intronic	
MAFs	 		 		 		 		 		 		 		
Controls	 6.02%	 29.09%	 2.82%	 5.16%	 21.91%	 30.71%	 16.49%	
Diverticulitis	 		
	 	 	 	 	
		
IBD	 4.83%	 41.71%	 1.69%	 9.60%	 30.30%	 42.57%	 26.69%	
UC	 6.02%	 35.37%	 1.28%	 4.27%	 22.84%	 39.29%	 18.24%	
		 		
	 	 	 	 	
		
CD	 4.46%	 43.66%	 1.81%	 11.24%	 32.73%	 43.63%	 29.37%	
male	 6.42%	 45.87%	 2.02%	 10.65%	 36.50%	 46.73%	 30.56%	
female	 3.13%	 42.14%	 1.68%	 11.64%	 30.20%	 41.45%	 28.57%	
A1	 8.70%	 52.17%	 0.00%	 15.91%	 47.37%	 54.35%	 36.96%	
A2	 4.29%	 42.24%	 1.82%	 10.98%	 30.37%	 42.51%	 27.71%	
A3	 3.85%	 46.08%	 1.16%	 9.62%	 35.71%	 46.00%	 32.69%	
B1	 4.62%	 43.75%	 0.82%	 13.08%	 35.00%	 44.26%	 32.58%	
B2	 4.92%	 42.50%	 1.75%	 12.28%	 32.41%	 43.86%	 28.33%	
B3	 4.78%	 43.48%	 1.43%	 9.05%	 30.56%	 43.36%	 26.32%	
L4*	 2.63%	 44.44%	 2.63%	 13.16%	 38.24%	 50.00%	 37.50%	
		 		 		 		 		 		 		 		
ileal	CD	 5.12%	 45.77%	 1.53%	 11.03%	 34.00%	 45.95%	 29.91%	
male	 7.14%	 47.25%	 2.47%	 10.56%	 37.50%	 47.80%	 30.56%	
female	 4.20%	 44.54%	 1.36%	 11.76%	 29.55%	 43.69%	 27.50%	
A1	 10.00%	 52.50%	 0.00%	 17.50%	 50.00%	 55.00%	 37.50%	
A2	 4.70%	 44.93%	 1.43%	 10.47%	 31.07%	 45.17%	 28.04%	
A3	 4.88%	 46.25%	 1.56%	 11.25%	 40.79%	 46.25%	 35.37%	
B1	 5.81%	 51.19%	 1.22%	 15.91%	 42.50%	 52.38%	 37.50%	
B2	 5.26%	 43.86%	 1.85%	 12.04%	 33.33%	 43.75%	 29.46%	
B3	 5.39%	 43.56%	 0.55%	 7.84%	 29.69%	 43.43%	 24.75%	
L4*	 2.63%	 44.44%	 2.63%	 13.16%	 38.24%	 50.00%	 37.50%	
*	the	same	 		 		 		 		 		 		 		
	
	
Vienna 
		 rs314756	 rs676318	 rs556442	 rs312788	 rs1127291	 rs638051	
		 SNP	1	 SNP	2	 SNP	3	 SNP	4	 SNP	5	 SNP	6	
		 intronic	 intronic	 exonic	V-->V	 intronic	 exonic	A-->V	 intronic	
VIENNA	 		 		 		 		 		 		
MAFs	 		 		 		 		 		 		
Controls	 13.94%	 9.24%	 41.63%	 43.43%	 1.34%	 39.63%	
IBD	 6.32%	 8.31%	 31.86%	 39.42%	 1.78%	 39.40%	
UC	 6.99%	 10.33%	 35.16%	 43.24%	 2.42%	 43.48%	
		 		 		 		 		 		 		
CD	 5.85%	 6.90%	 29.54%	 36.74%	 1.33%	 36.62%	
male	 5.04%	 8.62%	 29.57%	 38.56%	 0.85%	 40.34%	
female	 6.44%	 4.55%	 26.54%	 32.20%	 1.89%	 32.12%	
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A1	 4.17%	 6.25%	 27.08%	 35.42%	 0.00%	 36.00%	
A2	 5.66%	 6.97%	 29.85%	 37.44%	 1.42%	 36.74%	
A3	 8.62%	 6.90%	 29.31%	 32.76%	 1.72%	 36.21%	
B1	 3.30%	 6.31%	 27.18%	 35.71%	 0.94%	 40.57%	
B2	 12.50%	 3.13%	 25.00%	 33.33%	 0.00%	 27.08%	
B3	 5.09%	 8.41%	 33.33%	 38.43%	 2.34%	 35.71%	
L4*	 3.97%	 13.71%	 30.65%	 38.10%	 1.59%	 35.16%	
		 		 		 		 		 		 		
ileal	CD	 5.39%	 6.44%	 30.81%	 37.01%	 1.72%	 36.71%	
male	 4.35%	 8.33%	 32.39%	 39.67%	 1.10%	 41.76%	
female	 6.00%	 3.50%	 26.02%	 31.00%	 2.50%	 30.95%	
A1	 5.26%	 5.26%	 26.32%	 34.21%	 0.00%	 32.50%	
A2	 5.99%	 6.44%	 31.90%	 37.95%	 1.81%	 36.83%	
A3	 10.00%	 7.50%	 37.50%	 45.00%	 2.50%	 45.00%	
B1	 2.24%	 6.82%	 32.03%	 39.55%	 1.49%	 44.03%	
B2	 10.23%	 3.41%	 25.00%	 31.82%	 0.00%	 28.41%	
B3	 5.43%	 6.59%	 32.02%	 36.96%	 2.75%	 34.74%	
L4*	 3.97%	 13.71%	 30.65%	 38.10%	 1.59%	 35.16%	
*	the	same	
	 	 	 	 	 		
		 rs121908673	 rs3736228	 rs78219242	 rs61370283	 rs4988320	 rs4988319	
		 SNP	7	 SNP	8	 SNP	9	 SNP	10	 SNP	11	 SNP	12	
		 exonic	T-->I	 exon	A-->V	 exon	L-->R	 exon	L-->M	 intronic	 intronic	
VIENNA	 		 		 		 		 		 		
MAFs	 		 		 		 		 		 		
Controls	 0.00%	 21.70%	 0.00%	 0.00%	 16.06%	 13.22%	
IBD	 0.00%	 13.48%	 0.00%	 0.00%	 16.44%	 14.92%	
UC	 0.00%	 15.45%	 0.00%	 0.00%	 18.58%	 14.75%	
		 		 		 		 		 		 		
CD	 0.00%	 12.17%	 0.00%	 0.00%	 14.94%	 15.04%	
male	 0.00%	 12.08%	 0.00%	 0.00%	 17.52%	 15.55%	
female	 0.00%	 12.87%	 0.00%	 0.00%	 11.54%	 12.78%	
A1	 0.00%	 16.67%	 0.00%	 0.00%	 8.33%	 25.00%	
A2	 0.00%	 11.92%	 0.00%	 0.00%	 15.87%	 14.95%	
A3	 0.00%	 10.34%	 0.00%	 0.00%	 13.79%	 7.14%	
B1	 0.00%	 8.02%	 0.00%	 0.00%	 15.87%	 15.87%	
B2	 0.00%	 10.42%	 0.00%	 0.00%	 13.83%	 8.51%	
B3	 0.00%	 16.36%	 0.00%	 0.00%	 14.95%	 15.63%	
L4*	 0.00%	 8.73%	 0.00%	 0.00%	 13.93%	 14.29%	
		 		 		 		 		 		 		
ileal	CD	 0.00%	 12.62%	 0.00%	 0.00%	 15.17%	 14.95%	
male	 0.00%	 13.44%	 0.00%	 0.00%	 18.33%	 16.48%	
female	 0.00%	 12.50%	 0.00%	 0.00%	 11.62%	 10.89%	
A1	 0.00%	 18.42%	 0.00%	 0.00%	 7.89%	 23.68%	
A2	 0.00%	 11.45%	 0.00%	 0.00%	 16.16%	 14.67%	
A3	 0.00%	 12.50%	 0.00%	 0.00%	 20.00%	 10.53%	
B1	 0.00%	 8.82%	 0.00%	 0.00%	 17.42%	 17.69%	
B2	 0.00%	 9.09%	 0.00%	 0.00%	 13.95%	 9.30%	
B3	 0.00%	 17.20%	 0.00%	 0.00%	 13.74%	 15.26%	
L4*	 0.00%	 8.73%	 0.00%	 0.00%	 13.93%	 14.29%	
*	the	same	
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		 rs7126340	 rs634008	 rs12294029	 rs4988300	 rs3867143	 rs11606508	
		 SNP	13	 SNP	14	 SNP	15	 SNP	16	 SNP	18	 SNP	20	
		
intronic	PPP6R3	
Gen	(3´LRP5)	 intronic	
intronic	PPP6R3	Gen	
(3´LRP5)	 intronic	 3´	intronic	 intronic	
VIENNA	 		 		 		 		 		 		
MAFs	 		 		 		 		 		 		
Controls	 26.85%	 50.97%	 27.59%	 51.96%	 14.26%	 14.08%	
IBD	 24.66%	 45.87%	 24.94%	 47.54%	 12.10%	 13.28%	
UC	 27.03%	 49.46%	 27.39%	 50.54%	 14.40%	 14.86%	
		 		 		 		 		 		 		
CD	 22.99%	 43.32%	 23.19%	 45.44%	 10.47%	 12.17%	
male	 21.98%	 41.81%	 22.22%	 44.44%	 9.65%	 11.11%	
female	 21.76%	 42.42%	 21.97%	 43.56%	 10.38%	 11.74%	
A1	 18.75%	 39.58%	 18.75%	 39.58%	 14.58%	 6.25%	
A2	 24.04%	 44.02%	 24.29%	 46.43%	 10.44%	 12.62%	
A3	 18.97%	 41.38%	 18.97%	 43.10%	 7.14%	 13.79%	
B1	 21.36%	 41.83%	 21.63%	 43.75%	 8.25%	 13.94%	
B2	 22.92%	 45.83%	 22.92%	 48.96%	 11.70%	 11.46%	
B3	 25.70%	 42.52%	 25.93%	 44.44%	 11.43%	 11.57%	
L4*	 16.39%	 45.97%	 17.46%	 48.41%	 7.38%	 13.49%	
		 		 		 		 		 		 		
ileal	CD	 24.88%	 43.07%	 25.12%	 45.57%	 10.10%	 13.30%	
male	 26.11%	 42.78%	 26.37%	 46.15%	 11.36%	 13.19%	
female	 22.22%	 41.00%	 22.50%	 42.00%	 8.16%	 11.50%	
A1	 18.42%	 36.84%	 18.42%	 36.84%	 15.79%	 7.89%	
A2	 25.15%	 44.21%	 25.45%	 46.97%	 10.25%	 13.64%	
A3	 25.00%	 55.00%	 25.00%	 55.00%	 7.89%	 15.00%	
B1	 26.15%	 43.18%	 26.52%	 45.45%	 7.69%	 17.42%	
B2	 22.73%	 45.45%	 22.73%	 48.86%	 10.47%	 12.50%	
B3	 25.27%	 41.21%	 25.54%	 43.48%	 11.80%	 10.33%	
L4*	 16.39%	 45.97%	 17.46%	 48.41%	 7.38%	 13.49%	
*	the	same	
	 	 	 	 	 		
		 rs61889560	 CM053969	 rs312781	 rs599083	 rs12226585	 rs2137328	
		 SNP	21	 SNP	22	 SNP	23	 SNP	24	 SNP	25	 SNP	26	
		 exonic	Q-->R	 exonic	S-->L	 intronic	 intronic	
intronic	PPP6R3	
Gen	(3´LRP5)	 intronic	vor	5´	
VIENNA	 		 		 		 		 		 		
MAFs	 		 		 		 		 		 		
Controls	 11.32%	 0.00%	 31.40%	 33.25%	 37.06%	 35.20%	
IBD	 2.41%	 0.00%	 25.67%	 30.09%	 33.45%	 37.96%	
UC	 0.82%	 0.00%	 27.15%	 33.88%	 38.25%	 32.38%	
		 		 		 		 		 		 		
CD	 3.49%	 0.00%	 24.62%	 27.41%	 30.08%	 41.62%	
male	 3.31%	 0.00%	 23.71%	 26.32%	 31.20%	 43.83%	
female	 4.01%	 0.00%	 22.73%	 25.95%	 25.95%	 42.13%	
A1	 4.00%	 0.00%	 29.17%	 27.08%	 25.00%	 50.00%	
A2	 3.90%	 0.00%	 24.40%	 27.54%	 31.25%	 41.40%	
A3	 0.00%	 0.00%	 22.41%	 26.79%	 25.86%	 36.49%	
B1	 1.89%	 0.00%	 21.63%	 24.76%	 28.16%	 44.37%	
B2	 1.04%	 0.00%	 26.04%	 25.00%	 26.04%	 44.12%	
B3	 6.09%	 0.00%	 26.64%	 30.95%	 34.11%	 37.50%	
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L4*	 3.08%	 0.00%	 23.39%	 27.05%	 29.84%	 50.00%	
		 		 		 		 		 		 		
ileal	CD	 3.57%	 0.00%	 24.50%	 28.75%	 31.75%	 39.66%	
male	 2.15%	 0.00%	 23.89%	 29.55%	 35.56%	 39.47%	
female	 5.24%	 0.00%	 21.00%	 25.50%	 25.25%	 42.22%	
A1	 5.00%	 0.00%	 26.32%	 26.32%	 23.68%	 52.17%	
A2	 3.24%	 0.00%	 24.09%	 29.01%	 32.30%	 38.21%	
A3	 0.00%	 0.00%	 30.00%	 34.21%	 32.50%	 30.00%	
B1	 1.49%	 0.00%	 22.73%	 29.55%	 33.85%	 42.13%	
B2	 1.14%	 0.00%	 25.00%	 25.00%	 26.14%	 43.55%	
B3	 6.12%	 0.00%	 25.27%	 29.78%	 32.22%	 35.78%	
L4*	 3.08%	 0.00%	 23.39%	 27.05%	 29.84%	 50.00%	
*	the	same	
	 	 	 	 	 		
		 rs2306862	 rs17149104	 rs12416761	 rs2277268	 rs41494349	 rs491347	
		 SNP	27	 SNP	28	 SNP13	 SNP6	 SNP12	 SNP26	
		 exonic	N-->N	 exonic	D-->D	 LRP5	Int.	17	 LRP5	Ex.	9		 LRP5	Ex.	2		 LRP5	Int.	7	
VIENNA	 		 		 		 non	coding	 missense	 		
MAFs	 		 		 		 		 		 		
Controls	 15.61%	 1.80%	 5.72%	 5.67%	 0.36%	 27.64%	
IBD	 13.53%	 2.67%	 6.92%	 6.49%	 0.70%	 22.87%	
UC	 15.59%	 4.24%	 6.21%	 4.94%	 0.93%	 26.56%	
		 		 		 		 		 		 		
CD	 12.07%	 1.57%	 7.36%	 7.44%	 0.57%	 20.61%	
male	 11.21%	 0.88%	 6.91%	 7.72%	 0.00%	 20.25%	
female	 11.83%	 1.95%	 6.57%	 6.34%	 1.10%	 19.85%	
A1	 16.67%	 0.00%	 4.17%	 2.27%	 0.00%	 27.27%	
A2	 11.54%	 1.73%	 7.89%	 7.93%	 0.48%	 20.43%	
A3	 12.07%	 1.79%	 6.25%	 7.81%	 1.56%	 17.19%	
B1	 9.62%	 1.46%	 6.67%	 6.80%	 0.94%	 18.10%	
B2	 13.54%	 0.00%	 8.33%	 7.29%	 1.04%	 17.71%	
B3	 12.74%	 2.45%	 7.55%	 8.10%	 0.00%	 23.30%	
L4*	 6.56%	 1.67%	 4.76%	 6.56%	 0.00%	 21.77%	
		 		 		 		 		 		 		
ileal	CD	 12.44%	 2.05%	 8.05%	 7.67%	 0.49%	 21.29%	
male	 13.33%	 1.15%	 7.37%	 7.89%	 0.00%	 23.12%	
female	 10.10%	 2.58%	 7.62%	 6.86%	 0.96%	 18.27%	
A1	 15.79%	 0.00%	 5.26%	 2.94%	 0.00%	 29.41%	
A2	 12.27%	 2.20%	 8.79%	 8.23%	 0.30%	 20.73%	
A3	 15.00%	 2.50%	 4.76%	 7.14%	 2.38%	 19.05%	
B1	 10.61%	 2.31%	 8.21%	 7.69%	 0.75%	 20.90%	
B2	 12.50%	 0.00%	 9.09%	 7.95%	 1.14%	 17.05%	
B3	 13.89%	 2.87%	 7.53%	 7.61%	 0.00%	 23.33%	
L4*	 6.56%	 1.67%	 4.76%	 6.56%	 0.00%	 21.77%	
*	the	same	 		 		 		 		 		 		
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		 rs4988322	 rs4988331	 rs682429	 rs901824	 rs11607268	 rs12417014	
		 SNP11	 SNP20	 SNP23	 SNP8	 SNP38	 SNP	47	
		 LRP5	Int.	10	 LRP5	Int.	1	 LRP5	5´		 LRP5	Intron	20	 LRP5	E16	 LRP5	I17	
VIENNA	 		 		 regulatory	 		 missense	 intronic	
MAFs	 		
	 	 	 	
		
Controls	 6.18%	 7.36%	 28.64%	 7.47%	 0.16%	 5.27%	
IBD	 27.78%	 9.53%	 31.57%	 8.27%	 0.00%	 6.98%	
UC	 27.59%	 10.25%	 34.26%	 6.96%	 0.00%	 6.00%	
		 		 		 		 		 		 		
CD	 27.85%	 9.09%	 29.92%	 9.07%	 0.00%	 7.37%	
male	 25.00%	 11.79%	 29.27%	 7.92%	 0.00%	 7.56%	
female	 29.17%	 6.25%	 31.62%	 8.58%	 0.00%	 6.06%	
A1	 50.00%	 10.87%	 32.61%	 4.55%	 0.00%	 6.25%	
A2	 27.27%	 8.85%	 30.14%	 9.95%	 0.00%	 6.86%	
A3	 25.00%	 9.38%	 26.56%	 6.45%	 0.00%	 10.00%	
B1	 30.00%	 7.14%	 28.10%	 9.31%	 0.00%	 6.49%	
B2	 30.77%	 6.25%	 32.29%	 9.38%	 0.00%	 6.94%	
B3	 25.00%	 12.86%	 30.95%	 8.74%	 0.00%	 8.33%	
L4*	 29.41%	 7.26%	 27.42%	 5.93%	 0.00%	 3.19%	
		 		 		 		 		 		 		
ileal	CD	 28.57%	 8.58%	 32.11%	 10.05%	 0.00%	 7.14%	
male	 25.00%	 10.00%	 31.58%	 8.70%	 0.00%	 7.35%	
female	 30.00%	 7.21%	 33.65%	 9.80%	 0.00%	 6.58%	
A1	 50.00%	 13.89%	 38.89%	 5.88%	 0.00%	 7.69%	
A2	 27.78%	 7.88%	 32.42%	 11.11%	 0.00%	 6.61%	
A3	 25.00%	 9.52%	 23.81%	 5.00%	 0.00%	 11.54%	
B1	 31.82%	 4.48%	 31.34%	 11.72%	 0.00%	 6.25%	
B2	 30.77%	 6.82%	 32.95%	 10.23%	 0.00%	 7.58%	
B3	 25.00%	 12.50%	 32.61%	 8.89%	 0.00%	 7.69%	
L4*	 29.41%	 7.26%	 27.42%	 5.93%	 0.00%	 3.19%	
*	the	same	 		 		 		 		 		 		
	
		 rs2242339	 rs312778	 rs4988321	 rs545382	 rs554734	 rs643981	 rs686921	
		 SNP32	 SNP41	 SNP48		 SNP46	 SNP35	 SNP38	 SNP33	
		 LRP5	I11	 LRP5	 LRP5	E9	 LRP5	E8	 LRP5	I14	 LRP5	I2	 LRP5	I7	
VIENNA	 intronic	 intronic	 		 non	coding	 intronic	 intronic	 intronic	
MAFs	 		 		 		 		 		 		 		
Controls	 6.91%	 44.17%	 3.43%	 8.39%	 31.29%	 42.94%	 26.94%	
IBD	 9.75%	 36.94%	 4.98%	 8.62%	 29.38%	 35.63%	 22.30%	
UC	 6.25%	 40.13%	 5.88%	 9.74%	 31.88%	 39.58%	 25.68%	
		 		 		 		 		 		 		 		
CD	 11.05%	 35.68%	 4.64%	 8.22%	 28.46%	 34.07%	 21.03%	
male	 12.82%	 35.47%	 3.57%	 10.00%	 29.17%	 34.15%	 21.35%	
female	 7.39%	 33.50%	 5.38%	 6.25%	 25.00%	 32.11%	 20.00%	
A1	 9.38%	 40.63%	 6.67%	 18.75%	 34.38%	 40.00%	 28.13%	
A2	 10.74%	 34.74%	 5.14%	 7.27%	 28.81%	 33.33%	 21.84%	
A3	 12.50%	 38.10%	 0.00%	 8.33%	 20.00%	 34.21%	 10.00%	
B1	 9.42%	 35.71%	 2.00%	 7.83%	 23.33%	 34.67%	 17.09%	
B2	 12.07%	 32.43%	 6.06%	 4.55%	 26.39%	 27.42%	 20.00%	
B3	 11.59%	 35.42%	 7.14%	 10.00%	 32.39%	 34.29%	 24.67%	
L4*	 5.95%	 36.46%	 2.33%	 14.29%	 28.72%	 35.23%	 22.83%	
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ileal	CD	 10.53%	 36.58%	 5.67%	 8.84%	 30.21%	 35.00%	 23.15%	
male	 11.48%	 36.96%	 4.48%	 11.33%	 32.58%	 35.16%	 25.36%	
female	 8.09%	 33.55%	 6.43%	 5.88%	 25.00%	 32.88%	 19.74%	
A1	 11.54%	 39.29%	 7.69%	 19.23%	 38.46%	 37.50%	 30.77%	
A2	 10.19%	 34.43%	 6.09%	 7.78%	 30.25%	 33.33%	 23.39%	
A3	 12.50%	 53.85%	 0.00%	 9.38%	 20.83%	 50.00%	 12.50%	
B1	 8.89%	 41.84%	 3.19%	 10.78%	 28.26%	 40.43%	 21.43%	
B2	 13.46%	 32.35%	 5.00%	 4.88%	 27.27%	 26.79%	 20.31%	
B3	 10.66%	 33.85%	 7.94%	 9.15%	 32.03%	 33.59%	 25.37%	
L4*	 5.95%	 36.46%	 2.33%	 14.29%	 28.72%	 35.23%	 22.83%	
*	the	same	 		 		 		 		 		 		 		
	 	
Stuttgart 
		 rs314756	 rs676318	 rs556442	 rs312788	 rs1127291	 rs638051	
		 SNP	1	 SNP	2	 SNP	3	 SNP	4	 SNP	5	 SNP	6	
		 intronic	 intronic	 exonic	V-->V	 intronic	 exonic	A-->V	 intronic	
STUTTGART	 		 		 		 		 		 		
MAFs	 		 		 		 		 		 		
Controls	 8.45%	 6.74%	 29.14%	 42.55%	 1.41%	 41.37%	
C	Indeterminata	 6.25%	 10.42%	 29.17%	 43.75%	 2.08%	 47.92%	
Inflammatory	C	 11.90%	 9.52%	 38.64%	 45.24%	 0.00%	 50.00%	
IBD	 8.38%	 6.13%	 32.49%	 39.94%	 0.75%	 37.09%	
UC	 7.30%	 6.67%	 33.46%	 39.39%	 1.09%	 37.13%	
		 		 		 		 		 		 		
CD	 9.14%	 5.76%	 31.82%	 40.31%	 0.51%	 37.06%	
male	 6.77%	 6.45%	 35.05%	 38.17%	 0.52%	 39.58%	
female	 11.34%	 5.32%	 29.90%	 43.09%	 0.52%	 35.05%	
A1	 3.03%	 1.52%	 25.76%	 37.88%	 1.52%	 41.18%	
A2	 9.92%	 6.47%	 34.02%	 39.22%	 0.41%	 33.75%	
A3	 17.39%	 11.36%	 39.13%	 50.00%	 0.00%	 39.13%	
B1	 6.34%	 7.14%	 31.94%	 34.29%	 1.41%	 32.39%	
B2	 13.64%	 5.56%	 29.10%	 45.24%	 0.76%	 37.69%	
B3	 5.77%	 8.00%	 39.42%	 38.00%	 0.00%	 43.27%	
L4*	 4.55%	 13.64%	 54.55%	 45.45%	 9.09%	 50.00%	
		 		 		 		 		 		 		
ileal	CD	 10.06%	 5.88%	 30.56%	 38.24%	 0.31%	 35.22%	
male	 7.69%	 6.67%	 33.13%	 35.33%	 0.00%	 37.82%	
female	 12.34%	 5.41%	 29.49%	 41.89%	 0.66%	 33.12%	
A1	 3.85%	 1.92%	 27.78%	 36.54%	 0.00%	 38.89%	
A2	 10.50%	 6.84%	 33.82%	 38.42%	 0.50%	 33.84%	
A3	 20.59%	 9.38%	 35.29%	 46.88%	 0.00%	 32.35%	
B1	 6.12%	 4.17%	 26.00%	 29.17%	 0.00%	 28.00%	
B2	 14.17%	 6.14%	 28.69%	 43.86%	 0.00%	 36.44%	
B3	 7.89%	 9.72%	 39.74%	 34.72%	 0.00%	 39.47%	
L4*	 4.55%	 13.64%	 54.55%	 45.45%	 9.09%	 50.00%	
*	the	same	
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		 rs121908673	 rs3736228	 rs78219242	 rs61370283	 rs4988320	 rs4988319	
		 SNP	7	 SNP	8	 SNP	9	 SNP	10	 SNp	11	 SNP	12	
		 exonic	T-->I	 exon	A-->V	 exon	L-->R	 exon	L-->M	 intronic	 intronic	
STUTTGART	 		 		 		 		 		 		
MAFs	 		 		 		 		 		 		
Controls	 0.00%	 14.89%	 0.00%	 0.00%	 18.09%	 13.48%	
C	Indeterminata	 0.00%	 6.25%	 0.00%	 0.00%	 16.67%	 16.67%	
Inflammatory	C	 0.00%	 22.73%	 0.00%	 0.00%	 18.18%	 18.18%	
IBD	 0.00%	 17.60%	 0.00%	 0.00%	 13.80%	 16.91%	
UC	 0.00%	 19.78%	 0.00%	 0.00%	 14.75%	 17.50%	
		 		 		 		 		 		 		
CD	 0.00%	 16.08%	 0.00%	 0.00%	 13.13%	 16.50%	
male	 0.00%	 17.35%	 0.00%	 0.00%	 13.92%	 17.35%	
female	 0.00%	 15.46%	 0.00%	 0.00%	 12.89%	 15.79%	
A1	 0.00%	 12.12%	 0.00%	 0.00%	 17.65%	 15.15%	
A2	 0.00%	 16.67%	 0.00%	 0.00%	 11.48%	 16.39%	
A3	 0.00%	 21.74%	 0.00%	 0.00%	 18.18%	 13.64%	
B1	 0.00%	 13.19%	 0.00%	 0.00%	 9.72%	 15.97%	
B2	 0.00%	 15.67%	 0.00%	 0.00%	 15.38%	 16.67%	
B3	 0.00%	 19.23%	 0.00%	 0.00%	 15.09%	 17.65%	
L4*	 0.00%	 9.09%	 0.00%	 0.00%	 22.73%	 22.73%	
		 		 		 		 		 		 		
ileal	CD	 0.00%	 14.81%	 0.00%	 0.00%	 12.81%	 15.31%	
male	 0.00%	 15.63%	 0.00%	 0.00%	 13.92%	 15.63%	
female	 0.00%	 14.74%	 0.00%	 0.00%	 12.34%	 15.13%	
A1	 0.00%	 12.96%	 0.00%	 0.00%	 16.67%	 15.38%	
A2	 0.00%	 16.18%	 0.00%	 0.00%	 11.39%	 16.34%	
A3	 0.00%	 20.59%	 0.00%	 0.00%	 15.63%	 11.76%	
B1	 0.00%	 12.00%	 0.00%	 0.00%	 9.00%	 13.00%	
B2	 0.00%	 14.75%	 0.00%	 0.00%	 15.25%	 15.57%	
B3	 0.00%	 17.95%	 0.00%	 0.00%	 11.54%	 16.22%	
L4*	 0.00%	 9.09%	 0.00%	 0.00%	 22.73%	 22.73%	
*	the	same	
	 	 	 	 	 		
		 rs7126340	 rs634008	 rs12294029	 rs4988300	 rs3867143	 rs11606508	
		 SNP	13	 SNP	14	 SNP	15	 SNP	16	 SNP	18	 SNP	20	
		
intronic	
PPP6R3	Gen	
(3´LRP5)	 intronic	
intronic	PPP6R3	
gene	(3´LRP5)	 intronic	 3´	intronic	 intronic	
STUTTGART	 		 		 		 		 		 		
MAFs	 		 		 		 		 		 		
Controls	 21.69%	 47.86%	 22.30%	 50.35%	 11.15%	 13.67%	
C	Indeterminata	 20.83%	 41.67%	 20.83%	 41.67%	 8.33%	 8.33%	
Inflammatory	C	 26.19%	 54.76%	 26.19%	 61.90%	 17.50%	 16.67%	
IBD	 25.31%	 48.95%	 24.77%	 50.31%	 13.91%	 14.42%	
UC	 24.62%	 53.28%	 24.06%	 54.14%	 15.53%	 14.55%	
		 		 		 		 		 		 		
CD	 25.80%	 45.90%	 25.26%	 47.63%	 12.77%	 14.32%	
male	 26.63%	 43.62%	 26.88%	 45.16%	 14.52%	 17.02%	
female	 26.09%	 48.45%	 24.73%	 50.54%	 11.54%	 11.70%	
A1	 25.76%	 42.65%	 24.24%	 43.75%	 9.38%	 10.61%	
A2	 26.32%	 45.76%	 25.65%	 46.55%	 12.61%	 14.53%	
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A3	 23.81%	 47.83%	 25.00%	 52.27%	 16.67%	 9.09%	
B1	 26.43%	 44.44%	 26.43%	 45.71%	 10.87%	 12.14%	
B2	 21.31%	 46.88%	 22.22%	 48.41%	 12.10%	 13.49%	
B3	 29.00%	 48.08%	 26.00%	 53.06%	 14.29%	 18.63%	
L4*	 36.36%	 50.00%	 36.36%	 54.55%	 9.09%	 9.09%	
		 		 		 		 		 		 		
ileal	CD	 23.84%	 43.99%	 23.36%	 45.75%	 11.44%	 13.64%	
male	 24.32%	 39.61%	 24.67%	 42.00%	 12.67%	 15.13%	
female	 24.66%	 48.70%	 23.29%	 50.00%	 10.81%	 12.16%	
A1	 25.00%	 44.44%	 25.00%	 44.23%	 9.62%	 7.69%	
A2	 25.27%	 43.37%	 24.47%	 44.74%	 12.11%	 14.58%	
A3	 21.88%	 50.00%	 21.88%	 53.13%	 15.63%	 6.25%	
B1	 23.96%	 40.00%	 23.96%	 40.63%	 9.38%	 10.42%	
B2	 19.64%	 47.41%	 20.18%	 48.25%	 11.40%	 14.04%	
B3	 26.39%	 44.74%	 23.61%	 48.61%	 12.50%	 17.57%	
L4*	 36.36%	 50.00%	 36.36%	 54.55%	 9.09%	 9.09%	
*	the	same	
	 	 	 	 	 		
		 rs61889560	 CM053969	 rs312781	 rs599083	 rs12226585	 rs2137328	
		 SNP	21	 SNP	22	 SNP	23	 SNP	24	 SNP	25	 SNP	26	
		 exonic	Q-->R	 exonic	S-->L	 intronic	 intronic	
intronic	PPP6R3	
gene	(3´LRP5)	
intronic	
upstream	5´	
STUTTGART	 		 		 		 		 		 		
MAFs	 		 		 		 		 		 		
Controls	 1.79%	 0.00%	 27.50%	 25.54%	 28.62%	 34.55%	
C	Indeterminata	 0.00%	 0.00%	 28.26%	 27.08%	 31.25%	 42.19%	
Inflammatory	C	 4.55%	 0.00%	 38.10%	 35.71%	 38.10%	 33.33%	
IBD	 4.42%	 0.00%	 28.53%	 28.09%	 31.21%	 40.17%	
UC	 4.32%	 0.00%	 27.94%	 27.82%	 31.06%	 33.33%	
		 		 		 		 		 		 		
CD	 4.50%	 0.00%	 28.95%	 28.27%	 31.32%	 44.42%	
male	 4.59%	 0.00%	 26.88%	 31.18%	 33.51%	 48.09%	
female	 4.59%	 0.00%	 31.18%	 26.60%	 30.43%	 39.34%	
A1	 2.94%	 0.00%	 20.31%	 24.24%	 27.27%	 52.04%	
A2	 5.28%	 0.00%	 29.31%	 29.31%	 32.33%	 43.27%	
A3	 4.35%	 0.00%	 34.09%	 36.36%	 35.71%	 46.55%	
B1	 2.08%	 0.00%	 26.43%	 29.29%	 33.57%	 38.33%	
B2	 6.72%	 0.00%	 33.33%	 24.60%	 27.78%	 50.54%	
B3	 5.66%	 0.00%	 26.53%	 36.00%	 35.00%	 45.83%	
L4*	 0.00%	 0.00%	 36.36%	 50.00%	 50.00%	 40.00%	
		 		 		 		 		 		 		
ileal	CD	 5.56%	 0.00%	 27.78%	 26.14%	 29.41%	 46.96%	
male	 5.63%	 0.00%	 25.33%	 28.67%	 31.58%	 52.70%	
female	 5.77%	 0.00%	 30.41%	 25.00%	 28.77%	 39.06%	
A1	 3.70%	 0.00%	 21.15%	 25.00%	 26.92%	 56.25%	
A2	 6.37%	 0.00%	 29.47%	 28.95%	 31.58%	 45.80%	
A3	 5.88%	 0.00%	 31.25%	 28.13%	 31.25%	 42.86%	
B1	 3.00%	 0.00%	 21.88%	 22.92%	 28.13%	 42.19%	
B2	 7.38%	 0.00%	 31.58%	 22.81%	 26.72%	 51.18%	
B3	 7.69%	 0.00%	 25.00%	 34.72%	 33.33%	 50.00%	
L4*	 0.00%	 0.00%	 36.36%	 50.00%	 50.00%	 40.00%	
*	the	same	
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		 rs2306862	 rs17149104	
		 SNP	27	 SNP	28	
		 exonic	N-->N	 exonic	D-->D	
STUTTGART	 		 		
MAFs	 		 		
Controls	 11.43%	 3.85%	
C	Indeterminata	 6.25%	 4.35%	
Inflammatory	C	 21.43%	 0.00%	
IBD	 13.62%	 2.17%	
UC	 13.16%	 4.17%	
		 		 		
CD	 13.95%	 0.84%	
male	 14.13%	 1.14%	
female	 14.36%	 0.57%	
A1	 12.12%	 1.56%	
A2	 13.48%	 0.93%	
A3	 18.18%	 0.00%	
B1	 13.57%	 2.24%	
B2	 11.11%	 0.85%	
B3	 17.00%	 0.00%	
L4*	 13.64%	 10.00%	
		 		 		
ileal	CD	 11.76%	 0.69%	
male	 11.33%	 0.70%	
female	 12.84%	 0.71%	
A1	 11.54%	 0.00%	
A2	 12.63%	 1.12%	
A3	 15.63%	 0.00%	
B1	 11.46%	 1.06%	
B2	 9.65%	 0.00%	
B3	 13.89%	 0.00%	
L4*	 13.64%	 10.00%	
*	the	same	
	 		
	
	
	
